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ABSTRACT 
 
Glomerulonephritis is a major cause of kidney failure and current treatment is 
based on nonspecific immunosuppressive therapies. The purinergic P2X7 
receptor (P2X7R) is usually not detectable in renal tissue. However, previous 
studies have demonstrated an increased glomerular P2X7R expression in animal 
models of glomerulonephritis. Furthermore, P2X7R knock-out mice have been 
shown to be significantly protected from antibody-mediated glomerulonephritis. 
P2X7R activation represents a fundamental step for the activation of the NLRP3 
inflammasome which leads to the processing and release of IL-1β and IL-18. The 
role of the inflammasome activation in glomerulonephritis is not clear yet. The 
work presented in this thesis describes three aspects of P2X7R activation: 
cytokine production, signalling cascade following ATP stimulation and 
inflammasome activation. My data show that macrophages from wild type mice 
produce higher levels of IL-1β and IL-18 compared to macrophages from P2X7 
deficient mice. ATP stimulation activates several signalling pathways in 
macrophages. Among them, the ribosomal pathway appears to be strictly 
regulated by P2X7R. To investigate the role of the inflammasome activation in 
glomerulonephritis I have compared macrophages from the susceptible rat 
strain Wistar-Kyoto with macrophages from the resistant strain Lewis. WKY 
macrophages express higher P2X7 mRNA and protein levels, release higher 
levels of IL-1β and IL-18 and exhibit a greater caspase-1 activity. Similarly, WKY 
nephritic glomeruli show higher P2X7, IL-1β, IL-18 and caspase-1 levels 
compared to Lewis glomeruli. Finally, in the attempt to identify genes 
responsible for the inflammasome regulation, I have examined macrophages 
and nephritic glomeruli from congenic rats. My data seem to indicate that the 
susceptibility locus Crgn2 contains one or more genes that control IL-1β and IL-
18 release in macrophages. Further studies are certainly required to verify the 
relevance of these data. The results are important in understanding the 
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pathogenesis of glomerulonephritis and identification of new potential 
therapeutic targets. 
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CHAPTER ONE-GENERAL INTRODUCTION 
 
1.1 INTRODUCTION 
 
The work described in this thesis is a study of the role of P2X7R-mediated 
inflammasome activation in glomerulonephritis. Previously in my lab, using 
experimental models of glomerulonephritis, it has been shown that P2X7 
deficiency is significantly renoprotective compared to the wild-type controls, 
supporting a pro-inflammatory role for P2X7R in immune-mediated renal injury 
and suggesting P2X7R as a potential therapeutic target (Taylor et al., 2009). 
P2X7R activation is known to be a key step for the assembly and function of the 
NLRP3 (NLR family, pyrin domain containing 3) inflammasome which leads to the 
maturation and release of the pro-inflammatory cytokines IL-1β and IL-18. The 
role of these cytokines in glomerulonephritis is well established and in 
particular, treatment with interleukin-1 receptor antagonist has been 
demonstrated to be effective in reducing the severity of disease in anti-
glomerular basement membrane antibody-induced glomerulonephritis (Tang et 
al., 1998). However, a clear role of the NLRP3 inflammasome in the pathogenesis 
of glomerulonephritis has not been recognized yet. Therefore, the aim of this 
work was to establish a correlation between the P2X7R-mediated inflammasome 
activation and renal injury using in vitro studies and in vivo experimental models 
of glomerulonephritis. The thesis includes the subsequent chapters: Chapter 1, 
the general introduction, where mainly P2X7R structure and function as well as 
the inflammasome machinery are described, followed by a chapter of methods 
and materials (Chapter 2), then 3 chapters of results and finally a discussion 
chapter with conclusions and future directions. Chapter 3 describes the 
differences between bone marrow derived macrophages from wild-type and 
two different lines of P2X7R deficient mice in the release of the inflammasome-
dependent cytokines IL-1β and IL-18 in response to different stimuli and the 
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effects on their secretion of P2X7 selective inhibition. In Chapter 4, the cell 
signalling cascade following P2X7R activation is explored in bone marrow 
derived macrophages from wild-type and P2X7 deficient mice stimulated with 
ATP at different time points. Both a Western blotting and a mass-spectrometry 
phosphoproteomics approach have been used to carry on this analysis. In 
Chapter 5, the role of inflammasome activation in glomerulonephritis has been 
investigated using the rat model of nephrotoxic nephritis and examining the 
expression of several inflammasome-related genes and the secretion of IL-1β 
and IL-18 in bone marrow derived macrophages from Wistar-Kyoto (WKY) and 
Lewis rats. The analysis has then been extended to macrophages from single and 
double congenic rat strains. Additionally, glomeruli isolated from kidneys of 
WKY, Lewis and congenic rats at day 4 from the injection of nephrotoxic serum, 
an important time point that corresponds with the maximal P2X7R expression 
and macrophage infiltration as well as onset of proteinuria as previously 
described (Turner et al., 2007), were examined. Finally, Chapter 6 contains the 
general discussion of all the work presented in this thesis and the potential 
implications for the treatment of glomerulonephritis and outlines the key future 
work directions. 
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1.2 RECOGNITION OF ATP AS AN IMPORTANT INTERCELLULAR 
SIGNAL 
 
The first studies to indicate that purine nucleotides and nucleosides might have 
an additional role outside cells as signalling molecules were conducted by Drury 
and Szent-Györgyi in 1929 when, injecting cardiac extracts intravenously in 
whole animals, they noticed an alteration of the cardiac rhythm and 
demonstrated that the biologically active compound responsible for this effect 
was an “adenine compound” (Drury & Szent-Gyorgyi, 1929). Many other studies 
followed confirming the biological activity of purines in different systems, 
including the uterus and the intestine (Burnstock, Fredholm, North, & 
Verkhratsky, 2010). Then, in 1970, evidence was presented for ATP as a 
neurotransmitter in so-called nonadrenergic, noncholinergic neurotransmission 
(NANC) in the gut (Burnstock, Campbell, Satchell, & Smythe, 1970) and in 1972 
the word “purinergic” was used for the first time (Burnstock, 1972). In 1978, 
Burnstock classified the purinergic receptors into P1 and P2 receptors: 
adenosine acts on P1 receptors, whereas ATP and its breakdown products, ADP 
and AMP, act on P2 receptors (Burnstock, 2006b). Later, in 1985, Burnstock and 
Kennedy proposed a sub-classification of the P2 receptors, based on 
pharmacological criteria, dividing them into P2X and P2Y receptors (Burnstock & 
Kennedy, 1985). In 1994, Abbracchio and Burnstock described the P2X receptors 
as ionotropic ligand-gated ion channel receptors and P2Y metabotropic as G 
protein-coupled receptors (Abbracchio & Burnstock, 1994). Seven subtypes of 
P2X receptors and eight subtypes of P2Y receptors are currently recognized 
(Burnstock, 2006a). The seven P2X receptors subtypes are named as P2X1-7, the 
eight P2Y receptors subtypes include P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, 
P2Y13 and P2Y14. The P2Y receptors are G protein-coupled receptors (GPCRs) 
belonging to the rhodopsin family of G protein-coupled receptors also called 
Class A GPCRs characterized by seven transmembrane domains (Costanzi, Siegel, 
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Tikhonova, & Jacobson, 2009). The N-terminus locates on the extracellular side 
and the C-terminus on the cytoplasmic side of the plasma membrane (figure 
1.1). The P2Y receptors can be further sub-divided into two groups based on 
their coupling to specific G proteins (Abbracchio et al., 2006). The P2Y1, P2Y2, 
P2Y4, P2Y6, and P2Y11 receptors couple to Gq, to activate Phospholipase C beta 
(PLCβ), and the P2Y12, P2Y13, and P2Y14 receptors couple to Gi to inhibit 
adenylyl cyclase (Jacobson & Boeynaems, 2010). The P2Y11 receptor has the 
unique property to couple through both Gq and Gs. The different P2Y subtypes 
with their agonists and associated G proteins are summarized in table 1.1. 
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Figure 1.1 P2Y receptors structure 
P2Y receptors consist of a single polypeptide chain which crosses the plasma 
membrane seven times, forming seven trans-membrane domains. The amino 
terminal region is located outside the cell, while the carboxyl terminal region is 
located in the cytoplasm where the G proteins are activated. Figure adapted 
from the following article: “Purinergic signalling in neuron–glia interactions” 
(Fields & Burnstock, 2006). 
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Table 1.1 Properties of P2Y purinergic receptors. 
The P2Y family is composed of eight members activated by different nucleotides. 
The subtypes P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors couple to Gq, to 
activate Phospholipase C beta, while the P2Y12, P2Y13, and P2Y14 receptors 
couple to Gi to inhibit adenylyl cyclase. The P2Y11 receptor couples through both 
Gs and Gq. Adapted from (Jacobson & Boeynaems, 2010). 
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1.3 THE P2X RECEPTORS FAMILY 
 
P2X receptors (P2XRs) are membrane ion channels that open, within 
milliseconds, in response to the binding of extracellular adenosine triphosphate 
(ATP) (Di Virgilio, 1995). The first cDNAs encoding P2X receptor subunits were 
isolated in 1994 (North, 2002). There are seven genes for P2X receptor subunits. 
Their chromosomal locations in humans are summarized in table 1.2. P2X2, P2X3 
and P2X6 receptor genes are all on different chromosomes. P2X1 and P2X5 
subunit genes are located close on the short arm of chromosome 13. P2X4 and 
P2X7 subunit genes are also both located on the long arm of chromosome 12 
(North, 2002). The full-length of seven P2X receptors have 11-13 exons, and they 
all share a common structure, with well conserved amino acids in the outer loop 
and trans-membrane regions (Li, Liang, & Chen, 2008). These seven genes are 
considerable different in size. The P2X subunit proteins are 384 (P2X4) to 595 
(P2X7) amino acids long (North, 2002). A significant progress in the 
understanding of the P2X receptors structure has been achieved in 2009 when 
Kawate and colleagues reported the crystal structure of a truncated mutant of 
the zebrafish P2X4.1 receptor (DzfP2X4.1) (Kawate, Michel, Birdsong, & Gouaux, 
2009). This study has revealed that P2XRs form homomeric or heteromeric 
trimers and each subunit consists of two trans-membrane domains separated by 
a large extracellular loop and N- and C-terminal residues both on the 
cytoplasmic side of the plasma membrane (Nicke et al., 1998) (figure 1.2). All 
mammalian P2X receptors contain ten conserved cysteine residues in their 
extracellular domains, which are thought to form disulfide bond pairs (Young, 
2010). The most fully characterized complexes are: homomeric P2X1, P2X2, 
P2X3, P2X4, P2X5, and P2X7 channels and heteromeric P2X2/3 and P2X1/5 
channels (Dubyak, 2007). Initially it was thought that all P2XR subtypes, apart 
from P2X7R, were implicated in the assembly of heteromeric complexes. Then a 
study from Guo et al. has demonstrated the existence of heteromers P2X4/P2X7 
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which show properties in common with both of the parent homomeric receptors 
(Guo, Masin, Qureshi, & Murrell-Lagnado, 2007) (figure 1.3). However, there is 
still controversy whether structural heteromers of P2X4/P2X7 really exist (Nicke, 
2008; Skaper, Debetto, & Giusti, 2010). 
 
 
 
 
 
 
Table 1.2 Chromosomal localization of human P2X receptors. 
Chromosomal localizations are from the National Center for Biotechnology 
Information, NCBI (http://www.ncbi.nlm.nih.gov/). 
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Figure 1.2 Schematic representation of the P2X subunits structure. 
Schematic representation showing the membrane topology of a typical P2X 
receptor subunit characterized by  two trans-membrane domains, indicated as 
TM1 and TM2, separated by a large extracellular loop and intracellular NH3+ and 
COO- termini. Figure adapted from the following article: “P2X receptors as cell-
surface ATP sensors in health and disease” (Khakh & North, 2006). 
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Figure 1.3 Trimeric structure of P2X7R homomers, P2X4R homomers and 
P2X4R/P2X7R heteromers. 
P2X receptors form trimeric complexes composed of protein subunits. P2X7 
receptor can form homomeric trimers or heteromeric trimers in association with 
P2X4 receptor. Figure adapted from the following article: “Go it alone no more: 
P2X7 joins the society of heteromeric ATP-gated receptor channels” (Dubyak, 
2007). 
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1.4 THE UNIQUE PROPERTIES OF P2X7 RECEPTOR 
 
The P2X7 subunit, previously termed as the ‘P2Z receptor’ (Surprenant, 
Rassendren, Kawashima, North, & Buell, 1996), was initially cloned from rat and 
then from human brain (Collo et al., 1997) and human macrophages 
(Rassendren et al., 1997). The sequence identity with other P2X receptors is of 
approximately 40–50 % (Erb, Liao, Seye, & Weisman, 2006). At the beginning, 
P2X7R was thought to be selectively expressed on cells of hematopoietic lineage 
such as mast cells, lymphocytes, erythrocytes, fibroblasts, peripheral 
macrophages and epidermal Langerhans cells (Surprenant et al., 1996). More 
recent studies have demonstrated that P2X7R is also widely expressed in 
epithelial cells including salivary glands epithelial cells (Hwang et al., 2009), 
bronchial epithelial cells (Denlinger et al., 2009) and cervical epithelial cells 
(Wang et al., 2004). Within the central nervous system, functional P2X7Rs have 
been localized on microglia and Schwann cells as well as on astrocytes (Ferrari et 
al., 1996). Among all the P2XRs, the P2X7 subtype presents some peculiar 
characteristics: it has a low sensitivity for ATP (mM range), while it appears to be 
much more sensitive to the synthetic ATP analog 3’-O-(4-benzoyl) benzoyl ATP 
(BzATP), so that BzATP is often used experimentally to induce P2X7R activation 
(Bianchi et al., 1999); it shows a long intracellular C-terminus with an extra 200 
amino acid residues compared with the other receptors and it is characterized 
by two different states of permeability (Klapperstuck, Buttner, Schmalzing, & 
Markwardt, 2001): brief agonist stimulation induces a non-selective, cation-
carrying pore, permitting the permeation of monovalent and divalent cations 
such as sodium, potassium and calcium and leading to depolarization of the 
plasma membrane, whereas prolonged and repetitive agonist application leads 
to an increased membrane permeability to larger cations such as N-methyl-D-
glucamine (NMDG), (MW 195) (Pelegrin, 2011). Membrane permeability 
increases further under prolonged agonist stimulation allowing cellular uptake of 
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higher MW fluorescent dyes such as Yo-Pro-1 (MW 629) or ethidium bromide 
(MW 394) (Cankurtaran-Sayar, Sayar, & Ugur, 2009; Cankurtaran-Sayar et al., 
2009). Recent studies have reported that the dilatation of the pore in the plasma 
membrane following prolonged agonist stimulation is not a unique feature of 
P2X7 receptors but also occurs in cells expressing P2X2 or P2X4 receptors 
(Chaumont & Khakh, 2008).  
 
Mechanisms of pore formation 
Despite the large amount of attention that has been paid to understanding the 
mechanisms underlying this time-dependent increase in permeability associated 
with P2X7R activation, the exact mechanisms and the physiological role of the 
permeabilization response are not fully understood yet. At the beginning, it was 
thought that P2X7R itself was able to dilate allowing the passage of large 
molecules (Khakh, Bao, Labarca, & Lester, 1999). More recent studies have 
suggested instead that the permeation of large molecules was mediated by a 
gap-junction protein, pannexin-1, which is also known to form functional 
hemichannels (Pelegrin & Surprenant, 2009). Several studies have indeed 
demonstrated that Panx1 gene silencing by small interfering RNA could inhibit 
some functions of P2X7R, including pore formation (Locovei, Scemes, Qiu, Spray, 
& Dahl, 2007). A recent study from Marques-da Silva et al. has shown that 
colchicine, which is known to induce microtubule disruption, potently inhibits 
both P2X2 and P2X7R-dependent dye uptake without affecting receptor channel 
ionic currents, supporting the hypothesis of a distinct permeation pathway for 
high MW dyes (Marques-da-Silva, Chaves, Castro, Coutinho-Silva, & Guimaraes, 
2011).  
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The C and N termini of P2X7R 
The C terminus of the P2X7R has attracted a lot of interest because of its bigger 
length compared to the other P2X C-termini and it is thought to be involved in 
the majority of functions related to P2X7R including signaling pathway 
activation, cellular localization, protein–protein interactions, and post-
translational modification (Costa-Junior, Sarmento, & Coutinho-Silva, 2011).  In 
2001, Denlinger et al. demonstrated that the murine P2X7 C-terminus contains 
several protein-protein and protein-lipid interaction motifs with potential 
importance to macrophage signaling and LPS action (Denlinger et al., 2001). 
Among them, a putative Src homology (SH3)-binding domain has been described 
within residues 441–460, suggesting the involvement of the C terminus in 
regulating phospholipase D (PLD) activity by interacting with SH3 proteins that 
control Rho or other small G proteins. Residues 436–531 also have been shown 
to contain a conserved death domain, which may contribute to P2X7 receptor-
mediated caspase activity and apoptosis (Denlinger et al., 2001). In their study, 
Denlinger et al. also described a LPS-binding region and demonstrated that two 
basic residues (Arg 578, Lys 579) within this motif are essential for LPS binding to 
P2X7 in vitro. In a later study, they also showed that a mutation in these amino 
acid residues resulted in trafficking defects and impaired pore formation and 
channel activity (Denlinger et al., 2003). The P2X7R C terminus contains 12 
cysteine residues that are thought to participate in membrane localization 
(Gonnord et al., 2009). Mutations on these twelve cysteine residues have been 
shown to compromise the presence of P2X7R on the cell surface and to induce 
receptor expression on the endoplasmic reticulum and lysosomes (Gonnord et 
al., 2009). The N-terminal part of the P2X receptors is a very short region 
consisting of between 22 and 34 amino acids and there is a small amount of 
similarity in the N-termini of different P2X receptors (Soto, Garcia-Guzman, & 
Stuhmer, 1997). The N-terminus of the receptor has been linked to the 
activation of extracellular signal- regulated kinases ERK 1 and ERK2 (Amstrup & 
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Novak, 2003). Amstrup et al., using C- and N-terminal P2X7-receptor mutants 
demonstrated that the N-terminus is important in activation of ERKs, whereas 
deletion of the last 230 amino acids in the C-terminus did not affect ERK 
activation. On the other hand, Ca2+ entry was impaired in C-terminal but not in 
N-terminal mutants (Amstrup & Novak, 2003). The extracellular loop contains 
several conserved amino acid residues, including 10 cysteines that form a series 
of disulphide bridges, 13 glycines and 2–6 asparagines that may serve as N-
linked glycosylation sites (Brake, Wagenbach, & Julius, 1994). 
 
1.5 P2X7 DEFICIENT MOUSE LINES AND P2X7 SPLICE VARIANTS 
 
Mice lacking the P2X7R are healthy and fertile and demonstrate no overt 
phenotype upon gross examination. However, a study conducted by Ke et al. has 
demonstrated that P2X7 deficient mice have a unique skeletal phenotype, 
exhibiting smaller bone diameter and lower cortical mass, associated with a 
striking reduction in the rate of periosteal bone formation (Ke et al., 2003). In 
addition, mice lacking the P2X7R show higher trabecular bone resorption 
indicating a key role for this receptor in periosteal bone formation and 
trabecular bone remodelling (Ke et al., 2003). There are two strains of mice in 
which the P2X7 gene has been disrupted. One mouse line has been generated by 
the pharmaceutical company GlaxoSmithKline (GSK) by insertion of a lacZ 
transgene into exon 1 (Sim, Young, Sung, North, & Surprenant, 2004) (Figure 
1.4). In the mouse line generated by Pfizer, a neomycin cassette was inserted 
into exon 13, replacing a region that encodes Cys-506¬-Pro-532 of the 
intracellular C-terminus of the receptor (Fig 1.4). The P2X7 deficient mouse line 
generated by Pfizer has demonstrated a clear role of this receptor in bone 
formation and resorption (Ke et al., 2003) as well as in cytokine production and 
in inflammation (Labasi et al., 2002), while the knock-out mice generated by 
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GlaxoSmithKine have shown an important role of P2X7R in chronic inflammatory 
and neuropathic pain (Chessell et al., 2005). Experiments conducted on primary 
cells from the two P2X7 deficient mouse lines have demonstrated important 
differences between the two strains. One example is the difference in IL-6 
production following ATP stimulation in macrophages. Pfizer macrophages show 
a significant reduction in IL-6 production compared to macrophages from WT 
mice (Solle et al., 2001), while macrophages from GSK knock-out mice exhibited 
a significant increase in IL-6 secretion (Chessell et al., 2005). In experimental 
autoimmune encephalomyelitis, a mouse model of multiple sclerosis, the Pfizer 
knock-out mice showed exacerbation of disease (Chen & Brosnan, 2006), while 
GSK mice had a reduction in the incidence of disease (Sharp et al., 2008).  
 
P2X7 splice variants 
Several splice variants have been described for both the human and mouse 
isoforms of P2X7R, which differ in their functional properties from the full length 
P2X7A receptor (Feng, Li, Wang, Zhou, & Gorodeski, 2006a; Cheewatrakoolpong, 
Gilchrest, Anthes, & Greenfeder, 2005). In particular, nine variants of human 
P2X7 resulting from alternative splicing named P2X7A–J, have been identified, 
P2X7A being the well-characterized full-length P2X7 receptor 
(Cheewatrakoolpong et al., 2005). Of the 9 splice variants, 4, P2X7B, P2X7E, 
P2X7G, and P2X7J, lack the C terminus. One of these variants (P2X7B) is 
characterized by a large C-terminal deletion and it has been shown to be able to 
mediate calcium influx and membrane depolarization but it can no longer trigger 
membrane permeabilization to larger molecules (Adinolfi et al., 2010). This 
variant has also been shown to have a growth promoting activity (Feng, Li, Zeng, 
& Gorodeski, 2006). Another splice variant of human P2X7 containing a larger 
deletion at the C-terminus and lacking the second transmembrane domain was 
found in cervical cancer cells (Feng, Li, Wang, Zhou, & Gorodeski, 2006). This 
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truncated P2X7 isoform seems to interact with the full length receptor in a 
dominant negative fashion promoting uncontrolled growth of cells (Feng, Li, 
Zeng, & Gorodeski, 2006b). For the mouse P2X7R, a splice variant characterized 
by an alternative exon 1 encoding the N-terminus and part of the first trans-
membrane domain has been described. This variant, called P2X7K, showed much 
higher sensitivity to agonists such as BzATP than the original P2X7A, rapidly 
triggers membrane permeabilization and seems to be selectively expressed in 
spleen lymphocytes (Nicke et al., 2009). Being characterized by an alternative 
exon 1 and a different translation start point, this variant can escape gene 
inactivation in the Glaxo P2X7 knock-out mice. A recent study has described two 
further P2X7 variants in the mouse characterized by alternative exon 13’s which 
encode much shorter C-termini than the original exon 13 and are able to escape 
gene inactivation in the Pfizer knock-out mouse strain (Masin et al., 2011). These 
two variants are identical with P2X7A between residues 1-430, one of the 
variants then terminates at T431 (P2X7 13B) and the other has an additional 11 
amino acids at the C-terminus (P2X7 13C). Although they appear to form stable 
homotrimers, it has been demonstrated that the efficiency with which these 
trimers traffic out of the endoplasmic reticulum to reach the plasma membrane 
is considerably reduced compared to the full-length variant leading to a 
decreased amplitude of the whole cell currents compared to the P2X7A variant 
(Masin et al., 2011). In their study, Masin et al. have reported that the variant 
P2X7 13B, when co-expressed with the full-length P2X7R, acts in a dominant 
negative fashion reducing the surface expression of P2X7A and the amplitude of 
agonist-evoked whole cell currents. The identification of these splice variants 
can explain the diversity of P2X7 mediated responses in different tissues and 
leads to the conclusion that both the Glaxo and the Pfizer mouse strains are not 
null for P2X7R expression in all tissues. 
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Figure 1.4 Simplified representation of the Pfizer and GlaxoSmithKline P2X7 
knock-out constructs. 
The construct of the Pfizer P2X7 knock-out has nucleotides 1527-1607 deleted 
and a neomycin cassette inserted 5’ to 3’, whereas the construct of the Glaxo 
P2X7 knock-out mice (C) had a LacZ gene inserted after ATG at the 5’ end. Figure 
adapted from the following article: "Reanalysis of P2X7 receptor expression in 
rodent brain" (Sim, Young, Sung, North, & Surprenant, 2004).  
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1.6 GENETICS OF THE P2X7 RECEPTOR IN HUMAN DISEASE 
 
Single-nucleotide polymorphisms (SNPs) are the most common genetic variation 
in the human genome and are now widely used to identify susceptibility genes in 
human diseases. The P2RX7 gene contains 13 exons and has been mapped to 
the 12q24.31 chromosomal region (Buell et al., 1998). The P2RX7 gene is highly 
polymorphic and to date 32 non-synonymous, amino acid-altering SNPs have 
been identified (Fuller, Stokes, Skarratt, Gu, & Wiley, 2009). The majority of 
identified SNPs in P2RX7 confer a loss-of-function phenotype to various P2X7-
dependent downstream events (Gu et al., 2001), while one ectodomain SNP 
(His-155 to Tyr) confers a gain of-function effect (Cabrini et al., 2005). The first 
SNP to be functionally described was 1513A>C that changes glutamic acid to 
alanine at residue 496 (Glu496 to Ala) in the carboxyl terminus of the receptor. 
This amino acid substitution in native or transfected cells leads to an impairment 
of the pore formation activity, while the cation selective channel activity is not 
affected (Boldt et al., 2003). The polymorphism (489C>T) changes amino acid 
155 from histidine to tyrosine (His155 to Tyr) in the extra-cellular portion of the 
receptor and has an allele frequency of 0.455 in Caucasians (Cabrini et al., 2005). 
Functional analysis in recombinant HEK293 cells expressing the P2X7 489T 
mutant revealed that the His155 to Tyr substitution produces a gain-of-function 
effect leading to an increased ethidium uptake and calcium influx. Several 
genetic association case–control studies using synonymous and non-
synonymous SNPs have revealed a role for P2RX7 as a susceptibility gene in 
bipolar disorder and major depression (Roger et al., 2010) and in susceptibility to 
infections with intracellular pathogens such as tuberculosis (Fernando et al., 
2007). Three independent case-control studies from Canada, Germany and the 
UK have identified a SNP at nucleotide 1405 A>G in the gene which is strongly 
associated with both bipolar and major depressive disorders. This SNP is present 
in about 15% of the Caucasian population and changes Glutamine-460 to 
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Arginine in the long carboxyl tail of the receptor but the functional effect of this 
SNP on P2X7R is yet to be determined (Barden et al., 2006). P2X7R has also been 
shown to play an important role in the killing of phagocytosed Mycobacterium 
tuberculosis by extracellular ATP (Fairbairn, Stober, Kumararatne, & Lammas, 
2001a). Several epidemiological studies have confirmed the role of P2X7R in the 
control of tuberculosis. A study conducted on individuals from Southeast Asia 
revealed that the inheritance of the 1513A>C loss-of-function polymorphic 
variant of P2RX7 was associated with reduced killing of Mycobacterium 
Tuberculosis and with extrapulmonary tuberculosis (Fernando et al., 2007). 
Other conditions linked to P2RX7 gene polymorphisms include resistance to 
infection with Chlamydia (Coutinho-Silva, Perfettini, Persechini, Dautry-Varsat, & 
Ojcius, 2001), increased fracture risk in post-menopausal women (Ohlendorff et 
al., 2007) and multiple sclerosis (Oyanguren-Desez et al., 2011). 
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1.7 P2X7 RECEPTOR ANTAGONISTS 
  
Several P2X7R antagonists have been discovered so far and some of them have 
also been recently used in Phase I and Phase II clinical trials (Guile et al., 2009). 
The molecular structure of the main P2X7R antagonists is illustrated in figure 
1.5. The currently available P2X7 receptor antagonists can be classified into five 
main groups (North, 2002). The first group contains ions, such as calcium, 
copper, magnesium, zinc and protons which all inhibit ATP-evoked currents at 
the rat P2X7R (Friedle, Curet, & Watters, 2010; North, 2002). P2X7 receptors are 
distinct from other ATP-gated P2X receptors in that they are potently inhibited 
by submicromolar concentrations of zinc and copper (Liu et al., 2008). Similar 
concentrations seem instead to potentiate the current activity of the other 
members of the P2X family (North, 2002).  The second group is represented by 
non-selective P2X7R antagonists such as suramin, pyridoxal-phosphate-6-
azophenyl-2',4'-disulfonate (PPADS), Brilliant Blue G (BBG) and oxidized ATP. 
Suramin and PPADS were among the first antagonists identified. They both block 
P2X7 receptors with low affinity and typically show non-competitive antagonism 
and a low specificity (Jacobson, Jarvis, & Williams, 2002). Brilliant Blue G (BBG) is 
a more potent and selective antagonist with a 30- to 50-fold greater selectivity 
for rat versus human P2X7 receptors (Jiang, Mackenzie, North, & Surprenant, 
2000). Oxidized-ATP is an irreversible inhibitor of P2X7R but requires one-two 
hours incubation to completely block P2X7 function and furthermore is not 
selective leading also to the blockade of P2X1 and P2X2 receptors and to the 
inhibition of nuclear factor k-B (NF-kB) (Murgia, Hanau, Pizzo, Rippa, & Di 
Virgilio, 1993). The third group includes compounds that contain two large 
organic cations, such as the isoquinoline KN-62 (1-(N,O-bis[5-
isoquinolinesulfonyl]-N-methyl-L-tyrosyl)-4-phenylpiperazine) and the imidazole 
calmidazolium. The isoquinoline KN-62 potently blocks P2X7 receptor function in 
a non-competitive fashion (Gargett & Wiley, 1997). It has been shown that KN-
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62 blocks currents in cells expressing the human P2X7R but has little effect at 
the rat P2X7R (Humphreys, Virginio, Surprenant, Rice, & Dubyak, 1998). The 
fourth class of P2X7 antagonists described is represented by 17β-estradiol  
(Cario-Toumaniantz, Loirand, Ferrier, & Pacaud, 1998). In 1998, Cario-
Toumaniantz et al. have demonstrated that 2.17 β-Oestradiol rapidly and 
reversibly inhibited the ATP and BzATP evoked currents in COS cells expressing 
the human P2X7R and in the human monocytic cell line U937 (Cario-
Toumaniantz et al., 1998). Finally, a monocolonal antibody specific for the 
human P2X7R was generated in mice (Buell et al., 1998).  In 2003, two novel 
series of P2X7R antagonists, composed of cyclic imides (Alcaraz et al., 2003) and 
adamantane amides (Baxter et al., 2003), were shown to be effective P2X7R 
antagonists. These compounds however show a preferential affinity for the 
human versus the rat P2X7R. In 2006 two novel series of P2X7R antagonists have 
been discovered by Abbott Laboratories: disubstituted tetrazoles such as A-
438079 (Nelson et al., 2006) and cyanoguanidines (Honore et al., 2006). These 
new compounds demonstrated enhanced potency and selectivity as antagonists 
at rat and human P2X7 receptors compared to previous antagonists and their 
action was reversible (Donnelly-Roberts & Jarvis, 2007). Another P2X7R 
antagonist that belongs to the family of cyanoguanidines is A-740003 ((N-(1- 2,2-
dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide). (Honore et al., 2006). This 
compound shows similar properties as A-438079 but it has been shown to be 
more potent in blocking BzATP-evoked IL-1β release and pore formation in 
differentiated human THP-1 cells (Honore et al., 2006). Several Phase I and 
Phase II clinical trials investigating the safety and the efficacy of the P2X7R 
antagonists have been conducted (Arulkumaran, Unwin, & Tam, 2011). Current 
P2X7R antagonists have proven to be safe and well tolerated. Phase II clinical 
trials have investigated the use of P2X7R antagonists in rheumatoid arthritis, 
inflammatory bowel disease and chronic obstructive airway disease 
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(Arulkumaran et al., 2011). The main reported side effects were gastrointestinal 
symptoms such as nausea and diarrhoea, dizziness and headaches. 
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Figure 1.5 Molecular structure of P2X7 receptor antagonists. 
 Pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS), oxidized ATP, 
suramin and Brilliant Blue are non-selective antagonists. Brilliant Blue G shows a 
higher potency for rat versus human P2X7 receptors, while KN62 appears to be 
more effective in blocking the human versus the rat P2X7 receptor. Figure 
adapted from the following article: “Recent patents on novel P2X(7) receptor 
antagonists and their potential for reducing central nervous system 
inflammation” (Friedle, Curet, & Watters, 2010). 
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1.8 FUNCTIONAL CONSEQUENCES OF P2X7 RECEPTOR 
ACTIVATION 
 
P2X7R activation has been associated with many important cellular functions, 
including: pore-formation activity (Aga et al., 2002), maturation and release of 
pro-inflammatory cytokines (Pelegrin, Barroso-Gutierrez, & Surprenant, 2008), 
killing of pathogens (Fairbairn, Stober, Kumararatne, & Lammas, 2001), 
membrane blebbing formation (Pfeiffer et al., 2004), cell cycle regulation (Bianco 
et al., 2006), activation of phospholipases A2 and D (Alzola et al., 1998), 
activation of mitogen-activated protein kinase (MAPK) and nuclear factor-κB 
(NF-κB) and many others (Armstrong, Brust, Lewis, & MacVicar, 2002; Di Virgilio, 
1995; Ferrari, Stroh, & Schulze-Osthoff, 1999). One of the first studied cellular 
responses to P2X7R activation is represented by pore formation and rapid 
changes in ionic fluxes (Virginio, Mackenzie, Rassendren, North, & Surprenant, 
1999). Prolonged stimulation of the pore activity has been shown to have a 
cytotoxic effect (Le Feuvre, Brough, Iwakura, Takeda, & Rothwell, 2002) and lead 
to membrane blebbing and apoptosis, so that P2X7R has been historically 
defined “the suicide receptor (Chiozzi et al., 1997). More recent studies 
however, have shown that basal levels of ATP, naturally present in the 
extracellular milieu, cause a tonic activation of P2X7R which increases calcium 
influx in the mitochondria and this, in turn, induces ATP synthesis promoting cell 
survival and proliferation in the absence of serum (Adinolfi et al., 2005). In their 
study, Adinolfi et al. have demonstrated that this growth promoting function of 
the P2X7R is dependent on pore formation, since it does not occur in cells 
transfected with a truncated form that cannot form a pore. Consistent with 
these findings is also the observation that P2X7R is expressed at high levels in 
several malignancies (Adinolfi et al., 2002; Jelassi et al., 2011). P2X7R activation 
induces not only pore formation in the plasma membrane but activates a wide 
range of membrane trafficking responses such as shedding of plasma membrane 
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surface proteins, phagosome maturation and fusion with lysosomes, exocytosis 
of secretory lysosomes, that can modulate the direct interactions between 
P2X7R expressing cells and other cell types in sites of immune and inflammatory 
activation (Mackenzie, Young, Adinolfi, & Surprenant, 2005; Qu & Dubyak, 
2009). Several studies have reported that P2X7R activation is associated with the 
activation of the MAPK signalling pathway. These enzymes are a highly 
conserved family of protein serine/threonine kinases and include the 
extracellular signal-regulated kinases ERK1/2, the c-Jun NH2-terminal kinases 
JNK1/2, and the p38 stress-activated protein kinases (Dong, Davis, & Flavell, 
2002). These kinases can trigger the nuclear accumulation and activity of various 
transcription factors, such as NF-κB, and c-Jun, which can modulate cytokine and 
inflammatory mediator expression (Bhat, Zhang, & Bhat, 1999). Work by 
Bradford et al. has shown that P2X7R activation induced by ATP or BzATP, 
promotes an increase in both the activity and autophosphorylation of Protein 
Kinase D (PKD) in rat parotid acinar cells and this effect was also associated with 
an increased phosphorylation of ERK1 and ERK 2 (Bradford & Soltoff, 2002a). 
Studies conducted on primary astrocyte cultures have also demonstrated that 
activation of the purinergic P2X7R increases Monocyte Chemoattractant 
Protein-1 (MCP-1) expression via activation of the MAPK pathway (Panenka et 
al., 2001a). The activation of P2X7R has been also linked to the production of 
reactive oxygen species (ROS) in macrophages through the MAPKs ERK1/2 
signalling pathway and the nicotinamide adenine dinucleotide phosphate 
oxidase complex (NADPH) (Lenertz, Gavala, Hill, & Bertics, 2009). Transcription 
factors such as nuclear factor κB (NF-κB), nuclear factor of activated T cells 
(NFAT), cyclic AMP response element-binding (CREB) protein, and activator 
protein 1 (AP-1), whose activation and nuclear translocation are associated with 
the expression of inflammatory genes have been shown to be activated by 
P2X7R in microglia (Ferrari, Stroh, & Schulze-Osthoff, 1999; Potucek, Crain, & 
Watters, 2006).  Studies from Korcok et al. have also revealed that P2X7R 
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directly activates NF-kB in osteoclasts (Korcok, Raimundo, Ke, Sims, & Dixon, 
2004). P2X7R activation has also been associated with activation of different 
phospholipases including phospholipase A2 (Alzola et al., 1998) and 
phospholipase D (Coutinho-Silva et al., 2003).  A study conducted on microglial 
cells has also shown that P2X7R promotes cell proliferation positively regulating 
cell cycle progression (Bianco et al., 2006). Proteomic analysis performed on 
human embryonic kidney cells (HEK) revealed the existence of a P2X7R signalling 
complex formed by 11 proteins that interact directly with the rat P2X7R (Kim, 
Jiang, Wilson, North, & Surprenant, 2001). The majority of these proteins are 
involved in the cytoskeleton organization and include: the extracellular matrix 
protein laminin α3, the membrane spanning proteins integrin β2 and receptor 
protein tyrosine phosphatase β and eight intracellular proteins. In their study 
Kim et al also showed that P2X7R becomes dephosphorylated at Tyr 343 upon 
activation and the effects of this dephosphorylation are a delay in membrane 
blebbing and an inhibition of membrane currents (Kim et al., 2001). 
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1.9 P2X7 RECEPTOR AND MACROPHAGE FUNCTION 
 
Macrophages are cells that function as a first line of defence against invading 
microorganisms thanks to their ability to recognize and directly kill pathogens 
while recruiting and activating other inflammatory cells through the secretion of 
cytokines that act as danger signals (Zhang & Mosser, 2008). The ability of 
exogenous pathogen-associated molecular patterns (PAMPS) such as bacterial 
lipopolysaccharide (LPS) to induce the processing and the release of IL-1β by 
monocytes/macrophages was well established since the discovery of IL-1β as an 
endogenous pyrogen (Murphy, Simon, & Willoughby, 1980). It was observed, 
however, that LPS was a very efficient stimulus in inducing accumulation of pro-
IL-1β in the cytosol, while it was only a weak stimulator of IL-1β processing and 
release (Dinarello, 2004). This observation has led investigators to postulate a 
second stimulus to induce efficient IL-1β conversion and release. The first 
studies showing ATP as a strong IL-1β releasing molecule were conducted by 
Perregaux et al. who indicated the massive efflux of intracellular potassium 
following ATP stimulation as the underlying mechanism of IL-1β activation and 
release (Perregaux & Gabel, 1994). At that time the identity of the plasma 
membrane receptor involved in this process was unknown. Later studies 
performed in vitro and in vivo in P2X7 deficient mice conclusively recognised 
P2X7 as the receptor responsible for ATP-dependent IL-1β release (Ferrari et al., 
1997; Labasi et al., 2002). During inflammation, circulating blood monocytes 
migrate from the vasculature to the extravascular compartments where they 
mature into tissue macrophages (Takashiba et al., 1999). Several studies have 
reported that synthesis and release of IL-1β differ between monocytes and 
macrophages (Netea et al., 2009). Monocytes indeed, have constitutively 
activated caspase-1, leading to release of active IL-1β after a single stimulation 
event with bacterial ligands such as LPS, whereas in macrophages, the process of 
IL-1β secretion is thought to require two different steps (Ward et al., 2010) 
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(figure 1.6). The first signal is triggered by the so-called PAMPs such as LPS, 
which, through the interaction with Toll-Like-Receptors activate several 
intracellular signal transduction pathways including MAPK and NF-κB cascades 
leading to the increased production of pro-IL-1β within the cell (Bauernfeind et 
al., 2009). This LPS priming stimulus is necessary as ATP stimulation alone will 
not induce the release of active IL-1β (Mehta, Hart, & Wewers, 2001). The exact 
function of the LPS priming step however remains still unclear. It was thought 
that LPS priming was necessary to increase the levels of pro-IL-1β within the cells 
in order to generate enough substrate for caspase-1 activity. However, studies 
conducted on the other well recognized caspase-1 dependent cytokine IL-18 
have demonstrated that substrate generation is not the only function of LPS 
priming (Gu et al., 1997). Indeed, macrophages contain already high levels of 
pre-formed pro-IL18 even under basal conditions but they release no mature IL-
18 unless primed with LPS (Wewers & Sarkar, 2009). The second step required 
for IL-1β maturation and release can be triggered by different stimuli such as 
extracellular ATP, crystals (monosodium urate crystals), or pathogenic dusts 
(asbestos or silica) which induce the assembly of the multiprotein complex 
inflammasome with activation of caspase-1, ultimately responsible for the 
cleavage and secretion of the active cytokine (Martinon, Petrilli, Mayor, Tardivel, 
& Tschopp, 2006), (Dostert & Petrilli, 2008). P2X7R activation by ATP represents 
therefore a crucial event for the processing and release of active IL-1β (Hogquist, 
Unanue, & Chaplin, 1991). The exact mechanism by which P2X7R activation by 
ATP leads to the assembly of the NLRP3 inflammasome and the consequent 
activation of caspase-1 is not completely understood yet. It is known that ATP 
leads to a rapid efflux of potassium from the cell and triggers gradual 
recruitment and pore formation by the pannexin-1 hemichannel (Petrilli et al., 
2007; Kanneganti et al., 2007). It has been suggested that NLRP3 senses either 
low intracellular potassium or a breakdown in membrane integrity or that 
hemichannel pore formation allows extracellular NLRP3 agonists to access the 
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cytosol, to activate NLRP3 directly (Schroder, Zhou, & Tschopp, 2010). Blocking 
the potassium efflux by exogenous potassium, inhibits the ability of ATP to 
induce the release of active IL-1β and IL-18 suggesting that the formation of 
pores that allows potassium escape is a key step for the release of these 
caspase-1 dependent cytokines (Perregaux & Gabel, 1994). The constitutive 
caspase-1 activation in monocytes has been related to their ability to release 
ATP (Piccini et al., 2008). Endogenous ATP from monocytes can in turn activate 
the NLRP3 inflammasome and induce IL-1β secretion through P2X7R. In contrast, 
macrophages completely lack the capacity to release ATP, therefore they require 
a second stimulus to generate active IL-1β and IL-18 (Ferrari, Chiozzi, Falzoni, 
Hanau, & Di Virgilio, 1997). 
 
 
 
 
 
 
 
 
51 
 
 
Figure 1.6 Schematic representation of the processing and release of IL-1 beta 
and IL-18 in macrophages. 
Two different steps are required for the generation of active IL-1β and IL-18 in 
macrophages: the first stimulus is triggered by LPS which through the activation 
of the Toll-like receptor 4 (TLR4) activates the NF-kB signalling cascade leading to 
an increased synthesis of pro-IL-1β and pro-IL-18 within the cells. The second 
step is represented by P2X7 receptor activation by ATP, necessary for the NLRP3 
inflammasome assembly and activation of pro-caspase 1 which is now able to 
cleave pro-IL-1β and pro-IL-18 into their mature forms and these are 
immediately secreted outside the cells. Figure adapted from: 
http://www.invivogen.com/review-nlrp3-inflammasome. 
 
 
 
 
 
52 
 
1.10 IDENTIFICATION OF THE CATHELICIDIN PEPTIDE LL-37 
AS A NOVEL P2X7R AGONIST 
 
LL-37 is the only human member of a family of antimicrobial peptides called 
cathelicidins. It is an 18 KDa molecule, mainly expressed in neutrophils and 
epithelial cells (Larrick et al., 1996). LL-37 is synthesized as an inactive precursor 
and in neutrophils is stored within the peroxidase-negative granules (Elssner, 
Duncan, Gavrilin, & Wewers, 2004a). The precursor is then converted into its 
active form by serine proteases contained in the azurophil granules of 
neutrophils (Oren, Lerman, Gudmundsson, Agerberth, & Shai, 1999). LL-37 has 
been shown to exert antimicrobial activity toward both Gram-negative and 
Gram-positive bacteria and to directly mediate chemotaxis of neutrophils, 
monocytes and T cells through a member of the formyl peptide receptor family, 
formyl peptide receptor-like 1 (FPRL1) (De et al., 2000). The antibacterial 
function of LL-37 has been attributed to its membrane pore-forming activity 
(Johansson, Gudmundsson, Rottenberg, Berndt, & Agerberth, 1998). Perregaux 
et al. have documented that protegrins, a group of antimicrobial peptides 
derived by proteolytic cleavage of a porcine cathelicidin precursor, can induce IL-
1β processing and release in LPS-primed monocytes through a P2X7 
independent way (Perregaux, Bhavsar, Contillo, Shi, & Gabel, 2002). The 
mechanism by which protegrins were able to generate active IL-1β was related 
to their membrane-permeabilizing activity leading to a rapid efflux of potassium 
from the cells. The results of this study suggested that other antimicrobial 
peptides, such as LL-37 might promote IL-1β secretion in a similar manner. 
However, a study conducted by Elssner et al. has shown that LL-37 stimulation of 
LPS-primed monocytes led to maturation and release of IL-1β but this effect was 
completely abolished when monocytes were pretreated with P2X7R inhibitors 
such as oxidised ATP, KN04 and KN62, indicating that LL-37 acts via P2X7R 
(Elssner, Duncan, Gavrilin, & Wewers, 2004). However, the interaction between 
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LL-37 and P2X7R remains controversial since the antagonists used may have 
non-selective effects. Therefore, studies to investigate the effects of LL-37 in 
macrophages from WT mice and comparison with macrophages with P2X7R 
deficient mice will be informative to clarify this controversy. 
 
1.11 GENERATION OF ACTIVE IL-1β VIA CASPASE-1 INDEPENDENT 
PATHWAYS 
 
In 1988, Black et al. demonstrated that Chymotrypsin and Staphylococcus 
aureus protease were able to generate active IL-1β (Black et al., 1988). Further 
studies from Kapur et al. also showed that a cysteine protease derived from 
Streptococcus pyogenes was able to induce the cleavage of IL-1β precursor to 
produce active IL-1β (Kapur, Majesky, Li, Black, & Musser, 1993). Similarly, 
neutrophil-derived serine proteases such as cathepsin G, neutrophil elastase and 
proteinase 3 as well as mast cell derived serine proteases including granzyme A 
and chymase have been also shown to cleave the IL-1β precursor at distinct sites 
into a secreted biologically active form (Mizutani, Schechter, Lazarus, Black, & 
Kupper, 1991; Irmler et al., 1995). In vivo experiments conducted by Fantuzzi et 
al. on caspase-1 deficient mice to investigate their response to local 
inflammation, revealed that there were no differences between WT and 
caspase-1 knock-out mice in the development of the systemic acute phase 
response and that the levels of mature IL-1β were similar in the two mouse 
strains (Fantuzzi et al., 1997). Work from Schonbeck et al. demonstrated that 
several components of the family of matrix metalloproteinases (MMPs) 
including stromelysin-1 (MMP-3), gelatinases A (MMP-2) and B (MMP-9), 
process recombinant human IL-1β precursor into biologically active forms 
(Schonbeck, Mach, & Libby, 1998). MMPs are known to play an important role in 
extracellular matrix degradation and have been also shown to be markedly 
upregulated in macrophages at sites of inflammation (Lemjabbar et al., 1999). 
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Interestingly, IL-1β itself has been shown to regulate the expression of MMPs in 
different cell types (Mountain, Singh, Menon, & Singh, 2007; Yokoo & Kitamura, 
1996), indicating an important cross-regulation among these two classes of 
effectors of inflammation. 
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1.12 THE INFLAMMASOMES 
 
The innate immune system is an evolutionarily conserved system that 
represents the first line of protection against invading microbial pathogens 
through different processes such as phagocytosis and the induction of 
inflammation (Khare, Luc, Dorfleutner, & Stehlik, 2010). Host cells, in particular 
cells of the myeloid lineage, express germline encoded pattern recognition 
receptors (PRRs) for the detection of various microbial components (Taylor et 
al., 2005). PRRs belong to different classes of receptors such as trans-membrane 
toll-like receptors (TLRs), C-type lectin receptors (CLRs), the retinoic acid 
inducible gene-I (RIG-I) receptors which belong to the RNA helicases family that 
specifically detects RNA species derived from viruses in the cytoplasm, cytosolic 
Nod-like receptors (NLRs), and the recently identified HIN-200 family members 
(O'Neill & Bowie, 2010; Takeuchi & Akira, 2010; Skeldon & Saleh, 2011). These 
receptors are also able to sense and to respond to endogenous, host-derived, 
danger signals that are released in response to cell death, tissue injury or stress 
(Bianchi & Manfredi, 2009). Following the recognition of microbial components 
or danger stimuli, these receptors activate a signalling cascade that leads to the 
generation of the appropriate immune response. The inflammasome was first 
described in 2002 as a molecular platform activating pro-inflammatory caspases 
leading to the maturation and release of the pro-inflammatory cytokines IL-1β 
and IL-18 (Martinon, Burns, & Tschopp, 2002). Since, the interest for this 
complex has constantly increased and several inflammasome complexes with 
different specificities have been identified. To date, five cytoplasmic receptors 
have been described that form an inflammasome complex: NLR family, pyrin 
domain containing 1 (NLRP1; also called NALP1), NLRP3 (also called NALP3 or 
cryopyrin), NLR family, caspase recruitment domain (CARD) containing 4 (NLRC4; 
also called IPAF) and the more recent absent in melanoma 2 (AIM2) and retinoic 
acid inducible gene 1 (RIG-1) (Guarda & So, 2010). NLRP1, NLRP3 and NLRC4 
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belong to the NLR family of receptors, AIM2 is a member of the haematopoietic 
interferon inducible nuclear protein (HIN) family of proteins while RIG-1 is an 
RNA helicase that recognises viral RNA (Poeck et al., 2010). The NLRs are 
intracellular receptors characterized by a tripartite structure, consisting of an N-
terminal protein–protein interaction domain, a central NACHT [NAIP (NLR 
family, apoptosis inhibitory protein), CIITA (class II, major histocompatibility 
complex, transactivator), HET-E (plant het gene product involved in vegetative 
incompatibility) and TP-1 (telomerase-associated protein 1)] domain and a C-
terminal tail which in NLRs is a series of leucine-rich repeats (LRRs), as found in 
TLRs (Skeldon & Saleh, 2011). These receptors can be divided in three 
subfamilies according to the characteristics of their N-terminal domain: the NOD 
receptors, the NLRPs and the NLRC4/NAIP clade (Figure 1.7). In basal conditions, 
the NLRs are present in the cytoplasm in an inactive form. Upon stimulation, 
they undergo a conformational change to expose their NACHT domain, they bind 
and recruit the adaptor protein apoptosis speck protein with CARD (ASC) via a 
PYD–PYD interaction (Kufer, Fritz, & Philpott, 2005). The ASC protein is 
composed of an N-terminal PYD and a C-terminal CARD. Through its CARD, ASC 
interacts with the CARD of caspase-1, as shown in figure 1.6 (Srinivasula et al., 
2002).  On the other hand, both NLRP1 and NLRC4 contain a CARD themselves, 
and are potentially able to directly recruit caspase-1. The exact role of ASC in 
these two inflammasomes is not fully understood yet, although experimental 
evidence indicates that ASC could increase the stability of the overall structure 
(Faustin et al., 2007). In the case of NLRP3 and AIM2, however, which do not 
possess a CARD, ASC is strictly required for the formation of their respective 
inflammasomes. AIM2 receptors probably oligomerize and initiate 
inflammasome formation directly around the bound DNA strand (Schroder, 
Muruve, & Tschopp, 2009; Burckstummer et al., 2009). Several agonists have 
been identified that activate the inflammasomes, some of them showing a high 
specificity for a particular NLR. Among them, ATP appears to be a very effective 
57 
 
stimulus for the assembly and activation of the NLRP3 inflammasome (Schroder, 
Zhou, & Tschopp, 2010b). Elevated concentrations of ATP activate P2X7R, 
inducing potassium efflux and causing the recruitment of the pannexin-1 
channel which amplifies this response (Pelegrin & Surprenant, 2009). NLRP3 
inflammasome can also be activated by a variety of different stimuli including 
pore forming toxins such as the antimicrobial peptide LL-37, monosodium urate 
crystals (Martinon, Petrilli, Mayor, Tardivel, & Tschopp, 2006), haemozoin and 
pathogens such as Candida albicans (Hise et al., 2009). Due to the 
heterogeneous nature of the stimuli activating the NLRP3 inflammasome, it has 
been hypothesized that  other receptors, specific to the individual stimuli, are 
activated and proceed to induce NLRP3 inflammasome formation or  that a 
secondary messenger molecule, which is induced by the different activators, in 
turn directly activates NLRP3 (Bryant & Fitzgerald, 2009). Caspases are a large 
family of cysteine proteases that cleave their substrates after an aspartic acid 
residue. The majority of them are known to be involved in the apoptotic 
process; only a few of them, in particular caspase-1, -4, -5 and -12 in humans 
and caspase-1, -11 and -12 in the mouse and in the rat (Kersse, Vanden Berghe, 
Lamkanfi, & Vandenabeele, 2007), have an inflammatory activity playing a key 
role in the maturation and releasing of pro-inflammatory cytokines. Under basal 
conditions, caspase-1 is present in the cells in an inactive form. Once recruited 
within an inflammasome complex, caspase-1 undergo an autoproteolytic 
process, leading to the formation of two subunits of 10 (p10) and 20 (p20) 
kilodaltons (KDa) respectively. Caspase-1 once activated, converts pro-IL-1β, 
which has a molecular weight of approximately 31 KDa, into its active 17 KDa 
form. Caspase-5 and caspase-11 are thought to increase caspase-1 
autoproteolytic activity (Wang et al., 1998). Apart from IL-1β, caspase-1 cleaves 
other substrates such as the inflammatory cytokine IL-18 which is converted 
from the pro-IL-18 of about 24 KDa into its active 18 KDa form or the apoptotic 
caspase-7 (Gu et al., 1997). 
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Figure 1.7 Schematic representation of the NLR and HIN families of receptors. 
The NLRs can be divided into three subgroups: NLRPs, NODs and NLRC4/NAIP. 
They share a typical tripartite structure with an effector domain, which can be 
either a pyrin domain (PYD), a caspase recruitment domain (CARD) or a 
baculovirus IAP repeat (BIR) domain], the central NACHT [NAIP (NLR family, 
apoptosis inhibitory protein), CIITA (class II, major histocompatibility complex, 
transactivator), HET-E (plant het gene product involved in vegetative 
incompatibility) and TP-1 (telomerase-associated protein 1)] domain and the C-
terminal LRR. The majority of the NLRs also contain a NACHT-associated domain 
(NAD). Absent in melanoma 2 (AIM2), which belongs to the haematopoietic 
interferon-inducible nuclear protein (HIN) family of proteins, is characterized by 
an N-terminal PYD and a C-terminal HIN domain. The adaptor protein apoptosis 
speck protein with CARD (ASC) is also represented and consists of a PYD and a 
CARD domain, the further being fundamental for homotypic CARD–CARD 
interactions with caspase-1. Figure adapted from (Skeldon & Saleh, 2011). 
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Figure 1.8 Schematic representation of the NLRP3 and AIM2 inflammasome 
complexes. 
In response to a stimulus, NLRP3 changes conformation to expose its NACHT 
domain, recruits and binds  the adaptor protein apoptosis speck protein with 
CARD (ASC) via a PYD–PYD interaction. ASC, in turn, interacts with caspase1 
through its CARD domain. AIM2 is thought to oligomerize and form its complex 
around its ligand double-stranded (ds) DNA directly. Once recruited within the 
inflammasome complex, caspase-1 is activated through autoproteolytic cleavage 
and can then process its substrates, such as IL-1β. Figure adapted from (Skeldon 
& Saleh, 2011). 
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1.13 ROLE OF THE NLRP3 INFLAMMASOME IN HUMAN DISEASES 
 
The NLRP3 inflammasome has been implicated in the pathogenesis of several 
human inflammatory diseases (Schroder & Tschopp, 2010). Point mutations 
targeting the NACHT domain of the NLRP3 protein have been identified as the 
cause of a group of inflammatory disorders known as the cryopyrin-associated 
periodic syndromes (CAPS) (Conforti-Andreoni, Ricciardi-Castagnoli, & 
Mortellaro, 2011). These include: the familial cold autoinflammatory syndrome 
(FCAS), the Muckle–Wells syndrome (MWS) and the neonatal onset multi-
systemic inflammatory disease/chronic infantile neurological cutaneous articular 
syndrome (NOMID/CINCA) (Aganna et al., 2002). These cryopyrinopathies were 
once thought to be distinct conditions but now are used to describe different 
grades of disease severity (Yu & Leslie, 2011). Clinically, they are characterized 
by recurrent fevers, urticarial-like skin rashes, joint and ocular symptoms, 
amyloidosis and, in the case of NOMID/CINCA, severe neurological complications 
(Hoffman, 2009). In all three phenotypes of CAPS, there is a gain-of-function 
mutation of the NLRP3 gene which results in a constitutive activation of the 
NLRP3 inflammasome and overproduction of IL-1β (Agostini et al., 2004). This 
was also confirmed in in vitro studies that have demonstrated that monocytes 
and macrophages isolated from patients with MWS were able to spontaneously 
release high levels of IL-1β in the absence of any stimuli (Agostini et al., 2004). 
These observations provided a convincing rationale for the use of the 
recombinant form of the naturally occurring IL-1 receptor antagonist (IL-1Ra), 
Anakinra, which has been proved to be extremely successful in the treatment of 
these patients resulting in a complete cessation of clinical symptoms and 
biochemical changes within hours of administration (Hawkins, Lachmann, & 
McDermott, 2003). The NLRP3 inflammasome has been implicated in the 
pathogenesis of several additional autoinflammatory syndromes aside from 
CAPS incliding: Familial Mediterranean fever (FMF), pyogenic arthritis, pyoderma 
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gangrenosum and acne (PAPA) syndrome (Masters, Simon, Aksentijevich, & 
Kastner, 2009). FMF and and pyogenic arthritis are caused by mutations in the 
gene encoding for pyrin, while PAPA syndrome is due to a mutation in the gene 
that encodes for PSTPIP1 (proline-serine-threonine phosphatase interacting 
protein 1), a protein that directly interacts with pyrin. The interaction between 
PSTPIP1 and pyrin has been suggested to be very important for the regulation of 
the NLRP3 activation (Waite et al., 2009). FMF is an autosomal recessive disease 
characterized by recurrent episodes of fever associated with severe abdominal 
pain, pleuritic chest pain, arthritis and a skin rash (Wise, Bennett, Pascual, 
Gillum, & Bowcock, 2000). The PAPA syndrome is inherited in a dominant 
manner, and characterized by painful flares of recurrent sterile arthritis coupled 
to skin manifestations such as pyoderma gangrenosum and acne (Lindor, 
Arsenault, Solomon, Seidman, & McEvoy, 1997). IL-1 antagonism has proved to 
be an effective treatment for both conditions as in CAPS (Brenner, Ruzicka, 
Plewig, Thomas, & Herzer, 2009; Belkhir et al., 2007). More recently, the NLRP3 
inflammasome has been implicated in the development of major diseases such 
as gout, type 2 diabetes and obesity-induced insulin resistance (Kingsbury, 
Conaghan, & McDermott, 2011; Choi & Nakahira, 2011) and many other studies 
are currently exploring the role of this complex system in several human 
diseases. 
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Table 1.3 Clinical characteristics of cryopyrinopathies. 
 
Cryopyrinopathies are a group of rare autoinflammatory diseases characterized 
by a mutation in the gene that encodes for NLRP3. They include: the familial cold 
autoinflammatory syndrome (FCAS), the Muckle–Wells syndrome (MWS) and 
the chronic infantile neurologic cutaneous articular syndrome (also termed 
neonatal-onset multisystemic inflammatory disease) (CINCA/NOMID). They were 
initially considered different disease entities but are now recognized as different 
phenotypes of the same disease. Table adapted from the following 
article:”Cryopyrinopathies: update on pathogenesis and treatment” (Neven, 
Prieur, & Quartier dit, 2008). 
 
Feature FCAS MWS CINCA (NOMID) 
Inheritance 
Autosomal-
dominant 
Autosomal-dominant 
(typical) 
Or de novo (rare) 
De novo (typical) 
Or autosomal-
dominant (rare) 
Severity Low Medium High 
Frequency of 
fever and/ or 
rash 
Usually daily 
symptoms with 
circadian rhythm 
Variable: rare to daily 
symptoms with 
circadian rhythm 
Variable: usually rare 
fever with daily rash 
Joint 
involvement 
Arthralgia Arthralgia, arthritis 
Arthralgia, arthritis, 
overgrowth 
arthropathy 
Neurological 
involvement 
none none 
Chronic aseptic 
meningitis 
(headache, possible 
mental delay) 
Eye 
involvement 
Conjunctivitis Conjunctivitis, uveitis 
Uveitis, papillary 
edema, possible optic 
neuritis 
Deafness No Frequent (60-70%) Frequent (>60%) 
Amyloidosis No Frequent (~25%) Frequent (~25%) 
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1.14 ROLE OF P2X7R IN EXPERIMENTAL AND HUMAN 
GLOMERULONEPHRITIS 
 
Glomerulonephritis (GN) represents still a leading cause of end-stage renal 
disease and its current treatment relies on non-specific and toxic 
immunosuppression which may lead to severe side effects, including life-
threatening sepsis and reduced fertility (Tam, 2006). GN is characterised by 
inflammation and cell proliferation in the glomerulus, although injury typically 
extends to the renal tubules, interstitium and vasculature (Hricik, Chung-Park, & 
Sedor, 1998). Animal models of glomerulonephritis have been extremely useful 
to understand the pathogenesis of this disease. It is now well established that 
most cases of glomerulonephritis are secondary to an immunological response 
to a variety of endogenous and exogenous antigens. Deposition of antibodies 
against these antigens, in turn, activates a number of biological responses such 
as complement activation, leukocytes recruitment, cytokine release that result 
in glomerular inflammation and injury (Couser, 1999). The involvement of 
proinflammatory cytokines such as IL-1β, MCP-1 and TNF-α in the pathogenesis 
of most forms of glomerulonephritis is well documented in literature and 
treatments with either IL-1β receptor antagonist or TNF-α inhibitor have been 
found to be effective in reducing the severity of the disease in animal models of 
GN (Lan, Nikolic-Paterson, Zarama, Vannice, & Atkins, 1993; Karkar, Smith, & 
Pusey, 2001). P2X7R is not expressed or expressed at a very low level in normal 
kidney tissue (Hillman, Burnstock, & Unwin, 2005); cultured mesangial cells 
express the receptor when stimulated with TNF-α (Harada, Chan, Loesch, Unwin, 
& Burnstock, 2000) while in podocytes and in renal tubular cells an upregulation 
of the receptor has been shown under diseased conditions (Vonend et al., 2004; 
Turner et al., 2007). P2X7R expression in renal diseases was first described in a 
rat model of hypertension and diabete mellitus (Vonend et al., 2004). In their 
study, Vonend et al. showed that P2X7R was poorly expressed in normal rat 
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glomeruli, while a significant increase in P2X7R expression was detectable at 12 
weeks in a rat transgenic model of renin-dependent hypertension. A significant 
increase of glomerular P2X7R expression was also observed at 6 and 9 weeks in 
rats with streptozotocin-induced diabetes. The role of P2X7R and TGF-β in 
fibrosis was investigated in a mouse model of unilateral ureteral obstruction 
(UUO) (Goncalves et al., 2006). Goncalves et al. demonstrated that both the 
myofibroblast accumulation and collagen deposition were markedly reduced in 
P2X7 deficient mice compared with the WT ones in the UUO model. In this 
model, P2X7R was expressed only in tubular epithelial cells at day 7 of UUO WT 
mice. P2X7R expression appears to be significantly increased in both rat and 
mouse glomeruli in the animal model of accelerated nephrotoxic nephritis as 
well as in patients with lupus glomerulonephritis (Turner et al., 2007) suggesting 
an important role of this receptor in the pathogenesis of this disease. 
Furthermore, it has been reported that  P2X7 deficient mice develop a much less 
severe glomerulonephritis when injected with nephrotoxic globulin compared to 
the wild type mice in terms of a reduced glomerular macrophage infiltration, 
glomerular thrombosis, proteinuria and improved renal function (Taylor et al., 
2009). Similarly, pharmacologic inhibition of P2X7R using the antagonist A-
438079 has been shown to prevent the development of NTN in rats injected 
with nephrotoxic serum (Taylor et al., 2009). These studies demonstrated that 
there is increased renal P2X7R expression in glomerulonephritis and that P2X7R 
has a role in mediating renal inflammation representing therefore a potential 
target for the treatment of glomerulonephritis. 
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1.15 THE RAT MODEL OF NEPHROTOXIC NEPHRITIS 
 
The first animal model of glomerulonephritis has been established in 1900 by 
Lindeman who injected rabbits with heterologous antiserum to rabbit kidney 
raised in guinea pigs (Hoedemaeker & Weening, 1989). Since then, several 
animal models of glomerulonephritis have been developed. A reproducible 
model of crescentic glomerulonephritis characterized by acute glomerular 
inflammation and subsequent glomerulosclerosis and tubule-interstitial scarring 
leading to renal failure has been described by several research groups (Fujinaka 
et al., 1997; Tam et al., 1999). The principal method to induce crescentic 
glomerulonephritis (CRGN) in animals is the injection of a heterologous antibody 
raised against a preparation of glomerular antigen (Tam et al., 1999). The 
binding of the heterologous antibody to the glomerular basement membrane 
generates an acute injury which is followed by a second phase of injury in which 
there is an autologous immune response against the heterologous antibody 
(Sheerin, Springall, Abe, & Sacks, 2001). In the accelerated model of nephrotoxic 
nephritis this second phase is accelerated by preimmunization of animals with 
heterologous immunoglobulin (Sato et al., 1993).  In the rat model of NTN 
described by Tam et al., glomerulonephritis is induced in Wistar Kyoto rats by a 
single intravenous injection of 0.1 ml rabbit antiglomerular basement membrane 
antiserum. At day four from the injection of nephrotoxic serum, rats develop 
albuminuria and glomerular fibrinoid necrosis can be seen in kidney histology 
preparations. By day eleven at least 60% of glomeruli show the presence of 
cellular crescents. By six weeks, rats develop renal failure with more than 90% of 
glomeruli showing glomerulosclerosis.  
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Strain susceptibility to nephrotoxic nephritis 
One of the most interesting features of the rat NTN model is that WKY rats are 
uniquely susceptible to NTN, developing progressive proteinuria and 
proliferative necrotising crescentic glomerulonephritis at doses of NTS that are 
sub-nephritogenic in the other rat strains such as Lewis, Wistar and Brown 
Norway (Kawasaki, Yaoita, Yamamoto, & Kihara, 1992). The unique susceptibility 
demonstrated by the WKY rat compared to the Lewis rat, with which it shares 
the same MHC haplotype, along with the highly reproducible nature of the NTN 
model led to the study of its underlying genetic determinants (Aitman et al., 
2006). The F1 cross performed between the WKY and Lewis rats had 
intermediate phenotypes for Crgn disease including crescent formation, 
proteinuria and macrophage infiltration whilst the F2 generation demonstrated 
phenotypes that spanned the whole range of the phenotypes observed in the 
WKY and Lewis parental strains (Aitman et al., 2006). Analysis in the F2 rats 
demonstrated that crescent formation was highly correlated with proteinuria 
and macrophage infiltration and all the phenotypes were highly heritable 
(Behmoaras et al., 2010). The genome screen performed for NTN susceptibility 
loci in the F2 generation found two major quantitative trait loci (QTL) on 
chromosomes 13 and 16 which were designated as crescentic 
glomerulonephritis 1 (Crgn1) and 2 (Crgn2) (Behmoaras et al., 2010). Both loci 
were linked to crescent formation and proteinuria (with highly significant 
logarithm of odds (LOD) scores 7.4-9.1) and infiltration of macrophages was 
linked to Crgn1. A further 5 loci (Crgn3-7) were also identified with LOD scores > 
3. Haplotype mapping was used to positionally clone Fcgr3 as the candidate 
gene for Crgn1. In the WKY rat, deletion of the rat-specific Fcgr3 paralogue, 
Fcgr3-related sequence (Fcgr3-rs) was identified as the molecular basis for the 
QTL whilst in humans, low copy number of FCGR3B, an orthologue of rat Fcgr3, 
was associated with glomerulonephritis (Aitman et al., 2006). In order to map 
candidate genes responsible for the phenotype controlled by the QTL and to 
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characterize the biology of the QTL genes, Behmoaras et al have generated 
congenic strains. Congenic strains are new inbred strains generated by 
backcrossing one strain onto another to produce a rat with a particular genomic 
region from one strain whilst the remainder of its genome is from the other 
(Markel et al., 1997). The congenic lines for Crgn2 were generated by 
backcrossing (WKYxLEW) F1 rats onto the recipient WKY or LEW parental strains 
for nine generations (Behmoaras et al., 2010). As shown in figure 1.10, induction 
of nephrotoxic nephritis in WKY.LCrgn1 and WKY.LCrgn2 rats, generated by 
introgression of Crgn1 or Crgn2 respectively from the non-susceptible Lewis 
strain onto the WKY background produced markedly fewer glomerular crescents 
compared to control animals. Bone marrow transplant experiments 
demonstrated that susceptibility to crescent formation can be transferred by 
bone marrow cells. Indeed, Lewis rats that receive WKY bone marrow develop 
crescents but fewer compared to WKY rats receiving isologous bone marrow 
(Smith et al., 2007). It has been also shown however that not only circulating 
cells but also intrinsic renal cells contribute to this susceptibility as 
demonstrated by kidney transplant experiments. When kidneys were 
transplanted from WKY to LEW rats and vice versa, acute rejection occurred 
despite the shared MHC haplotype between the strains. F1 rats derived from 
crossing WKY with LEW exhibit an intermediate susceptibility phenotype to NTN 
and transplants from the parental strains into the F1 rat were successful with no 
rejection seen (Smith et al., 2007). In the analysis of these transplants, the 
severity of disease in the transplanted kidney was compared with the native 
kidney to mitigate the effects of the transplantation process. These results found 
that following the injection of NTS, LEW kidneys developed Crgn when 
transplanted into the F1 rats. However the severity relative to native kidneys 
was less than that of transplanted WKY kidneys indicating that the kidney itself 
contributed to susceptibility to Crgn (Smith et al., 2007). If susceptibility was 
mediated just by circulating cells, the degree of disease should have been the 
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same whether a LEW or WKY kidney was transplanted into the F1 rats. The data 
therefore showed that whilst bone marrow derived cells do make the major 
contributions to disease; the susceptibility to Crgn is not solely dependent upon 
them (Smith et al., 2007).  
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Figure 1.9 Renal histology in WKY and LEW rats at day 10 from NTS injection. 
Injection of a small dose of nephrotoxic serum in WKY rats induces a rapid onset 
of nephrotoxic nephritis with presence of crescents in 80% of glomeruli at day 
10. The same dose of NTS induces only mild glomerular hypercellularity with no 
crescents in Lewis rats. Macrophages infiltration is shown by 
immunohistochemistry using ED-1 monoclonal antibody. 
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Figure 1.10 Percentage of glomerular crescents in single and double congenic 
strains in comparison with parental WKY rats. 
 Introgression of Lew Crgn2 into the WKY recipients reduces by 8% the number 
of crescents; introgression of Crgn1 leads to a reduction of 18%, while the 
introgression of both Crgn1 and Crgn2 has a synergistic effect with a reduction 
by 34% of glomerular crescents. Figure adapted from the following article: 
”Genetic Loci Modulate Macrophage Activity and Glomerular Damage in 
Experimental Glomerulonephritis” (Behmoaras et al., 2010). 
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1.16 ROLE OF BONE MARROW DERIVED MACROPHAGES IN 
CRESCENTIC GLOMERULONEPHRITIS 
 
Macrophages are known to play a central role in the pathophysiology of 
crescentic glomerulonephritis (Cook et al., 1999). Indeed, 
monocytes/macrophages represent the major cell type in the glomerular 
infiltrate and macrophage depletion studies have shown that the accumulation 
correlates with the degree of histological and functional injury (Nikolic-Paterson 
& Atkins, 2001). As previously discussed, bone marrow transplant experiments 
have demonstrated that the susceptibility to crescent formation can be 
transferred, so that the glomerulonephritis resistant rats Lewis that receive WKY 
bone marrow develop crescents but fewer compared to WKY rats receiving 
autologous bone marrow (Smith et al., 2007).  Macrophages migrate into the 
inflamed glomerulus and once activated, release proinflammatory cytokines, 
reactive oxygen species and proteases that disrupt the integrity of the 
glomerular basement membrane and finally lead to fibrin deposition (Lai et al., 
2001). Macrophages display different phenotypes that can switch in response to 
their micro-environment (Stout et al., 2005). It has been proposed by many 
researchers that macrophages develop into two major functional subsets that 
display inflammatory versus anti-inflammatory patterns of function in 
association with Th1 or Th2 driven responses respectively (Goerdt et al., 1999). 
This finding is very important because it means that is not only the number of 
macrophages influences the progression of the disease but also their phenotypic 
properties. Defining these phenotypic variants and how they may be induced 
could be extremely important in altering the outcome of experimental and 
human glomerulonephritis (Chavele et al., 2010). 
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1.17 PROJECT AIMS 
 
Given that P2X7R is thought to play an important role in glomerulonephritis, 
understanding the cell signalling cascade following P2X7R activation and the role 
of P2X7-mediated inflammasome activation in the pathogenesis of the disease 
can be relevant to identify new mechanisms of disease progression and new 
potential therapeutic targets. Thus, my key hypothesis is that P2X7R and the 
NLRP3 inflammasome activation are critical in the pathogenesis of 
glomerulonephritis. The study of the P2X7R mediated cytokine production and 
cell signalling cascade will provide a deeper understanding of the mechanisms 
relevant to the hypothesis. 
Specific project aims: 
1. To study and compare the processing and release of IL-1β and IL-18 in 
response to P2X7R agonists in macrophages from WT and P2X7 deficient 
mice. 
2. To characterize the cell signalling pathways that are switched on in 
response to ATP stimulation in macrophages from WT and P2X7 deficient 
mice. 
3. To analyse and compare the expression of inflammasome genes and 
downstream activities in macrophages from glomerulonephritis-
susceptible (WKY) and glomerulonephritis-resistant (LEW) rats. 
4. To identify a genetic link between inflammasome activation and disease 
severity in the rat model of nephrotoxic nephritis. 
 
 
 
73 
 
CHAPTER TWO-MATHERIALS AND METHODS 
 
 
2.1 P2X7 DEFICIENT AND CONTROL MICE 
 
Mice used in the experiments described in this thesis were housed in the 
Biological Services Unit at Hammersmith Hospital. Mice were kept in a standard 
animal house environment and experiments were performed according to 
institutional and Home Office guidelines. Experimental groups were matched for 
age, gender and strain. Two to three-month old male wild-type (WT) and P2X7 
receptor knockout mice (P2X7−/−) both from GlaxoSmithKline (GSK) and from 
Pfizer were sacrificed by CO2 asphyxiation in accordance with local institutional 
guidelines. Homozygous P2X7 receptor deficient mice were bred on a 
background of C57BL/6 for at least 7 generations. The Pfizer P2X7 knock out line 
was purchased from the Jackson laboratory, while the GSK line was a kind gift 
from the company (Chessell et al., 2005b). Genomic DNA was isolated from the 
tails of WT and P2X7−/− animals, and the genotypes were confirmed by PCR 
analysis. 
 
2.2 WKY, SINGLE CONGENIC, DOUBLE CONGENIC AND LEWIS RAT 
STRAINS 
 
Wistar Kyoto (WKY) and Lewis (LEW) rats were purchased from Charles River 
(Margate, UK).  Congenic strains are new inbred strains generated by 
backcrossing one strain onto another to produce a rat with a particular genomic 
region from one strain whilst the remainder of its genome is from the other. The 
double-congenic line, a single strain in which both Crgn1 and Crgn2 were 
introgressed from Lewis rats on the WKY genetic background, was previously 
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constructed by Dr Behmoaras et al. as follows: WKY.LCrgn1 and WKY.LCrgn2 
strains were crossed to produce an F1 generation. The F1 rats were backcrossed 
with WKY.LCrgn1. The F2 rats heterozygous for Crgn2 and homozygous for Crgn1 
were crossed by brother–sister mating to obtain an F3 generation double 
congenic for LEW Crgn1 and LEW Crgn2 on a WKY background. The single 
congenic line WL16 was generated by introgression of Crgn2 from Lewis rats 
onto a WKY genetic background, while the single congenic strain LW16 was 
created by introgression of Crgn2 from WKY rats onto a Lewis background 
(Behmoaras et al., 2008; Behmoaras et al., 2010). 
 
2.3 PREPARATION OF MURINE AND RAT BONE MARROW DERIVED 
MACROPHAGES 
 
After sacrifice, whole mice or rats were soaked in 100% ethanol and taken to the 
tissue culture hood. Femurs and tibiae were isolated and cleaned from hair and 
soft tissues, both ends of the cleaned bones were then cut and bone marrow 
cells were flushed out with a 20 gauge needle using 10 mL of cold Hanks buffer 
and collected into a 50 mL centrifuge tube. Cells were then spinned down at 
1500 rpm (300 x g) for five minutes at 40C and resuspended in 10 mL Hanks 
buffer. The 50 mL centrifuge tube was then placed in the CO2 incubator in a 
horizontal position for 10 minutes to hypotonically lyse the red blood cells.  
After that, cells were centrifuged again at 1500 rpm (300 x g) for 5 minutes, the 
supernatant was aspirated and the cell pellet was resuspended in DMEM 
(Invitrogen, UK) culture medium containing 25 mM Hepes, 25% L929 cell line 
conditioned medium, 25% FBS, 2 mM L-glutamine, 100 IU/mL penicillin and 100 
µg/mL streptomycin. The L929 conditioned medium, rich in Macrophage Colony 
Stimulating Factor (M-CSF) was prepared by culturing the L929 cell line, a murine 
fibroblast cell line available in the lab, in DMEM supplemented with 10% FBS, 2 
75 
 
mM L-glutamine, 100 IU penicillin and 100 µg/mL streptomycin. The bone 
marrow cells were then cultured in T150 tissue culture flasks for 5 days. At day 
5, cells were removed from the flasks after 30 minutes- one hour incubation 
with cell dissociation buffer, counted with a hemocytometer and 1x106 cells 
were plated into each well of a 6 well plate containing 2 mL of pre-warmed full 
culture medium. Cells were left to adhere overnight and on day 6 the full culture 
medium was replaced with serum free DMEM prior to any stimulations. 
 
 
2.4 STIMULATION OF BONE MARROW DERIVED MACROPHAGES 
 
In order to analyse the secretion of IL-1β and IL-18, both murine and rat bone 
marrow derived macrophages after five days of differentiation in L929 medium, 
were non-enzymatically detached by cell dissociation buffer (Invitrogen, UK) and 
counted on a haemocytometer. Macrophages were then plated into six-well 
plates at a density of 1 x 106 cells per well in complete L929 conditioned medium 
(3 ml per well) and incubated at 370 C overnight to let them adhere. On day 6 of 
differentiation, the medium was aspirated and macrophages were primed for 
five hours, unless differently specified, with Lipopolysaccharides from 
Escherichia Coli purified by phenol extraction (LPS) (Sigma, UK) used at a 
concentration of 1 µg/mL in serum free DMEM supplemented with 100 IU of 
penicillin and 100 µg/mL of streptomycin. After LPS priming, the medium was 
aspirated, cells were washed with HBSS and fresh serum free medium containing 
ATP at a concentration of 5 mM was added. After thirty minutes of ATP 
stimulation, both culture medium and cell layers were collected by scraping and 
samples were then stored at -200C. To evaluate the effects of ATP stimulation on 
the phosphorylation of proteins, macrophages at day 5 of differentiation, were 
76 
 
detached by cell dissociation buffer and counted using a haemocytometer.  For 
Western blotting detection of phosphorylated proteins, about one million cells 
per well were seeded into six-well plates in complete L929 conditioned medium 
and incubated at 370C for 24 hours. The day before the stimulation with ATP, 
macrophages were serum starved overnight using DMEM supplemented with 
100 IU of penicillin and 100 µg/mL of streptomycin. Prior to ATP stimulation, the 
medium was aspirated, cells were washed once with 1 ml of pre-warmed HBSS 
and 1 ml of serum free medium containing ATP at a concentration of 5 mM was 
added. At the end of ATP stimulation cell lysates were prepared as described in 
the Western blotting section. When P2X7R antagonist was used, it was added in 
the medium together with ATP at a concentration of 3 µM. 
 
2.5 ISOLATION AND CULTURE OF RAT NEPHRITIC GLOMERULI 
 
Glomeruli were isolated sequentially using stainless steel meshes of the 
following pore sizes: 250, 150 and 75 μm. A wash solution of cold 1 x PBS was 
used. With this process, connective tissue and tubular fragments are retained by 
the first two sieves, whereas glomeruli are retained by the final sieve. Using a 
Pasteur pipette and small amounts of buffered saline, glomeruli were collected 
from the final sieve by repeated rinsing and aspiration, followed by 
centrifugation at 1500 rpm for 5 minutes, and suspension of the glomerular 
pellet in DMEM supplemented with penicillin and streptomycin. Glomerular 
yield was determined by counting the number of glomeruli in three separate 10 
μl samples of each preparation under the light microscope at × 100 power. A 
number of 1 x 104 glomeruli were seeded into each well of a six-well plate using 
one ml of DMEM per well. After 48 hours of incubation at 370C, supernatants 
and cell layers were collected and stored at -200C for future analysis. 
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2.6 INDUCTION OF NEPHROTOXIC NEPHRITIS IN RATS 
 
 Nephrotoxic nephritis (NTN) was induced in male rats weighing 200-250 g by a 
single intravenous injection of 0.1 ml of nephrotoxic serum (rabbit anti-rat GBM 
anti-serum). Four days after nephrotoxic serum injection, rats were sacrificed 
and kidneys were removed for glomeruli isolation. The nephrotoxic serum 
injection is known to cause a rapid influx of monocytes/macrophages into 
glomeruli within hours of administration, followed by segmental fibrinoid 
necrosis by day 4. This is a well-chatacterized model with the onset of detectable 
proteinuria and maximal macrophage infiltration of glomeruli occurring 4 days 
after the nephrotoxic serum injection (Tam et al., 1999). 
 
 
2.7 RNA EXTRACTION AND qRT-PCR 
 
2.7.1 Extraction of RNA 
 
Precautions against contaminating samples with RNAses were observed. The 
bench working area was wiped with RNAse Zap (Ambion Ltd., UK), disposable 
gloves were worn at all times and sterile disposable plasticwear and pipettes 
reserved for RNA work only were used. Total RNA was extracted from 
macrophages or isolated glomeruli using Trizol/chloroform extraction and 
isopropyl alcohol precipitation. After the required time of incubation in the 
presence or absence of a stimulus, cell culture medium was removed by 
aspiration and about 1 x 106 cells  were resuspended in 1 ml of Trizol (Invitrogen 
Ltd., Renfrew, UK) and passed through a pipette several times to ensure a 
homogeneous suspension. Two hundred microliters of chloroform were added 
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and the samples were mixed thoroughly, incubated for 3 minutes at room 
temperature and then centrifuged at 12000 x g for 15 minutes at 40C. After 
centrifugation, the upper aqueous phase containing the RNA was removed to a 
separate clean tube and the lower organic phase was discarded. RNA was 
precipitated from the aqueous phase by addition of 500 μl of isopropyl alcohol 
(Sigma-Aldrich Co., Ltd., Poole, UK), incubated at room temperature for 10 
minutes and then centrifuged at 12000 x g for 10 minutes (40C). The resulting 
RNA pellet was washed with 75% ethanol and centrifuged at 7500 x g for 5 
minutes (40C). The final pellet was air dried and resuspended in RNAse free 
distilled water (Promega UK Ltd., Southampton, UK). RNA concentration and 
purity were determined by measuring the absorbance of RNA in water at 260 
nm using a spectrophotometer (Beckman DU 650 Spectrophotometer, High 
Wickam, Bucks, UK). RNA concentration was calculated using the formula A260 * 
40 = μg RNA/ml. In distilled water, the RNA had an A260/280 ratio of 1.9-2.1 
indicating RNA free of contamination. RNA samples were stored at -800C until 
further use. 
 
2.7.2 Synthesis of copy DNA (cDNA) 
 
One μg of total RNA was reverse transcribed with 0.5 μg oligo(dt) 12-18 primer 
and a first strand cDNA synthesis kit, Superscript II RNase H- reverse 
transcriptase (Invitrogen Ltd., Renfrew, UK). The reaction buffer contained 20 
mM Tris-HCl (pH 8.4), 50 mM KCl, 500 μM each of dATP, dCTP, dGTP, dTTP, 5 
mM Dithiothreitol, 40 units of RNaseOUTTM Recombinant Ribonuclease Inhibitor 
and 50 units of superscriptTM reverse transcriptase in a 20 μl reaction volume. 
The reaction was incubated for 50 minutes at 420C in a Hybaid sprint 
thermocycler (Thermo Electron Molecular Biology, USA). To inactivate the RT 
enzyme, samples were heated to 700C for 10 minutes, storage was at -200C. 
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2.7.3 Real-time PCR amplification 
 
The resulting cDNA transcripts were used for PCR amplification using the Roche 
Lightcycler (Roche diagnostics, Penzberg, Germany) and QuantiTect SYBR Green 
PCR kit (Qiagen, Crawley, UK). QuantiTect SYBR Green I PCR master mix contains 
SYBR Green I, HotStarTaq DNA Polymerase and a dNTP mix (including dUTP). 
SYBR Green I, present in the PCR mix, only emits light when bound to double-
stranded DNA and once bound, it is excited at 494 nm and emits light at 521 nm. 
The lightcycler fluorimeter monitors emissions at 521 nm and values are 
recorded by a computer (Dell Computers, Bracknell, UK). Each PCR reaction mix 
contained 1 μl cDNA template, 5 pmol forward and 5 pmol reverse primers, 10 
μl of 2x QuantiTect SYBR Green I PCR master mix and distilled water to a final 
volume of 20 μl. Primer sequences are indicated in Table 2. The PCR cycling 
conditions were initial denaturation at 950C for 15 minutes, denaturation at 940C 
for 15 seconds, annealing at 600C for 20 seconds and extension at 720C for 30 
seconds. The temperature of fluorescence acquisition was set at 780C for 5 
seconds, 200C below the product melting temperature. The product melting 
temperature was determined in a test run by examining the melting curve. All 
experiments were performed in duplicate and for each sample the gene of 
interest and the control gene were run in parallel. A ratio of relative abundance 
of the gene of interest to the constitutively expressed gene hypoxanthine 
phosphoribosyl transferase (HPRT) was calculated by the Lightcycler Relative 
Quantification Software version 1.0 (RelQuant) (Roche Diagnostics, Penzberg, 
Germany). HPRT was chosen as a control gene for the quantification of P2X7 
mRNA levels because its expression level is similar to P2X7 gene. In other 
reactions the house keeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as control gene. After completion of the PCR amplification 
cycles, a melting curve was determined for each PCR product. Each double-
stranded DNA has its own melting temperature (Tm) based on the strand length 
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and the G-C content. Therefore melting curve analysis can be used to identify 
unwanted by-products of the PCR reaction such as primer dimers. A melting 
curve is produced by plotting fluorescence against temperature. The PCR 
products were heated to 650C and then the temperature was increased slowly 
(0.50C per second) whilst fluorescence was continually monitored. At low 
temperatures all DNA is double-stranded, SYBR Green I is binding and 
fluorescence is maximal. As the temperature increases, DNA products are 
denaturated and the fluorescence decreases. Primer dimers and other short 
non-specific products can be distinguished because they usually melt at lower 
temperatures than the desired product. 
 
2.74 Agarose gel electrophoresis 
 
Agarose gel electrophoresis of PCR amplified DNA samples was performed in 
electrophoresis tanks with 1xTAE buffer used as the gel and running buffer. Gels 
were prepared by heating 100ml of 1xTAE buffer with 1.5-2% agarose added 
until the agarose was dissolved. Following cooling in running water, 1ìl of 
ethidium bromide was added to the agarose-1xTAE buffer mix and the mixture 
poured into a gel mould. DNA samples were mixed using 2ìl Orange G per 10ìl 
PCR product and loaded into the agarose gel. A 2-log ladder (New England 
Biolabs) was used as a DNA size standard. The samples were electrophoresed at 
120V for 1 hour and the gels visualised on an ultra-violet transilluminator (Bio-
Rad, Hemel Hempstead, Hertfordshire, UK) and photographed using the gel doc 
system (Bio-Rad). 
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Table 2 Primer sequences used for qPCR. 
Gene Forward primer Reverse primer 
IL-1b CTTTTCTGTGTGATGCCCCT GTGAAGATGGTGTTTGGGCT 
IL-18 ACCGCAGTAATACGGAGCAT TAGGGTCACAGCCAGTCCTC 
IL-18 bp ATGAGACACTGTGGCTGTGC ACTGCTGGAGACCAGGAAGA 
Pyrin (ASC) GCAATGTGCTGACTGAAGGA TGTTCCAGGTCTGTCACCAA 
Caspase-1 GGAGGGAATATGTGGGATCA CCCTCTTCGGAGTTCCCTAC 
P2RX7 GTGCCATTCTGACCAGGGTTGTATAAA GCCACCTCTGTAAAGTTCTCTCCGATT 
MMP-9 TTATTGTGAGCATCCCTAGGG AGTGTCCGAGGAAGATACTTG 
HPRT GCTACCTGCTGGATTACATTA CCACTTTCGCTGATGACACAA 
GAPDH GCCATCAATGACCCCTTCAT GAGGGGGCAGAGATGATGAC 
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2.8 WESTERN BLOTTING 
 
2.8.1 Cell lysate preparation 
 
Lysis buffer was prepared as follows: 10 mM Tris-HCl pH 7.6, 5mM EDTA, 50 mM 
NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 100 µM Na3VO4, 1% Triton-
X100, 1 mM phenylmethylsulfonyl fluoride. Immediately before use, 1 µg/ml 
pepstatin, 2 µg/ml aprotinin, 5 µg/ml leupeptin and 5 µg/ml antipain were 
added. The cell monolayer was then washed once with cold 1xPBS and lysis 
buffer was added; cells were scraped and transferred to an eppendorf tube and 
left on ice for twenty minutes to ensure complete lysis of the cells. Lysates were 
then clarified by centrifugation (13,500 g, 20 minutes) and the supernatants 
were transferred to fresh tubes and stored at -200C. To analyse excreted 
proteins, cells were scraped and both cells and supernatant were collected and 
stored at -20 0C. The supernatant containing the cells was then filtered using 
Amicon ultra centrifugal filters for protein purification and concentration 
(Millipore) and the concentrated sample was collected and stored at -200C.  The 
concentration of protein in cell lysates was measured using the BCA TM Protein 
assay kit (Pierce) following the manufacturer’s instructions. 
 
2.8.2 Electrophoresis, transfer and developing 
 
Cell lysates were diluted with 5x sample buffer containing 200 mM Tris-HCl, 6% 
SDS, 2mM EDTA, 4% 2- Mercaptoethanol, 10% glycerol and boiled for 10 
minutes. The samples were then resolved by SDS polyacrylamide gel 
electrophoresis (PAGE). Seven percent resolving gels were prepared to detect 
proteins with a high molecular weight, such as mTOR. Fifteen percent resolving 
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gels were used to detect proteins with a low molecular weight, such as cleaved 
IL-1β and cleaved caspase 1. On the basis of the percentage of the running gel 
selected, gels were prepared using varying volumes of the following 
components: distilled water, 1.5M Tris-HCl solution, pH 8.8, 30% 
acrylamide/bisacrylamide solution, 10% Sodium dodecyl sulphate (SDS), 10% 
APS and tetramethylethylenediamine (TEMED). When the resolving gel had 
polymerized, the stacking gel (5%) was prepared using the following 
components: distilled water, 1 M Tris-HCl solution, pH 6.8, 30% 
acrylamide/bisacrylamide solution, 10% Sodium dodecyl sulphate (SDS), 10% 
APS and tetramethylethylenediamine (TEMED). SDS-PAGE electrophoresis was 
carried out at 100V using the following running buffer: (0.025M Tris, 0.192 M 
glycine, 0.1% SDS). Transfer of protein from SDS- PAGE gel onto polyvinylidene 
difluoride (PVDF) membrane was carried out using cold 1x transfer buffer (48 
mM Tris, 412 µM Glycine, 0.03% SDS and 0.1% Methanol) at 100 V for 1 hour. 
Membranes were then blocked for 1 hour with 5% skimmed dry milk prepared in 
TBS containing 0.1% Tween-20 ( TBST, pH 7.6) and membranes were then 
incubated with primary antibody diluted by 1:1000 with 5% Bovine Serum 
Albumin (BSA) in TBS/1% Tween 20 overnight. Immunoreactive proteins were 
identified using polyclonal goat anti-mouse or anti rabbit antibodies horseradish 
peroxidase (HRP) (Dako). Secondary antibodies were diluted 1:3000 with 5% dry 
milk in TBST.  The incubation period for secondary antibodies was one hour. 
Visualization of these immunoreactive proteins was achieved with the ECL 
(enzyme-linked chemiluminescence) system (Amersham). Films were exposed 
and developed using a CanoScan 8000F scanner. 
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2.8.3 Removal of bound antibodies from membranes 
 
Membranes previously immunoprobed were incubated in stripping buffer 
(62mm Tris ph 6.8, 2% SDS, 100 mM 2-Mercaptoethanol) for 15 minutes twice at 
60°C, then washed twice with TBST for 10 minutes and blocked for 30 minutes 
with 5% dry milk prior to reprobe them. 
 
2.84 Densitometry 
 
For some of the most relevant Western blot results, including caspase-1 
expression in macrophages from WT and P2X7 deficient mice, phospho-S6, 
phospho-mTOR and phospho-ERK levels in response to ATP stimulation in 
macrophages from WT and P2X7 deficient mice, densitometry was performed 
on scanned immunoblot images using the ImageJ software. The gel analysis tool 
was used to obtain the absolute intensity for each experimental band and 
corresponding actin band used as control.  Relative intensity for each 
experimental band was calculated by normalizing the experimental absolute 
intensity to the corresponding control absolute intensity.   
 
2.9 ENZYME-LYNKED IMMUNOSORBENT ASSAY (ELISA) 
 
To quantify cytokines secreted by macrophages, supernatants were analysed by 
sandwich ELISA using kits from R&D Systems. A 96 well microplate was coated 
with the appropriate dilution of the capture antibody and incubated overnight. 
The wells were then washed with the appropriate wash buffer and blocked for 
one hour with reagent diluent containing 1% BSA. After further washing, serial 
dilutions of the standard and the samples were loaded into the wells in duplicate 
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and incubated at room temperature for two hours. The plates were then 
washed and detection antibody in the appropriate dilution was added to the 
wells and incubated for two hours at room temperature. The plates were then 
washed again and working dilution of Streptavidin-HRP was added. After 20 
minutes incubation and further washing substrate solution was added to the 
plates for 20 minutes. The colorimetric reaction was then stopped with the 
addition of stop solution and the optical density of each well was determined 
using a microplate reader set to 450 nm. 
 
 
2.10 TRANSFECTION OF MACROPHAGES WITH SMALL 
INTERFERING RNA (siRNA) 
 
siRNA knockdown was carried out to silence JUND expression in BMDMs from 
WKY rats. The siRNA used was siGENOME SMARTpool, rat JUND (24518) M-
092127-00-0010, 10nmol (Dharmacon, Lafayette, CO, USA) and the scrambled 
control siRNA was siGENOME Non-targeting siRNA Pool #1 D-001206-13-20, 
20nmol (Dharmacon, Lafayette, CO, USA). siRNA was resuspended as per 
manufacturer’s instructions by adding RNase-free water to achieve a working 
concentration of 20 nmol and then incubated at room temperature on an orbital 
mixer for 30 minutes. Aliquots were made to ensure minimisation of freeze thaw 
events on the siRNA. Transfection with siRNA was performed on day 6 of 
culture. To prepare the transfection mixture, 2.64 ml Optimem (Invitrogen) was 
incubated with 60 μl Dharmafect 1 (Dharmacon) for 5 minutes at room 
temperature. At the same time 240μl of Optimem was incubated with 60μl 
siRNA (20μM) for 5 minutes at room temperature. The two preparations were 
then mixed and incubated at room temperature for 20 minutes with frequent 
mixing by tube inversion to allow the integration of siRNA particles into the 
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liposomal particles contained within Dharmafect transfection reagent. 
Meanwhile the media in the 6 well culture plates was aspirated, the cells 
washed with pre-warmed DMEM and then 1.5 ml DMEM with no 
supplementation was added to each well. Five hundred microlitres of the 
transfection mixture was then added to each well and mixed resulting in a final 
siRNA concentration of 100nM. The cells were incubated for 48 hours in a 5% 
CO2 incubator at 37oC. On day 8 the cells were primed with LPS 1 μg/ml for 1 
hour and then stimulated with ATP 5 mM for 30 minutes. 
 
2.11 MASS SPECTROMETRY-BASED QUANTITATIVE  
PHOSPHOPROTEOMICS 
 
Phosphorylation of proteins is a very important post translational modification 
that regulates multiple effects including translocation, protein–protein 
interactions, and activation or inactivation (Pawson & Nash, 2000). In many 
cases, a protein can be phosphorylated on multiple sites, which can either act 
independently or synergistically when phosphorylated simultaneously (Han et 
al., 2009). It is therefore important to investigate not only the level of 
phosphorylation for individual sites on a given protein but also the overall level 
of protein phosphorylation. The main difficulties in the detection of 
phosphorylation sites are due to the fact that phosphorylation usually occurs at 
low stoichiometry or can occur on a protein with low expression level (Schmelzle 
& White, 2006). In the past few years, several advances in mass spectrometry 
(MS) based approaches have enabled the analysis of thousands of 
phosphorylation sites so that MS combined with enrichment strategies for 
phosphorylated proteins and peptides is nowadays the tool of choice for the 
identification of novel phosphorylation sites (Larsen, Thingholm, Jensen, 
Roepstorff, & Jorgensen, 2005).  
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2.11.1 Cell lysis and protein digestion 
 
Cell pellets were resuspended in an appropriate volume (1 ml per 10 x 106 cells) 
of Lysis Buffer with the following composition: 8M Urea in 20 mM Hepes (pH 8). 
Cell suspension was then sonicated at 50% intensity 3 times for 15 seconds and 
centrifuged at 20000 x g for 10 minutes at 40C. Supernatants were collected and 
transferred into a protein low-bind tube. (Montoya et al., 2011). 
2.11.2 Protein denaturation and digestion 
 
For Disulphide bridges reduction, 10 μl of 1M Dithiothreitol (DTT) were added to 
each sample. Samples were then vortexed vigorously and incubated at room 
temperature in the dark for 15 minutes. Cysteines alkylation was obtained by 
addition of 40 μl of 415 mM Iodoacetamide (IAM) to each sample followed by a 
further 15 minutes incubation at room temperature in the dark. Protein 
digestion was achieved with the use of immobilized Trypsin beads. About 80 μl 
(centrifuged volume) of Trypsin beads were required for digestion of 500 μg of 
proteins. Before addition to the samples, trypsin beads were resuspended in an 
equal volume of 20 mM Hepes and samples were then incubated at 370C for 16 
hours with shaking. Digestion was stopped by addition of TFA at a final 
concentration of 1%. (Montoya et al., 2011). 
 
2.11.3 Desalting of Tryptic protein digests 
 
The resultant peptide solutions were desalted by solid phase extraction (SPE) 
using Oasis HLB extraction cartridges (Waters UK Ltd., Manchester, UK) 
according to manufacturer instructions with some modifications. Briefly, 
cartridges were activated with 1 mL of 100% ACN and equilibrated with 1.5 mL 
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of wash solution (2% ACN, 0.1% TFA in water). After the cartridges were loaded 
with peptide solution, they were washed with 1 mL of wash solution. Peptides 
were eluted with 0.5 mL of glycolic acid solution (1 M Glycolic acid in 80% ACN 
and 5% TFA). All the steps were done in a vacuum manifold set at 5 mm Hg. 
(Montoya et al., 2011). 
 
2.11.4 Phosphopeptide enrichment with TiO2 beads 
 
Titanium dioxide at acidic pH has a positively charged surface that selectively 
adsorbs phosphorylated compounds and is currently the most popular metal 
oxide resin used to capture phosphopeptides (Pinkse, Uitto, Hilhorst, Ooms, & 
Heck, 2004). Briefly, eluates from Oasis cartridges were normalized to 1 mL with 
glycolic acid solution and incubated for 5 minutes at room temperature with 
varying volumes of TiO2 solution (50% slurry, GL Sciences Inc., Japan). TiO2 
beads were then packed by centrifugation in equilibrated C-18 spin columns 
(PepClean C-18 Spin Columns, Thermo Scientific, Rockford, IL). Beads were 
sequentially washed with 300 μL of glycolic acid solution, 50% ACN and 
ammonium acetate solution (20 mM ammonium acetate pH 6.8 in 50% ACN). An 
extra 50% ACN wash can be also added after the ammonium acetate solution. 
For phosphopeptide elution, beads were incubated three times with 50 μL 5% 
NH4OH for 1 min at room temperature and centrifuged. The three eluates of 
each fraction were pooled and acidified by addition of formic acid (FA) to a final 
concentration of 10%. Samples were then dried using a SpeedVac and pellets 
were stored at −80 °C. (Montoya et al., 2011). 
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2.11.5 Nanoflow-liquid chromatography tandem mass 
spectrometry (LC–MS/MS) 
 
Phosphopeptide pellets were dissolved in 10–20 μl of 0.1% TFA and run in a LTQ-
Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead, 
UK) coupled online to a nanoflow ultra-high pressure liquid chromatography 
(UPLC, nanoAcquity, Waters). (Montoya et al., 2011). 
 
2.11.6 Mass-spectrometry data analysis 
 
For phosphorylated peptides identification, mass-spectrometry data were 
analysed using the software Mascot Daemon (v2.2.2; Matrix Science, London, 
UK). This software takes the mass spectrometry data and searches it against 
molecular sequence databases to identify the constituent proteins and to 
characterize post-translational modifications. For phosphorylated peptide 
quantification, a program in Visual Basic created by Dr Pedro Cutillas called 
Pescal (Peak Statistic Calculator) was used and incorporated it into an Excel 
macro (Cutillas & Vanhaesebroeck, 2007). This program uses m/z and retention 
time (tR) values for each identified peptide ion to generate extracted ion 
chromatograms (XICs) and uses them to calculate the peak heights and areas. 
The resulting quantitative data were parsed into Excel files for normalization and 
statistical analysis. Peptide intensities were normalized to the total 
chromatogram intensity and further expressed as a percentage relative to the 
largest intensity value across samples (Montoya et al., 2011). 
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Figure 2.1 Workflow of TiO2 based phosphopeptide enrichment technique. 
Cell pellets are lyzed, reduced, alkylated, digested with trypsin and desalted. The 
protocol for TiO2 enrichment includes the binding of peptides to TiO2 beads 
followed by the removal of unphosphorylated peptides by sequential washing 
with glycolic acid solution. Phosphopeptides are then eluted using NH4OH, 
acidified and reconstituted in TFA prior to LC–MS/MS analysis. Figure adapted 
from the following article:”Characterization of a TiO2 enrichment method for 
label-free quantitative phosphoproteomics” (Montoya et al., 2011). 
 
91 
 
2.12 Gelatin zymography 
 
Twenty μg of total protein, measured using the Micro BCA™ Protein Assay kit 
(Thermo Scientific/Pierce, Rockford, IL), was mixed with an equal volume of 
Novex® Tris-glycine SDS native sample buffer (Invitrogen™ Carlsbad, CA, USA) 
and the mixture was loaded into wells of pre-cast 10% Novex® zymogram gelatin 
gels (Invitrogen™). Pre-stained molecular weight standards were also run on the 
gels. The gels were electrophoresed at a constant voltage of 100 V for 
approximately 2 h. Following electrophoresis, the gels were rinsed in distilled 
water and then gently shaken in a renaturing solution of 2.7% Triton X-100 
(Novex® zymogram renaturing buffer, Invitrogen™) for 1 h at 37°C to reactivate 
MMPs. The gels were then incubated on a rotary shaker in a developing buffer 
(Novex® zymogram developing buffer, Invitrogen™) for 24 h at 37°C to allow 
denatured MMPs to digest the gelatin substrate. After the digestion phase, the 
gels were rinsed and stained by incubation with Coomassie Blue Rapid stain 
(Diversified Biotech, Boston, MA, USA) for 1 h. Gels were destained with a 
solution of acetic acid, methanol and water (10: 50: 40) to maximize contrast 
between proteolytic areas and non-digested areas. Proteolytic activity was 
visualized as areas of clear bands against a dark blue background. 
 
2.13 STATISTICAL ANALYSES 
 
Each experiment was performed in triplicate and repeated 3 independent times, 
unless stated otherwise. Results were then expressed as mean ± SEM, with n 
being the number of independent observations. Statistical significance of 
differences between means was evaluated using computer-based software 
(Prism, Graphpad, San Diego, CA, version 4.0). Either a paired student t test, two 
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tailed or two-way ANOVA with Bonferroni correction for multi-comparison test 
were performed. A P value of P≤0.05 was regarded a statistically significant. 
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3.1 INTRODUCTION 
 
As previously described, both IL-1β and IL-18 are synthesized as intracellular 
precursors and they need to be enzymatically cleaved in order to become 
biologically active. In macrophages the process of IL-1β and IL-18 secretion 
requires two different steps: a primary pro-inflammatory stimulus, which can be 
experimentally reproduced by LPS, is needed to induce high levels of pro-IL1-β 
and pro-IL-18 synthesis within the cells, but, applied alone, results in minimal IL-
1β and IL-18 secretion. A second stimulus is then required to activate caspase-1 
and ATP, acting on the P2X7R, is widely recognized as having this role. The 
function of caspase-1 in the release of mature IL-1β has been demonstrated in 
several in vitro and in vivo studies which have shown that cells that do not 
express caspase-1 such as fibroblasts and keratinocytes (Young, Hazuda, & 
Simon, 1988; Cerretti et al., 1992), as well as caspase-1 knock- out mice (Kuida et 
al., 1995), lack the capacity to release active IL-1β. Although the caspase-1 
dependent IL-1β secretion is the most well established, other proteases have 
been identified that are also able to generate active IL-1β from its precursor in a 
caspase-1 independent manner including bacterial enzymes and several 
components of the family of metalloproteinases, particularly gelatinase A (MMP-
2) and B (MMP-9). Furthermore, studies from Maelfait et al. have demonstrated 
that also caspase-8 is able to induce IL-1β maturation in response to TLR3 and 
TLR4 stimulation (Maelfait et al., 2008). ATP’s effect on P2X7R is maximum at 
concentrations of 1-5 mM range and induces a rapid efflux of potassium from 
the cells which is necessary for the assembly and activation of the NLRP3 
inflammasome (Kahlenberg & Dubyak, 2004). The importance of the rapid 
potassium efflux in inducing the NLRP3 inflammasome activation is also 
confirmed by the observation that molecules capable of inducing pores in the 
plasma membrane, such as the antibiotic nigericin or antimicrobial peptides 
such as protegrins can activate caspase- 1 in a P2X7R independent manner 
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(Perregaux, Bhavsar, Contillo, Shi, & Gabel, 2002). Macrophages are known to 
express high levels of P2X7R and therefore represent a good model to 
investigate the functions of this receptor. Since macrophages can express at the 
same time multiple P2X and P2Y receptors, the use of primary macrophages 
from WT and P2X7 deficient mice is extremely important to differentiate the 
responses that might involve other purinergic receptors from the ones that are 
selectively mediated by P2X7R. Furthermore, I have used primary macrophages 
from two different P2X7 deficient mouse lines for my experiments, which have 
been shown to behave differently in several in vivo models of disease. The 
comparison between the two P2X7 deficient lines could also contribute to a 
better understanding of P2X7R functions, particularly in view of the recent 
findings that both of them might express P2X7 splice variants. 
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3.2 EXPRESSION OF P2X7R IN BONE MARROW DERIVED 
MACROPHAGES FROM WILD TYPE AND P2X7 DEFICIENT MICE 
 
Aims and experimental design 
 
There is a growing literature that describes new splice variants for both the 
mouse and the human P2X7. Nicke et al. have described a P2X7 splice variant 
(P2X7k) characterized by an alternative N terminus and trans-membrane domain 
1 which, due to a different exon 1 and translation start, escapes gene 
inactivation in the GSK P2X7 knock-out mice (Nicke et al. 2009). In this study the 
P2X7k variant is shown to be expressed in the spleen of the GSK P2X7 knock-out 
mice. Two further P2X7 variants have been more recently described in the 
mouse which are characterized by alternative exon 13’s encoding much shorter 
C-termini than the original exon 13 and that are able to escape gene inactivation 
in the Pfizer knock out mouse strain (Masin et al. 2011). I therefore examined 
the expression of the full length P2X7R and P2X7K splice variant in WT, GSK and 
Pfizer BMDMs through PCR and Western blotting.  
 
Results 
 
As shown in figure 3.2A, a band of the predicted size of 75 KDa was detected in 
both WT and GSK BMDMs under basal conditions while no band was detected in 
the Pfizer BMDMs. Compared to WT, BMDMs from GSK mice show much lower 
levels of the protein. The primary antibody used for P2X7 protein detection is a 
rabbit polyclonal antibody from Alomone Labs (Israel) that recognizes the 
peptide (C)KIRK EFPKT QGQYS GFKYP Y, corresponding to amino acid residues 
576-595 of rat P2X7 which has an identical homology of 18/20 amino acid 
residues in the mouse. Among the functional mouse P2X7 variants described so 
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far, the only one that could be detected by the Alomone Labs antibody is the 
variant P2X7k, since the isoforms 13B and 13C, as shown in figure 3.2B, are 
characterized by much shorter C termini.  In the P2X7k variant, the alternative 
exon 1 encodes 39 amino acid residues instead of the 42 amino acid residues of 
the P2X7a subunit, so that the molecular masses of the proteins are similar. 
Furthermore, in their study Nicke et al., after transfecting X. Laevis oocytes with 
both a and k isoforms, have shown that upon separation by SDS-PAGE and 
immunoblotting the two subunits revealed a similar band of 77 KDa using the 
same anti P2X7 antibody from Alomone Labs that I used. To assess whether the 
band detected in the GSK BMDMs corresponded to the P2X7k variant, I have 
performed a PCR using specific forward primers for the exon 1 of P2X7a and 
exon 1’ of P2X7k isoforms (5’-CACATGATCGTCTTTTCCTAC-3’ AND 5’-
GCCCGTGAGCCACTTATGC-3’ respectively) and a common antisense primer in 
exon 4 (5’-GGTCAGAAGAGCACTGTGC-3’). As shown in figure 3.2C, using primers 
specific to exon 1, I could detect a band in both the WT and the Pfizer BMDMs, 
while no band was seen in the GSK BMDMs. However, using primers specific to 
the alternative exon 1 I could not detect any bands in BMDMs from all of the 
three mouse strains. 
 
 
 
 
 
 
 
99 
 
 
 
 
 
Figure 3.2A P2X7R expression in WT and P2X7 deficient BMDMs. 
Aliquots of protein (20 μg) from cell lysates of primary BMDM from WT, GSK and 
Pfizer knock-out mice under basal conditions were separated by gel 
electrophoresis and transblotted to PVDF membrane. Detection of P2X7 was 
performed by Western blotting using a rabbit polyclonal anti-P2X7 antibody 
from Alomone Labs (APR-004). Beta actin was used as loading control. 
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Figure 3.2B Schematic representation of the P2X7 full length receptor and the 
C-truncated P2X7 isoforms 13b and 13c. 
The full length receptor is 595 amino acids long, while the splice variants 13b 
and 13 c contain 431 and 441 amino acid residues respectively. The epitope 
corresponding to the amino acids 576-595 recognized by the anti-P2X7 antibody 
from Alomone Labs (APR-004) is also represented. Figure adapted from the 
following article: The P2X7 Receptor: “A Key Player in IL-1β Processing and 
Release” (Ferrari et al., 2006). 
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Figure 3.2C Analysis of P2X7k variant expression in BMDMs from WT, GSK and 
Pfizer P2X7 deficient mice by PCR. 
Exon 1 and alternative exon 1 specific forward primers were combined with 
reverse primers in exon 4. Exon 1 was expressed in both WT and Pfizer BMDMs, 
but not in BMDMs from GSK mice. The alternative exon 1 of the P2X7 k variant 
was expressed by none of them. 
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3.3 IL-1BETA SECRETION IN RESPONSE TO BZATP, ATP OR LL37 
IN BMDM FROM WT AND P2X7 DEFICIENT MICE 
 
Aims and experimental design 
 
Previous work from Pelegrin et al. has analysed patterns of ATP-mediated 
release of IL-1β and IL-18 from different macrophage types. In their study, they 
used peritoneal macrophages from the GSK P2X7R deficient mouse line and 
found that release of IL-1β and IL-18 by ATP was completely abolished in P2X7 
knock-out peritoneal macrophages even when supramaximal concentration  of 
LPS were used to prime the cells (Pelegrin, Barroso-Gutierrez, & Surprenant, 
2008). Due to the discovery of distinct release mechanisms of IL-1β and due to 
the presence of discordant data in the literature, probably secondary to the 
different techniques used to detect the mature forms of IL-1β and IL-18, I have 
investigated the secretion of both IL-1β and IL-18 by both Western blotting and 
ELISA methods in response to several P2X7R agonists in LPS primed bone 
marrow derived macrophages from wild type mice and from  the two P2X7 
deficient mouse lines, the GSK and Pfizer respectively. BzATP and ATP are well 
known P2X7R agonists and more recently, the antimicrobial peptide LL-37 has 
been shown to induce caspase-1 activation and release of active IL-1β in LPS-
primed monocytes through P2X7R activation (Elssner, Duncan, Gavrilin, & 
Wewers, 2004). In order to evaluate and to compare the levels of IL-1β secreted 
by BMDMs from WT, GSK and Pfizer P2X7 deficient mice in response to these 
stimuli, I have primed the macrophages with LPS used at a concentration of 1 
μg/mL for 5 hours and I have then stimulated them with either BzATP (final 
concentration in the medium 150 μM), ATP (final concentration in the medium 5 
mM) or LL-37 (final concentration in the medium 10 μM) for 30 minutes. 
Supernatants were then collected and analysed by sandwich ELISA. To optimize 
the conditions for this experiment, I have tried two different concentrations of 
103 
 
LPS (100 ng/ml and 1μg/ml) and I have used different time points for the priming 
step, starting from 1 hour incubation up to an overnight incubation. I have also 
used two different media for LPS priming and ATP stimulation: serum free 
DMEM and complete L929 conditioned medium. Of the two LPS concentrations 
used, 1μg/ml resulted much more efficient compared to the lower one leading 
to much higher levels of both IL-1β and IL-18. Although the current view is that 
the priming step is necessary to increase the precursors synthesis, I could detect 
active IL-1β and IL-18 even after one hour LPS priming, which clearly is not a 
sufficient time for new protein synthesis. On the other hand, an overnight 
incubation with LPS followed by 30 minutes stimulation with ATP did not induce 
any active IL-1β or IL-18 secretion probably as a consequence of the LPS-
tolerance phenomenon described in literature, characterized by a 
downregulation of proinflammatory genes after prolonged exposure to LPS 
(West & Heagy, 2002). The levels of active IL-1β and IL-18 in response to ATP 
stimulation were significantly lower when L929 medium was used instead of 
serum free DMEM. I could not establish however, whether it was the presence 
of serum or other components of the L929 conditioned medium to affect IL-1β 
and IL-18 processing. I have also tried two different concentrations of ATP (3 
mM and 5 mM) and the highest concentration appeared to be the most effective 
one, while there was no difference in cytokine production when the stimulation 
was prolonged for 30 minutes or 1 hour. I did not try any longer stimulation with 
ATP because of the known cytotoxic effect which was already visible under the 
microscope after 30 minutes when the cells started showing a round-shape 
morphology. A dose-dependent effect was also observed with BzATP and LL-37 
and the concentrations of 150 μM and 10 μM respectively were the most 
effective ones. 
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Results 
 
As illustrated in figure 3.3 A, BMDMs from WT mice produce significant higher 
levels of IL-1β compared to both GSK and Pfizer BMDMs in response to BzATP 
and ATP. After stimulation with the anti-microbial peptide LL-37, macrophages 
from WT mice produce higher levels of IL-1β compared to GSK and Pfizer 
BMDMs, although the difference between WT and GSK BMDMs was not 
statistically significant. GSK BMDMs exhibit significant higher levels of IL-1β in 
response to all the agonists tested compared to Pfizer P2X7 deficient mice. ATP 
stimulation appears to be the most effective stimulus, leading to the highest 
levels of IL-1β compared to BzATP and LL-37 in WT mice. However, much higher 
concentrations of ATP, in the millimolar range were required for this effect in 
comparison with BzATP and LL-37 for which concentrations within the 
micromolar range were used. ATP also seems to be the most selective agonist 
compared to BzATP and LL-37 leading to the highest production of IL-1β in 
BMDMs from WT mice and to the lowest in BMDMs from the Pfizer Knock-out 
mice.  To confirm the ELISA data, I have examined the secretion of IL-1β in 
response to ATP in LPS-primed BMDMs from WT and P2X7 knock-out mice by 
Western blotting. As shown in figure 3.3 B, in response to ATP, a band of the 
predicted size of 17 KDa, corresponding to the active form of IL-1β was 
detectable in BMDMs from WT and GSK mice but not in BMDMs from Pfizer 
mice. BMDMs from WT mice, in accordance with the ELISA results show higher 
levels of active IL-1β compared to macrophages from GSK mice. 
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Figure 3.3A IL-1β release in BMDMs cultured from WT, GSK and Pfizer P2X7 
deficient mice in response to BzATP, ATP and LL-37. 
BMDM from WT, GSK and Pfizer P2X7 deficient mice were plated in six-well 
plates at a density of 1 x 106 cells per well, primed with LPS 1μg/mL for 5 hours 
and then stimulated with either BzATP 150 μM, ATP 5mM or LL37 10 μM for 30 
minutes. Supernatants were then collected and analysed by sandwich ELISA 
using the mouse IL-1β Duoset ELISA Kit from R&D Systems. Data are 
representative of three independent experiments. 
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Figure 3.3B IL-1β secretion in BMDMs from WT and P2X7 deficient mice in 
response to ATP. 
BMDMs from WT, GSK and Pfizer P2X7 deficient mice were plated in six-well 
plates at a density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours 
and then stimulated with or without ATP 5 mM for 30 minutes. Supernatants 
and cell layers were collected, filtered using Amicon ultra centrifugal filters 
(Millipore) and analysed by Western blotting. Detection of pro- and mature IL-1β 
was performed using a specific anti IL-1β antibody from New England Biolabs 
(UK). 
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3.4 IL-18 SECRETION IN RESPONSE TO ATP IN LPS PRIMED BMDM 
FROM WT AND P2X7 DEFICIENT MICE 
 
Aims and experimental design 
 
To evaluate and compare IL-18 production in BMDMs cultured from WT, GSK 
and Pfizer P2X7 KO mice, I have primed these cells with LPS 1μg/mL for five 
hours and then stimulated them with ATP used at a concentration of 5 mM for 
30 minutes. Both supernatants and cell layers were then collected, filtered using 
Amicon ultra centrifugal filters for protein concentration and purification 
(Millipore) and analysed by Western blotting. Unfortunately, I could not find a 
reliable ELISA kit for mouse IL-18 detection, therefore a quantitative analysis was 
not possible. The active form of the cytokine was detectable only when 
supernatants and cell layers where analysed together, while in the cell lysates I 
could only detect the precursor. 
 
Results 
 
As shown in figure 3.4, in response to ATP, BMDMs from WT and GSK mice 
produce similar levels of active IL-18. Macrophages from Pfizer mice show only a 
faint band of the predicted size of 18 KDa when stimulated with ATP. 
Macrophages from WT and GSK mice also release active IL-18 after stimulation 
with LPS alone. The levels of active IL-18 produced by WT and GSK BMDMs in 
response to LPS alone are similar to the levels of active IL-18 secreted by 
macrophages from Pfizer mice in response to ATP. 
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Figure 3.4 IL-18 secretion in response to ATP in BMDMs from WT and P2X7 
deficient mice. 
BMDMs from Pfizer, GSK and WT mice were seeded into six-well plates at a 
density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and then 
stimulated with or without  ATP 5 mM for 30 minutes. Supernatants and cell 
layers were then collected, filtered using Amicon ultra centrifugal filters 
(Millipore) and analysed by Western blotting. Detection of pro- and mature IL-18 
was performed using a specific anti IL-18 antibody from Santa Cruz 
Biotechnology. 
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3.5 EFFECTS OF P2X7R INHIBITION ON THE SECRETION OF IL-1 
BETA IN BMDMs FROM WT AND P2X7 DEFICIENT MICE 
 
Aims and experimental design 
 
Previous studies from Grahames et al. have shown that the use of the non-
selective P2X7 antagonists KN-62, PPADS and oxidized ATP significantly inhibited 
5mM ATP-induced IL-1β release in human monocytic cells THP-1 (Grahames, 
Michel, Chessell, & Humphrey, 1999). Later studies from Honore’ et al. 
demonstrated that the selective P2X7 antagonist A-740003 potently blocks the 
BzATP-evoked IL-1β release in THP-1 cells (Honore et al., 2006). To assess 
whether P2X7R inhibition by A-740003 affects also ATP-evoked IL-1β secretion, I 
have primed BMDMs from WT, GSK and Pfizer mice with LPS 1 μg/mL for 5 
hours, cells were then incubated for 30 minutes with either the inhibitor or 
serum free DMEM and then stimulated with ATP 5 mM in the presence or 
absence of the P2X7 receptor antagonist A-740003 used at a final concentration 
in the medium of 3 μM. Although A-740003 is a selective P2X7R antagonist and 
BMDM from GSK and Pfizer mice for definition should not express the full length 
receptor, in order to evaluate the specificity of the inhibitor I have analysed its 
effects on IL-1β release also in BMDM from the two P2X7 deficient lines GSK and 
Pfizer. Supernatants and cell layers were then collected, filtered using Amicon 
ultra centrifugal filters for protein concentration and purification (Millipore) and 
analysed by Western blotting. 
Results 
 
As shown in figure 3.5A, the use of the P2X7R antagonist A-740003 dramatically 
decreases IL-1β secretion in WT BMDM. Surprisingly, in the GSK BMDM, the use 
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of the P2X7RA seems to slightly increase the production of IL-1β. No effects 
were seen in the Pfizer BMDMs.  
      
 
 
Figure 3.5 Effects of P2X7RA on IL-1 β secretion in response to ATP in LPS 
primed macrophages from WT and P2X7 deficient mice. 
BMDMs from WT, GSK and Pfizer knock-out mice were plated into six-well plates 
at a density of 1 x 106 cell per well, primed with LPS 1 μg/ml for 5 hours and then 
stimulated with ATP for 30 minutes in the presence or absence of the P2X7R 
antagonist A-740003 used at a final concentration in the medium of 3 μM. 
Supernatants and cell layers were collected, filtered using Amicon ultra 
centrifugal filters (Millipore) and analysed by Western blotting. 
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3.6 CASPASE-1 ACTIVATION IN RESPONSE TO ATP IN BMDM FROM 
WT AND P2X7 DEFICIENT MICE 
 
  Aims and experimental design 
 
As previously described, both IL-1β and IL-18 require to be enzymatically cleaved 
in order to become biological active and this process is mediated by the IL-1β 
converting enzyme, caspase-1. Caspase-1 is synthesized as an inactive, 
monomeric zymogen (pro-caspase-1) that is thought to be activated by 
dimerization and autoproteolytic processing (Martinon, Mayor, & Tschopp, 
2009) which leads to the generation of two subunits of 20 and 10 KDa 
respectively, termed p20 and p10. Although the function of caspase-1 in the 
release of mature IL-1β and IL-18 is well established, some studies have 
demonstrated that, aside from caspase-1, other proteases such as the 
metalloproteinases MMP-9 and MMP-12 are capable of generating active IL-1β.  
Therefore, to establish whether the secretion of mature IL-1β and IL-18 involved 
caspase-1 activity, I have assessed the expression of the active fragment p10 in 
BMDMs from WT and P2X7 deficient mice after priming with LPS 1 μg/ml and 
stimulation with ATP 5 mM. The antibody used for caspase-1 detection by 
Western blotting was from Santa Cruz Biotechnology and recognized both the 
precursor and the active p10 fragment. I could detect the active p10 fragment 
only analysing cell layers and supernatants together, while I could not detect any 
active form in the cell lysates indicating that caspase-1 is released from the cells 
soon after the conversion as demonstrated by several studies (Laliberte, Eggler, 
& Gabel, 1999). 
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Results 
 
As shown in figure 3.6, in response to ATP, the p10 subunit was detectable only 
in BMDMs from WT mice, whereas macrophages from GSK and Pfizer KO 
expressed only the precursor. BMDMs from WT and GSK mice exhibit similar 
levels of the precursor, while Pfizer macrophages showed much lower levels.  
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BMDMs from WT, GSK and Pfizer BMDM were seeded into six-well plates at a 
density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and then 
stimulated with ATP 5 mM for 30 minutes. Supernatants and cell layers were 
collected, filtered using Amicon ultra centrifugal filters for protein purification 
and concentration and analysed by Western blotting. Detection of pro-caspase 1 
and its active subunit p10 (A) was performed using a specific anti-caspase 1 p10 
antibody from Santa Cruz Biotechnology (sc-514). (B) Quantification by Western 
blot densitometry for active caspase-1 as indicated. *P<0.05 Student paired T 
test for indicated comparisons. The blots are representative of at least n=3 
independent experiments. 
 
 
 
 
Figure 3.6 A and B. Caspase-1 activation in response to ATP in BMDMs from WT 
and P2X7 deficient mice. 
B 
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3.7 DISCUSSION 
 
 My studies lead me to the following conclusions: 
 
1. Western blotting analysis of P2X7 protein expression in macrophages from WT 
and P2X7 deficient mice revealed the presence of a band of the predicted size of 
the full length P2X7R (75 KDa) in both WT and GSK macrophages, while no band 
was detectable in the Pfizer ones. The band intensity in GSK macrophages was 
however much lower compared to the one detected in WT macrophages. 
 
2. BMDMs from WT produce higher levels of active IL-1β compared to BMDM from 
GSK and Pfizer P2X7 deficient mice in response to all the agonists tested (BzATP, 
ATP and the human cathelicidine LL-37). 
 
 
3. Among all the agonists tested, ATP appears to be the most efficient and selective 
agonist leading to the highest levels of active IL-1β in BMDM from WT mice and 
the lowest in BMDM from Pfizer knock-out mice. 
 
4. BMDMs from GSK knock-out mice show an intermediate phenotype between 
WT and Pfizer macrophages, releasing much higher levels of active IL-1β 
compared to macrophages from Pfizer KO mice in response to all the agonists 
tested. 
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5. The use of the selective P2X7 inhibitor A-740003 dramatically affects IL-1β 
secretion in response to ATP in BMDMs from WT mice. 
 
6. Only BMDMs from WT mice are able to generate active caspase-1 in response to 
ATP. 
 
 
Analysis of P2X7R expression in BMDM from WT and P2X7 deficient mice 
 
As previously described, 12 splice variants of mouse P2X7 have been identified 
so far, although only three are thought to be functional. The variant P2X7k, 
which appears to be strongly expressed in the liver and spleen, is characterised 
by an alternative exon 1 and escapes gene deletion in the GSK mouse strain. The 
alternative exon 1 of P2X7k encodes 39 amino acid residues which replace the 
first 42 amino acid residues of the P2X7a subunit. This includes the intracellular 
N-terminus and about 80% of the first transmembrane domain. In their study, 
Nicke et al. have transfected Xenopus Laevis oocytes with both isoforms P2X7a 
and P2X7k and have shown that, upon separation by SDS-PAGE and 
immunoblotting, both P2X7a and P2X7k revealed bands of a similar size of about 
77 KDa. The two other splice variants identified are characterized by alternative 
exon 13 which encode much shorter C-termini than the original exon 13a. As 
illustrated in figure 3.2B, the variant 13b has a C-terminus truncated at position 
430, while the variant 13c has an alternative C-terminus with specific 11 amino 
acid residues beyond the common residue 430. When I examined the expression 
of P2X7R protein in WT, GSK and Pfizer mice by Western blotting, I could detect 
a band of the predicted size of about 75 KDa in both WT and GSK BMDM under 
basal conditions. The antibody that I used for the detection of P2X7 protein is a 
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highly specific antibody from Alomone Laboratories, Israel, directed against an 
antigenic epitope, corresponding to residues 576-595 of rat P2X7 (18/20 
residues identical in mouse sequence). Since the variant 13b terminates at 
residue 431 and the variant 13c has an additional 11 amino acids at the C-
terminus, both these variants should not be detected by the Alomone Labs 
antibody which can instead bind to the C-terminus of the P2X7k variant. To 
verify whether macrophages from GSK mice effectively expressed the variant 
P2X7k, I have performed a PCR analysis using forward primers specific to the 
normal and alternative exon 1 combined with reverse primers in exon 4. As 
expected, the normal exon 1 was expressed only by BMDMs from WT and Pfizer 
mice and not by GSK BMDMs. However, unfortunately I could not demonstrate 
the expression of the alternative exon 1 of the P2X7k variant in none of the 
three mouse strains BMDMs. The impossibility to demonstrate by PCR the 
expression of the alternative exon 1 in GSK macrophages could be due to a 
technical issue or might indicate that GSK BMDMs express instead another P2X7 
variant with an alternative exon 1 different from the one expressed by the 
variant P2X7k. Further studies are certainly needed to investigate the latter 
hypothesis. 
 
IL-1β secretion in response to BzATP, ATP and LL-37 in BMDM from WT and 
P2X7 deficient mice. 
 
BzATP, ATP and the human cathelicidine LL-37 are all known to be powerful 
P2X7R agonists. It is well established that one unique property of P2X7R is its 
low sensitivity to ATP, so that concentrations within the millimolar range are 
usually used in vitro to activate the receptor. The antimicrobial peptide LL-37 
has emerged only recently as a molecule able to generate biologically active IL-
1β, although the exact mechanisms by which LL-37 activates P2X7R is not fully 
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understood yet. In order to evaluate the efficiency of these agonists in activating 
P2X7R and also their specificity, I have analysed the effects of these compounds 
on IL-1β secretion in LPS-primed BMDMs from WT and P2X7 deficient mice. 
Sandwich ELISA was used as quantitative analysis. As shown in figure 3.3 A, 
whatever agonist I used, BMDMs from WT mice always release more IL-1β 
compared to BMDM from the two P2X7 deficient mouse lines. When stimulated 
with BzATP or ATP, BMDMs from WT mice produce significant higher levels of IL-
1β compared to both GSK and Pfizer macrophages. However, when LL-37 was 
used to activate P2X7R, the difference in IL-1β levels between WT and GSK 
macrophages was not statistical significant. Interestingly, BMDMs from GSK mice 
produce significant higher levels of IL-1β compared to BMDMs from Pfizer mice 
in response to all the agonists tested. These results would be in agreement with 
the hypothesis that GSK BMDMs express P2X7k or another P2X7 splice variant. 
In their study Nicke et al. have shown that the isoform P2X7k has 8-fold higher 
BzATP sensitivity and a slower deactivation compared to the P2X7a variant. My 
data however seem to be not in accordance with these findings.  BMDMs from 
WT mice produce significant higher levels of IL-1β (up to 2500 pg/ml) in 
response to ATP compared to BzATP or LL-37 (less than 1000 pg/ml). It is true 
that mM rather than μM concentrations have been used for ATP stimulation, 
due to the low sensitivity of the receptor to the compound; however, higher 
concentrations in the mM range could not be used for BzATP or LL-37 because 
they would have induced cell death rather than an increased secretion of IL-1β. 
Among the agonists tested, ATP appears to be also the most selective one, 
leading to the highest IL-1β secretion in WT BMDM and to the lowest in the 
Pfizer BMDM. These data were reproduced in at least three independent 
experiments. Given that ATP stimulation seems to be the most effective and the 
most specific, I have used ATP as the main P2X7 agonists in all the following 
experiments to induce P2X7R activation. 
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Analysis of IL-1β and IL-18 secretion in response to ATP by Western blotting 
 
The ELISA technique is generally a reliable and rapid method to quantify 
cytokines released in the supernatant. To be sure that by ELISA I was effectively 
measuring only the active form of IL-1β and not also the pro-form, I decided to 
analyse both IL-1β and IL-18 secretion in response to ATP in BMDM from WT and 
P2X7 deficient mice by western blotting. The anti-IL-1β and anti-IL-18 antibodies 
that I used were able to recognize both the precursors and the cleaved forms. As 
shown in figure 3.3B, a band of the predicted size of 17 KDa, corresponding to 
the active form of the molecule was detected both in WT and GSK BMDMs but 
not in macrophages from Pfizer mice. In accordance with the ELISA data WT 
BMDMs show higher levels compared to the GSK ones although the difference 
does not seem to be significant as shown by ELISA. Western blotting indeed is 
not a quantitative method, therefore only when the differences are dramatic as 
between WT and Pfizer macrophages can be easily evaluated by the presence or 
absence of the band of interest. This might explain why when I analysed by 
Western blotting IL-18 secretion in response to ATP I could not see any 
differences between the WT and the GSK BMDMs (Figure 3.4), while it was clear 
that Pfizer BMDMs produce much lower levels of IL-18. In figure 3.4 it is also 
shown that in response to LPS alone, both WT and GSK macrophages but not the 
Pfizer BMDMs are able to generate active IL-18 although the levels are much 
lower than the ones secreted after ATP stimulation. It is well known that LPS 
alone induces the release of a small amount of both IL-1β and IL-18 particularly 
after a prolonged stimulation of five hours. Before adding ATP to the cells, the 
medium containing LPS was aspirated and replaced by fresh medium with ATP. 
This means that the levels of both IL-1β and IL-18 produced in response of ATP 
have been released in only 30 minutes which is a very short time compared to 
five hours stimulation with LPS alone. When quantified by ELISA, the levels of IL-
1β released after 30 minutes of ATP stimulation were about 10 fold higher 
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compared to the levels of IL-1β secreted in response to 5 hours stimulation with 
LPS alone (data not shown). 
 
Effects of the P2X7R antagonist A-740003 on IL-1β secretion in response to ATP 
 
As previously described, A-740003 is a highly selective P2X7R inhibitor and 
previous studies from Honore et al. have already shown that it potently blocks 
agonist-evoked IL-1β release in human monocytes. To confirm these data, I have 
analysed the effects of A-740003 on IL-1β secretion in BMDMs from WT, GSK 
and Pfizer mice. Being a highly selective P2X7R inhibitor, it should not affect IL-
1β secretion in the GSK and Pfizer BMDM, which, for definition, should not 
express the receptor. However, due to the potential expression of other P2X7 
splice variants in BMDMs from GSK and Pfizer mice, I decided to analyse the 
effects of the inhibitor also in the knock-out macrophages. As shown in figure 
3.5A, treatment of WT BMDM with A-740003 dramatically affects IL-1β secretion 
in response to ATP. In the GSK BMDM surprisingly, the use of the inhibitor seems 
to slightly increase the production of IL-1β, although it seems to be more a 
loading issue rather than a real effect, while no effect at all was observed in 
Pfizer BMDMs. 
 
Caspase-1 activation in response to ATP in WT and P2X7 deficient BMDM 
 
A condition necessary for the release of the biologically active forms of IL-1β and 
IL-18 is the activation of caspase-1 which is thought to occur through an 
autocatalytic activity. The cleavage of the precursor leads to the generation of 
fragments of 20 and 10 KDa. To evaluate whether IL-1β secretion was caspase-1 
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dependent in WT BMDMs, I have analysed the expression of both the precursor 
and the active forms by Western blotting. The antibody used was able to 
recognise the precursor of about 50 KDa and a fragment of 10 KDa (p10). As 
shown in figure 3.6, a band of the predicted size of 10 KDa, corresponding to the 
active form of caspase-1 was detectable only in BMDMs from WT mice. WT and 
GSK BMDMs exhibit similar levels of pro-caspase-1, while Pfizer BMDMs show 
lower levels of the precursor compared to WT and GSK BMDMs. The expression 
of the full length P2X7R appears to be therefore required for caspase-1 
activation. 
 
Key discoveries in this chapter 
To my knowledge, this is the first study in which P2X7R mediated cytokine 
release is analysed comparing macrophages from WT mice with the ones from 
two different P2X7 deficient mouse lines. ATP stimulated LPS primed BMDMs 
from both lines of P2X7R deficient mice release lower concentration of both IL-
1β and IL-18 in comparison to macrophages from WT mice. BMDMs from GSK 
P2X7 deficient mice behave very differently compared to macrophages from the 
Pfizer ones releasing much higher levels of both IL-1β and IL-18 in response to 
ATP. Interestingly, when stimulated with LL-37, LPS-primed BMDMs from GSK 
mice release similar levels of IL-1β as macrophages from WT mice. In addition, 
Western blotting analysis of lysates from GSK BMDMs revealed the expression of 
a band of about 75 kDa using a specific anti-P2X7R antibody, which might 
represent a novel P2X7 splice variant with functional activity and would explain 
the more active phenotype of GSK macrophages compared to the Pfizer ones.  
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CHAPTER FOUR-INVESTIGATION OF THE SIGNALLING 
CASCADE FOLLOWING P2X7R ACTIVATION IN RESPONSE TO 
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4.1 INTRODUCTION 
 
 Extracellular nucleotides such as adenosine triphosphate (ATP) have been 
recognised as important intercellular signals in many biological processes, 
including neurotransmission, muscle contraction, pain sensation and different 
immune responses (Bours, Swennen, Di, Cronstein, & Dagnelie, 2006). ATP 
represents the physiologic P2X7R agonist and many questions still remain 
concerning P2X7 signalling and the regulation of its activity via intracellular 
trafficking. It has been reported that P2X7 promotes ROS production in human 
monocytes through the activation of the MEK/ERK cascade (Lenertz, Gavala, Hill, 
& Bertics, 2009). In other studies conducted on astrocytes, application of the 
P2X7 agonist BzATP led to the activation of the MAP kinases ERK1, ERK2 and p38 
and this effect was prevented by the use of a selective P2X7 antagonist (Panenka 
et al., 2001b). Historically P2X7 has been linked with apoptosis, due to the 
observation that prolonged application of ATP led to cell death (Schulze-Lohoff 
et al., 1998). However, there is now a growing literature regarding a growth 
promoting activity of this receptor but the exact mechanisms by which in certain 
condition P2X7 promotes cell proliferation are not fully understood yet 
(Baricordi et al., 1999). The regulation of cell proliferation is a complex process, 
which is primarily regulated by external growth factors provided by surrounding 
cells (Zhang & Liu, 2002). Two signalling pathways which have been closely 
linked to cell proliferation and survival are the ERK/MAPK and the mTOR 
pathways (Roux & Blenis, 2004; Fingar et al., 2004). The mitogen-associated 
protein kinases (MAPKs) are an evolutionarily conserved family of enzymes that 
phosphorylate target proteins both in the cytoplasm and nucleus (Kondoh, Torii, 
& Nishida, 2005). Four conventional MAPK pathways have been characterized: 
the extracellular signal-regulated kinases 1/2 (ERK1/2), the c-JUN N-terminal 
kinases 1-3 (JNK1-3) or stress-activated protein kinases (SAPKα, β and γ), the p38 
MAPKs (p38α, β, γ and δ), and the big MAPK (BMK1/ERK5) modules (Kostenko, 
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Dumitriu, Laegreid, & Moens, 2011). The MAPK cascade includes many proteins 
which are sequencially phosphorylated such as MAPKKK (also known as Raf) and 
MAPKK (also known as MEK1/2) which ultimately phosphorylates p44 MAPK and 
p42 MAPK, also known as ERK1 and ERK2 (figure 4.1). Then the activated ERKs 
translocate to the nucleus and activate transcription factors such as Elk-1(E-
twenty six-like transcription factor 1) and Myc, changing gene expression to 
promote growth, differentiation or mitosis (Costa et al., 2006). Activated ERKs 
can also phosphorylate cytoplasmic and nuclear kinases, for example MNK1, 
MNK2, MAPKAP-2, RSK, and MSK1,2 (Junttila, Li, & Westermarck, 2008). Most of 
the signals activating the ERK pathway are initiated through receptor-mediated 
activation of the small G-protein Ras, a membrane-bound protein activated 
through the exchange of bound GDP to GTP (McKay & Morrison, 2007). 
Activated Ras then recruits cytoplasmic Raf (MAPKKK) to the cell membrane for 
activation. The role of the MAPK signalling pathway in the regulation of cell 
proliferation and cell survival has been demonstrated in many in vitro and in 
vivo studies (Zhang & Liu, 2002). Chemical inhibition of ERK1/2 has been shown 
to be effective in suppressing tumor growth in a mouse model of colon cancer 
and ERK pathway inhibition is still considered a powerful tool in anticancer 
therapy (Sebolt-Leopold, 2000) (Roberts & Der, 2007). The mTOR signalling 
pathway was originally discovered about 15 years ago studying the mechanisms 
of action of the immunosuppressive agent rapamycin (Hwang, Perez, Moretti, & 
Lu, 2008). This highly conserved pathway represents a key regulator of cell 
growth and proliferation in response to environmental stimuli (Ramirez-Valle, 
Braunstein, Zavadil, Formenti, & Schneider, 2008). MTOR is a relatively large 
protein of 289-kDa that contains a catalytic domain with homology to the 
phosphatidylinositol-3-kinase enzymes but, instead of phosphoinositide kinase 
activity, mTOR is a protein kinase (Chiang & Abraham, 2004). MTOR exists in two 
distinct multi-protein complexes termed mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) (Huang & Manning, 2009). MTOR integrates stimuli from a 
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number of sources. These include nutrients such as glucose and aminoacids, 
metabolic status and growth factor-mediated signal transduction pathways 
(Tato, Bartrons, Ventura, & Rosa, 2011). Growth factors such as insulin, activate 
the PI3K class I PI3K enzymes that phosphorylate phosphatidylinositol-4,5-
bisphosphate (PIP2) to produce phosphatidylinositol-3,4,5-triphosphate (PIP3) 
(Hietakangas & Cohen, 2007). PIP3 binds and translocates pleckstrin homology 
(PH) domain-bearing proteins such the phosphoinositide dependent kinase 
(PDK) family members and Akt. PDK1 and Akt are recruited to the membrane 
where PDK1 phosphorylates and activates Akt (Scheid, Parsons, & Woodgett, 
2005). In turn, Akt phosphorylates the tuberous sclerosis complex 2 (TSC2) 
which forms a complex with tuberous sclerosis 1 (TSC1/TSC2). AKT-mediated 
phosphorylation of tuberous sclerosis TSC2 inhibits the TSC complex (Coleman, 
Marshall, & Olson, 2004). Signalling through the RAF–MEK–ERK/MAPK pathway 
also leads to phosphorylation and inhibition of the TSC complex (Ma, Chen, 
Erdjument-Bromage, Tempst, & Pandolfi, 2005). The GTPase-activating protein 
domain of TSC2 would otherwise drive the small GTPase Rheb into the inactive 
GDP-bound state (Inoki, Li, Xu, & Guan, 2003). Therefore, inhibition of the TSC 
complex results in Rheb activation, which signals to target of rapamycin (TOR), 
which, in turn, phosphorylates several proteins including S6 kinase and 
ribosomal protein S6 (figure 4.2). 
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Figure 4.1A Schematic representation of the MAPK cascade. 
Growth factors activate the MAPK cascade in a multistep process. The first 
kinase to be activated is Raf, which is activated by the GTP-binding protein Ras 
and in turn phosphorylates MAPKK including MEK 1 and MEK 2. Finally, the 
MEKs activate through phosphorylation ERK 1 and 2 which translocate to the 
nucleus activating transcription factors such as Elk-1 and c-myc that regulate cell 
cycle progression and proliferation. Figure adapted from the following article:” 
ERK Inhibitors as a Potential New Therapy for Rheumatoid Arthritis” (Ohori, 
2008). 
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Figure 4.1B Schematic representation of the mTOR signalling pathway. 
mTOR is activated by different stimuli including growth factors, hormones, 
amino acids and cellular energy levels. MTOR also integrates stimuli from 
upstream signalling pathways such as the PI3K/Akt pathway. Once activated, 
mTOR phosphorylates and activates downstream effectors such as S6 kinase and 
the ribosomal protein S6 regulating protein synthesis and cell growth. Figure 
adapted from the following article:” The phosphatidylinositol 3-
Kinase/Akt/Mammalian target of rapamycin signaling network as a new target 
for acute myelogenous leukemia therapy” (Martelli et al., 2011). 
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4.2 EFFECTS OF ATP STIMULATION ON THE PHOSPHORYLATION 
OF ERK IN BMDM FROM WT AND P2X7 DEFICIENT MICE 
 
Aim and experimental design 
 
Activation of P2X7R has been demonstrated to induce ERK1/2 activation in 
microglia, monocytes and macrophages (Hide et al., 2000). Previous studies 
from Papp et al. have shown that ATP stimulation significantly increases p38 
MAPK phosphorylation in hippocampal slices of WT mice while these effects 
were absent in hippocampal slices from P2X7 knock-out mice (Papp, Vizi, & 
Sperlagh, 2007). To confirm the role of P2X7 in the activation of ERK signalling 
pathway, I have stimulated primary bone marrow derived macrophages from 
WT, GSK and Pfizer P2X7 knock-out mice with ATP 5 mM for different times (5, 
15 and 30 minutes). After 5 days of differentiation in L929 conditioned medium, 
macrophages were plated into six-well plates at a density of 1 x 106 and 
incubated at 370C for 24 hours to let them adhere. The cells were then serum 
starved overnight before the stimulation with ATP. Intentionally, macrophages 
were not primed with LPS prior to ATP treatment because it has been already 
reported that LPS itself increases the phosphorylation of ERK1/2 (Durando, 
Meier, & Cook, 1998). Furthermore, the aim of this experiment was to evaluate 
the effects of P2X7R activation on the phosphorylation of proteins, therefore the 
priming step was not required. At the end of the stimulation, the medium was 
aspirated and cell lysates were prepared as described in Materials and methods. 
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Results 
 
As shown in figure 4.3, ATP induces a rapid and time-dependent increased 
phosphorylation of ERK1/2 in BMDMs from wild type mice, while no effects 
were seen in macrophages from both the GSK and the Pfizer P2X7 knock-out 
mouse lines. The highest levels of phosphorylation were seen after 15 minutes 
of ATP stimulation, while they start to decrease at 30 minutes. 
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4.3 EFFECTS OF ATP STIMULATION ON THE PHOSPHORYLATION 
OF MTOR AND S6 RIBOSOMAL PROTEIN IN BMDM FROM WT AND 
P2X7 DEFICIENT MICE 
 
Aim and experimental design 
 
Due to the more recent findings that P2X7R might also promote cell growth and 
proliferation I have also investigated the effects of ATP stimulation on the 
activation of another important pro-survival pathway: the mTOR signalling 
pathway. Many studies have documented that MTOR activity is regulated by 
nutrient/energy status and some studies have also proposed that mTOR directly 
senses ATP levels in the cell (Dennis et al., 2001). As markers of mTOR activation 
I have used mTOR and one of its downstream effector, the ribosomal protein S6. 
To date, 4 different mTOR phosphorylation sites have been described, however, 
a functional role for site-specific mTOR phosphorylation has not been 
demonstrated (Acosta-Jaquez et al., 2009). The antibody that I used for the 
detection of phosphorylated mTOR recognizes the phosphorylation site Serine 
2448. Chiang et al.  have shown that phosphorylation of mTOR at Ser 2448 is 
mediated by p70S6 kinase which is a downstream effector of mTOR and is in 
turn activated through phosphorylation by mTOR itself representing therefore a 
feedback signal to mTOR from its downstream target (Chiang & Abraham, 2005). 
Serine 2448 is also considered a nutrient regulated phosphorylation: in response 
to insulin becomes phosphorylated via Akt, while phosphorylation at this site is 
attenuated with amino acid starvation (Cheng, Fryer, Carling, & Shepherd, 2004). 
S6 is a protein of the 40S ribosomal subunit which plays a key role in protein 
synthesis (Dufner & Thomas, 1999). Phosphorylation of S6 ribosomal protein 
correlates with an increase in translation of mRNA transcripts that contain an 
oligopyrimidine tract in their 5' untranslated regions (Meyuhas & Dreazen, 
2009). These particular mRNA transcripts (5'TOP) encode proteins involved in 
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cell cycle progression as well as ribosomal proteins and elongation factors 
necessary for translation (Ferrari, Bandi, Hofsteenge, Bussian, & Thomas, 1991). 
S6 ribosomal protein can be phosphorylated at 4 different sites: Serine 235, 
Serine 236, Serine 240 and Serine 241. All these phosphorylation sites are 
located within a small, carboxy-terminal region of the S6 protein (Flotow & 
Thomas, 1992). The antibody I used for detection of phosphorylated S6 
recognizes Serine 235 and Serine 236 phosphorylation sites.  
 
Results 
 
As shown in figure 4.3, ATP stimulation leads to a time dependent increased 
phosphorylation of mTOR in macrophages from WT mice, while only a mild  
increase was seen after prolonged exposure in macrophages from the two P2X7 
deficient mouse lines. ATP also induces a time dependent increased 
phosphorylation of S6 both in macrophages from WT and P2X7 deficient mice, 
however the levels of phosphorylation were much higher in the wild tipe 
macrophages compared to macrophages from P2X7 knock-out mice. The 
macrophages from the GSK knock-out mouse line show higher levels of 
phosphorylated S6 compared to macrophages from the Pfizer P2X7 deficient 
mice. 
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Figure 4.3 A, B and C. Effects of ATP stimulation on the phosphorylation of 
mTOR, p42/p44 MAPK and S6 ribosomal protein. 
BMDMs from WT and P2X7 knock-out mice (GSK and Pfizer) were plated into six-
well plates at a density of 1x 106 cells per well, serum starved overnight and 
stimulated with or without ATP 5 mM at the indicated time points. Aliquots of 
protein (20 μg) from cell lysates were separated by gel electrophoresis and 
transblotted to PVDF membrane. Detection of phospho-mTOR (Ser 2448), 
phospho-p42/p44 MAPK and phospho-S6 (Ser 235-236) (A) and of their 
correspondent total forms (B) was performed by Western blotting using specific 
antibodies from New England Biolabs (UK). The blots are representative of at 
least n=3 independent experiments. (C) Quantification by Western blot 
densitometry for p-mTOR, pERK and pS6 as indicated. *P<0.05 Student paired T 
test for indicated comparisons. 
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4.4 PHOSPHOPROTEOMIC ANALYSIS OF THE CELL SIGNALING 
CASCADE FOLLOWING ATP STIMULATION IN MACROPHAGES 
FROM WT AND P2X7 DEFICIENT MICE 
 
Aim and experimental design 
 
Protein phosphorylation controls many basic cellular processes, such as cell 
growth, differentiation, migration, metabolism, and cell death, and its study can 
provide key insights into the signal transduction pathways that are activated in 
cells in response to different stimuli (Cohen, 2002). This post-translational 
modification is controlled by two families of proteins: kinases and phosphatases, 
which add or remove the phosphate group, respectively (Montoya et al., 2011). 
Recently, quantitative proteomics has emerged as a powerful tool to study cell 
signalling on a proteome-wide scale (de la Fuente van Bentem, Mentzen, de la 
Fuente, & Hirt, 2008). Compared to western blotting which typically focus on 
one protein at a time, the phosphoproteomic approach has the advantage of 
studying many phosphoproteins and phosphorylation sites at once (Jensen, 
2006). Furthermore, the phosphoproteomic approach provides a quantitative 
analysis of the proteins that are phosphorylated and on the level of 
phosphorylation, compared to western blotting which is a semiquantitative 
technique (Schmelzle & White, 2006). The questions I wanted to answer using 
the mass-spectrometry based phosphoproteomic approach were two: 1) which 
are the signalling pathways that are activated in response to ATP stimulation and 
2) which are the pathways that are regulated selectively by P2X7R. To answer 
these important questions, I stimulated BMDMs from WT and from the two 
P2X7 deficient mouse strains GSK and Pfizer with or without ATP 5 mM using 
three different time points: 5, 15 and 30 minutes. In order to reduce as much as 
possible the basal levels of protein phosphorylation and to syncronize the cells, I 
have serum starved them for 12 hours. Due to the high protein concentration 
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required (500 μg) for mass spectrometry analysis, I collected bone marrow cells 
from three different mice per strain. After five days of differentiation in L929 
medium, cells were counted and seeded into 100 mm culture dishes at a density 
of 5 x 106 cells per condition. At the end of the stimulation, I aspirated the 
medium and washed the cell layers with cold PBS. I then collected the cells by 
scraping and centrifuge them at 4 0C for five minutes at 15000 x g. Cell pellets 
were then stored in -800 C until further analysis. 
  
Results 
 
The number of phosphoserine- or phosphothreonine-containing peptides 
detected by mass-spectrometry was 1271. The level of phosphorylation of these 
peptides was mostly low under basal conditions and increased after stimulation 
with ATP. The phosphorylation levels at time zero were generally similar 
between macrophages from the three mouse strains. However, some peptides 
showed high basal phosphorylation levels in WT BMDMs and low in the P2X7 
deficient ones and vice versa. In many cases more than one peptide within the 
same protein were phosphorylated. To compare the levels of phosphorylation of 
peptides at different time points and between macrophages from the 3 mouse 
strains a heat map has been generated (figure 4.4A) in which the colour intensity 
correlates with the level of phosphorylation of each protein or peptide. To 
investigate P2X7R involvement in the phosphorylation of these peptides, I have 
analyzed and compared the phosphorylation levels between macrophages from 
the three mouse strains both under basal conditions and after ATP treatment. 
The analysis of the phosphorylation levels under basal conditions of the 1271 
phospho-peptides detected by mass-spectrometry, revealed that 31 were 
significantly different between WT and P2X7 KO BMDMs. Interstingly, 16 
peptides were much more highly phosphorylated in both GSK and Pfizer 
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macrophages (table 4.2), while 15 resulted more phosphorylated in the WT ones 
(table 4.1). Among the peptides that showed higher basal phosphorylation levels 
in WT compared to P2X7 KO macrophages, several of them belong to proteins 
that play an important role in translation such as the eukaryotic translation 
initiation factors 4 gamma and beta, Pre-mRNA 3' end processing factor Fip1, 
High mobility group protein HMG-I/HMG-Y and Heterogeneous nuclear 
ribonuclear proteins C1/C2 (Khaleghpour, Pyronnet, Gingras, & Sonenberg, 
1999), (Du & Maniatis, 1994). Other peptides that exhibit higher 
phosphorylation levels in macrophages from WT mice compared to the ones 
from P2X7 deficient mice belong to proteins involved in cytoskeleton 
organization and cell migration including, Microfibrillar associated protein 1 and 
Marcks related protein 1 (Finlayson & Freeman, 2009). The peptides that were 
more phosphorylated in P2X7 deficient macrophages belong to proteins with 
very different biological functions. These include proteins involved in the 
translation process such as the La-related protein 1 (LARP-1) and Pumilio 
homolog 2 (Burrows et al., 2010). The latter is a sequence-specific RNA-binding 
protein that regulates translation and mRNA stability by binding the 3'-UTR of 
mRNA targets (Burrows et al., 2010), (Jenkins, Baker-Wilding, & Edwards, 2009). 
Some peptides belong to proteins that regulate cell cycle progression such as E3 
ubiquitin protein ligase Rbbp6 also called Retinoblastoma binding protein 6. This 
protein interacts with both p53 and pRb, and has been identified as an E3 
ubiquitin ligase due to the presence of a RING finger domain. It has been shown 
that RBBP6 promotes the degradation of p53, thereby increasing cell 
proliferation (Motadi, Bhoola, & Dlamini, 2011).  Another protein that appears 
to be more phosphorylated in P2X7 KO macrophages under basal conditions is 
the regulator of G protein signalling 14 (RGS 14), a member of the G protein  
signalling family, which has been shown to act as accelerator of Gα-mediated 
GTP hydrolysis but it has also been reported that RGS14 facilitates the formation 
of a selective Ras-GTP-Raf-MEK-ERK multiprotein complex to promote sustained 
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ERK activation which is critical for neuronal cell differentiation (Willard et al., 
2009). Serine/threonine-protein kinase ULK1 is also highly phosphorylated in 
P2X7 KO macrophages. This kinase is involved in autophagy, a homeostatic 
process by which cells adapt to nutrient starvation breaking down their own 
components (Levine, Mizushima, & Virgin, 2011). Ulk1 has been shown to act 
both as a downstream effector and negative regulator of mammalian target of 
rapamycin complex 1 (mTORC1) (Kim, Kundu, Viollet, & Guan, 2011). More than 
30 different signalling pathways were activated in response to ATP, the most 
activated ones are summarized in table 4.3. Among them, the MAPK pathway 
appears to be the most important one with a total of 20 proteins involved. The 
phosphorylated proteins that belong to the MAPK signalling pathway are listed 
in table 4.4. To establish the relative contribution of P2X7R in the activation of 
the MAPK pathway, I have compared the phosphorylation levels of proteins 
involved in this pathway in WT and P2X7 deficient BMDMs both under basal 
conditions and after stimulation with ATP. As shown in figure 4.4.D, ATP 
stimulation leads to an increase phosphorylation of Protein phosphatase 3, 
Stathmin and Tao kinase 3 only in WT BMDMs, while in macrophages from both 
GSK and Pfizer knock-out mice the phosphorylation levels of these proteins 
remained the same as when unstimulated. These results indicate that P2X7R is 
playing a key role in this process. Protein phosphatase 3, also called calcineurin, 
is a key signaling molecule which has been shown to be involved in diverse types 
of physiological processes (Bandyopadhyay et al., 2002). It is a calcium 
dependent serine/threonine phosphatase which is known to regulate the 
transcription of the T-cell growth factor and interleukin-2 as well as to mediate 
the dephosphorylation of the transcription factor NF-ATp (nuclear factor–
activated T cells), an important step necessary for the translocation of NF-AT 
from the cytoplasm to the nucleus, where it induces the transcription of various 
immune response genes in T lymphocytes as well as genes with diverse 
functions in other cell types (Sanna, Bueno, Dai, Wilkins, & Molkentin, 2005). 
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Stathmin is a ubiquitous, highly conserved 18-kDa cytoplasmic protein which 
triggers the depolymerization of microtubules into short tubulin oligomers and  
has been shown to be a critical regulator of cell migration and cell cycle 
progression through its control of interphase microtubule dynamics and the 
assembly of the mitotic spindle (Ng, Zhao, Yeap, Ngoei, & Bogoyevitch, 2010). 
Tao (Thousand and one amino acids) kinase 3 is known to act upstream of 
MAPKs activating p38 MAPK in response to DNA damage. TAO kinases have 
been implicated in regulation of cytoskeleton stability, G protein-coupled 
receptor signaling to p38, and cell survival (Hutchison, Berman, & Cobb, 1998), 
(Chen et al., 2003). Other proteins such as Fas death domain associated protein, 
Mitogen associated kinase 8, and Phospholipase A2 showed higher 
phosphorylation levels in WT BMDMS compared to the GSK and Pfizer ones, 
however also macrophages from P2X7 deficient mice exhibit an increased 
phosphorylation in response to ATP suggesting that other purinergic receptors 
might contribute to the phosphorylation of these proteins (figure 4.4.E). 
Interestingly, JunD appeared to be more phosphorylated in the knock-out 
BMDMs compared to the WT ones following ATP stimulation, which might 
suggest that P2X7R negatively regulates JunD phosphorylation in response to 
ATP (figure 4.4 E). However, it is important to consider that phosphorylation 
does not necessarily mean activation. Many proteins, indeed, become 
inactivated when phosphorylated. Among the signalling pathways that appear to 
be more activated in response to ATP stimulation is the mTOR signalling 
pathway. Nine peptides within this pathway showed an increased 
phosphorylation after treatment with ATP in macrophages from WT and P2X7 
deficient mice (figure 4.4F). Apart from AKT1 and Ribosomal protein S6 kinase 
which shows higher phosphorylation levels in response to ATP in WT BMDMs, all 
the other peptides surprisingly were more phosphorylated in macrophages from 
P2X7 deficient mice (figures 4.4F and 4.4G). One other important signalling 
pathway that appears to be activated by ATP is the ribosome pathway with 15 
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phosphorylated peptides. Interestingly, all these peptides showed an increased 
phosphorylation following ATP stimulation only in macrophages from WT mice 
and not in the P2X7 deficient ones (figures 4.4H and 4.4J). This is a very 
important finding which clearly demonstrates a fundamental role of P2X7R in 
the regulation of the translation process. Many other proteins showed an 
increased phosphorylation only in macrophages from WT mice after treatment 
with ATP. Some of these proteins are implicated in endocytic membrane 
trafficking such as intersectin 1 which is known to regulate the formation of 
clathrin-coated vesicles (Pechstein et al., 2010). As shown in figure 4.4K 
intersectin 1 appears to be phosphorylated in two different sites in response to 
ATP and in both of them an increased phosphorylation occurred only in WT 
BMDMs. Two other proteins that participate in vesicular transport from the 
endoplasmic reticulum to the Golgi complex, Bet 1 and COG3, showed an 
increased phosphorylation in response to ATP stimulation only in WT BMDMs 
confirming the important role of P2X7R in the regulation of vesicle transport 
(Zhang & Hong, 2001) (figure 4.4L). 
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Figure 4.4A Heat map of phosphorylated peptides in BMDMs from WT and 
P2X7 deficient mice treated with or without ATP. 
The phosphorylation data obtained by mass spectrometry analysis were used to 
generate a heat map. Each column of the heat map represents one time point of 
the time course experiment and the colour intensity correlates to the intensity 
(log ratio) of the phosphorylation of each peptide at the specified time point, 
with blue representing the highest level of phosphorylation and yellow the 
lowest one. 
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Peptide/protein Phosphorylation site 
Osteopontin 1 S263 
Marcks related protein 1 T86 
Eukaryotic translation initiation factor 4 gamma S1190 
Heterogeneous nuclear ribonuclear proteins C1/C2 S233 
Heat Shock Protein 105 KDa S811 
Eukaryotic initiation translation factor 4b S407 
Pre-mRNA 3' end processing factor Fip1 S281 
High mobility group protein HMG-I/HMG-Y S100 
Pleckstrin S118 
Calpastatin S445 
Hepatoma derived growth factor related protein 2   S367-S368 
Myosin regulatory light chain RLC-a T20-T21 
Microfibrillar associated protein 1 S117-S119 
Probable ATP dependent RNA helicase Ddx46 S805 
Histone deacetylase 1   S422-S424 
Table 4.1 List of peptides/proteins showing higher basal phosphorylation levels 
in WT macrophages compared to the P2X7 deficient ones. 
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Figure 4.4B Heat map representing the differences in basal phosphorylation 
levels of peptides between WT and P2X7 deficient macrophages. 
 
 
 
 
 
 
 
144 
 
Peptide/protein Phosphorylation site 
Pyruvate dehydrogenase E1 component subunit alpha S233 
Protein transport protein Sec61 subunit beta S18 
Cullin 4a S11 
Myosin9 S1944 
Phosphoacetylglucosamine mutase3 T63 
Heat shock protein HSP 90 beta S256 
E3 ubiquitin protein ligase Rbbp6 S1180 
Nardilysin 1 S86 
Pumilio homolog 2 S137 
La related protein1 S69 
NAD kinase S65 
DNA Ligase 1 S52 
Regulator of G protein signalling 14 S290 
Receptor expression enhancing protein 4 S153 
Proteasome subunit alpha type  3 S251 
Serine-threonine protein kinase Ulk1 S638 
Table 4.2 List of peptides showing higher basal phosphorylation levels in P2X7 
deficient macrophages compared to the WT ones. 
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Figure 4.4C Heat map representing the differences in basal phosphorylation levels of 
peptides between WT and P2X7 deficient macrophages. 
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Pathway Number of phosphorylated 
peptides/proteins 
MAPK signalling pathway 20 
Fc-gamma receptor mediated 
phagocytosis 
18 
Insulin signalling pathway 16 
Chemokine signalling pathway 16 
Endocytosis 16 
Ribosome 15 
Regulation of actin cytoskeleton 15 
B cell receptor signalling pathway 10 
Apoptosis 10 
Toll-like receptor signalling pathway 10 
T cell receptor signalling pathway 10 
mTOR signalling pathway 9 
Phosphatidylinositol signalling system 9 
Table 4.3 Signalling pathways activated in BMDMs from WT and P2X7 deficient 
mice in response to ATP. 
Mass spectrometry analysis of BMDMs from WT and P2X7 deficient mice 
revealed that in response to ATP stimulation 35 signalling pathways were 
activated. Here are represented the most activated ones with the number of 
phosphorylated peptides within each pathway. 
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Table 4.4 List of peptides/proteins belonging to the MAPK signalling pathway 
that show an increased phosphorylation in response to ATP in macrophages 
from WT and P2X7 deficient mice. 
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Figure 4.4D Phosphorylation of Protein phosphatase 3, Stathmin and Tao 
kinase 3 (members of the MAPK pathway) in response to ATP in macrophages 
from WT and P2X7 deficient mice. 
ATP stimulation led to an increased phosphorylation of Protein phosphatase 3, 
Stathmin and Tao kinase 3 in WT BMDMs, while both GSK and Pfizer P2X7R 
deficient macrophages showed similar levels of phosphorylation as under basal 
conditions. 
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Figure 4.4E Phosphorylation of Fas death domain associated protein, Mitogen-
activated kinase 8, Phospholipase A2 and Jun D proteins in response to ATP in 
BMDMs from WT and P2X7 deficient mice. 
In response to ATP, WT BMDMs showed higher phosphorylation levels of Fas 
death domain associated protein, Mitogen-activated kinase 8 and Phospholipase 
A2 compared to GSK and Pfizer BMDMs. JunD was more phosphorylated in GSK 
and Pfizer macrophages compared to the WT ones. 
 
 
 
150 
 
 
 
GENE ID PHOSPHORYLATED PEPTIDES/PROTEINS 
PDPK1_MOUSE 3-phosphoinositide dependent protein kinase-1 
ULK1_MOUSE Unc 51- like kinase 1 (C.elegans) 
IF4B_MOUSE Eukaryotic translation initiation factor 4B 
PI3R5_MOUSE Phosphoinositide- 3-kinase, regulatory subunit 5, p101 
RS6_MOUSE Ribosomal protein S6 
RPTOR_MOUSE Regulatory associated protein of mTOR, complex 1 
KS6A1_MOUSE Ribosomal protein S6 kinase, polypeptide 1 
KS6A3_MOUSE Ribosomal protein S6 kinase, polypeptide 3 
AKT1_MOUSE Thymoma viral proto-oncogene 1; similar to serine/threonine protein 
kinase 
Table 4.5 List of peptides/proteins belonging to the mTOR signalling pathway 
that show an increased phosphorylation in response to ATP in macrophages 
from WT and P2X7 deficient mice. 
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Figure 4.4F Levels of phosphorylation of different peptides belonging to the 
mTOR signalling pathway in response to ATP in WT and P2X7 deficient 
BMDMs. 
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Figure 4.4G Phosphorylation levels of different peptides belonging to the 
mTOR signalling pathway in response to ATP in WT and P2X7 deficient 
BMDMs. 
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Figure 4.4H Phosphorylation levels of ribosomal proteins in WT and P2X7 
deficient BMDMs in response to ATP. 
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Figure 4.4J Phosphorylation levels of ribosomal proteins following ATP 
stimulation in macrophages from WT and P2X7 deficient mice. 
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Figure 4.4K Intersectin-1 phosphorylation levels in response to ATP stimulation 
in BMDMs from WT and P2X7 deficient mice. 
ATP stimulation leads to an increased phosphorylation of intersectin-1 at two 
different sites only in BMDMs from WT mice. GSK and Pfizer macrophages 
exhibit similar levels of phosphorylation as when unstimulated. 
 
 
 
Figure 4.4L Bet-1 and COG-3 phosphorylation levels in response to ATP in 
BMDMs from WT and P2X7 deficient mice. 
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4.5 DISCUSSION 
My studies led me to the following conclusions: 
According to the Western blotting results 
1. ATP stimulation leads to a time dependent increased phosphorylation of 
ERK1/2 in macrophages from WT mice, while no increase was seen in 
macrophages from both GSK and Pfizer P2X7 deficient mice.  
2. ATP induces a greater time dependent increased phosphorylation of 
mTOR (Ser 2448) in BMDMs from WT mice compared to macrophages from 
P2X7 knock-out mice.  
3. ATP increases the phosphorylation of S6 ribosomal protein (Ser 235-236) 
in macrophages from WT and P2X7 deficient mice in a time dependent manner, 
however the levels of phosphorylation were much higher in macrophages from 
the WT mice compared to the P2X7 knock-out ones. 
According to the mass spectrometry analysis 
1. A thousand two hundred and 71 peptides were phosphorylated in 
macrophages from WT and P2X7 deficient mice both under basal conditions and 
after treatment with ATP. 
2. Under basal conditions, the majority of peptides exhibited low 
phosphorylation levels which were similar in macrophages from the three 
mouse strains. 
3. Among the 1271 phosphorylated peptides, 31 showed significantly 
different basal phosphorylation levels between WT and P2X7 KO macrophages: 
16 appeared to be much more phosphorylated in P2X7 KO macrophages, 
whereas 15 showed higher basal phosphorylation levels in the WT ones. 
4. Thirty five distinct signalling pathways were activated in macrophages 
from WT and P2X7 deficient mice. 
157 
 
5.   The signalling pathway that appears to be the most activated one with 
20 different phosphorylated peptides involved is the MAPK pathway. 
6. Among the phosphorylated proteins belonging to the MAPK pathway, 
Protein phosphates 3, Stathmin and Tao kinase 3 showed an increased 
phosphorylation following ATP treatment only in macrophages from WT mice, 
while BMDMs from both GSK and Pfizer KO mice exhibited similar levels as when 
unstimulated. 
7. Other proteins within the MAPK signalling pathway such as Fas death 
domain associated protein, Phospholipase A2 and Mitogen activated kinase 8 
showed an increased ATP dependent phosphorylation both in macrophages 
from WT mice and in the ones from P2X7 deficient mice, however the levels of 
phosphorylation were higher in WT BMDMs compared to the KO ones. 
8. JunD (Ser101) showed higher levels of phosphorylation after treatment 
with ATP in macrophages from P2X7 deficient mice, compared to the ones from 
WT mice. 
9. ATP stimulation induced the activation of the mTOR signalling pathway, 
leading to an increased phosphorylation of nine peptides. Among them, only S6 
kinase and Akt showed higher levels of phosphorylation in macrophages from 
WT mice compared to the ones from P2X7KO mice. All the other peptides 
appeared to be more phosphorylated in macrophages from the P2X7 deficient 
mice. 
10. ATP strongly activated the ribosome pathway, leading to an increased 
phosphorylation of 15 different peptides.  
11. All the peptides belonging to the ribosome pathway exhibited an ATP 
dependent increased phosphorylation only in macrophages from WT mice and 
not in BMDMs from the two P2X7 deficient mouse strains. 
12. Several proteins involved in the regulation of vesicle transport and actin 
cytoskeleton organization, such as Bet1 and COG3 showed an increased 
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phosphorylation following ATP treatment only in macrophages from WT and not 
P2X7 KO mice. 
 
Analysis of the cell signalling cascade following P2X7R activation by ATP 
My Western blotting results clearly demonstrate an important role of P2X7R in 
the activation of the MAPK signalling pathway. Indeed, only macrophages from 
WT mice show an increased phosphorylation of ERK1/2 in response to ATP, 
while no effects at all were seen in both GSK and Pfizer macrophages. Several 
studies have established that extracellular nucleotides acting via P2X7R can 
induce the activation of the MAPK signalling pathway. Papp et al. have shown 
that ATP treatment significantly increases p38 MAPK phosphorylation in 
hippocampal cells from WT mice, and these effects were absent in the 
hippocampal cells of P2X7R KO mice (Papp et al., 2007). Another study from 
Noguchi et al. also revealed that ATP induces an increased phosphorylation of 
p38 MAPK in Raw 264.7 cells and that this effect is completely abolished by the 
use of a selective P2X7 antagonist (Noguchi et al., 2008). Further studies from 
Bradford et al. also showed that exposure of parotid acinar cells to ATP and the 
P2X7 agonist BzATP produced time-dependent increases in ERK1/2 activity 
(Bradford & Soltoff, 2002). My Western blotting results appear to be therefore 
in accordance with these studies.  
Phosphoproteomic analysis 
The data obtained by mass spectrometry analysis confirm the ability of ATP to 
activate the MAPK signalling pathway and more importantly reveal that among 
the 35 different signalling pathways activated in response to ATP the MAPK 
pathway was the most activated one with 20 different proteins showing an 
increased phosphorylation in response to the treatment. However, surprisingly 
nor p38 MAPK nor p42/p44 were among the phosphorylated proteins detected. 
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One possible explanation could be that the instrument settings for mass-
spectrometry analysis were not appropriate for the detection of these 
phosphorylated proteins. The instrument was set to select the five most 
abundant multiply charged ions present in the survey spectrum, therefore it is 
possible that both p38 and p42/p44 were not included in this selection. In this 
case, additional runs of the samples extending the spectrum of analysis are 
necessary to detect phospho-ERK and phospho-p44/42. Furthermore, among 
the 20 phosphorylated proteins belonging to the MAPK pathway, three of them 
(Calcineurin or Protein phosphates 3, Stathmin and Tao kinase 3) showed an 
increase phosphorylation following ATP treatment only in macrophages from 
WT mice. This clearly indicates that P2X7R is playing an important role in this 
process and its expression is needed for the increased phosphorylation to occur. 
Interestingly, the family of Tao kinases have been shown to activate p38 MAPK 
in response to DNA damage and other stimuli (Raman et al., 2007). Other 
proteins within the MAPK signalling pathway such as Phospholipase A2 showed 
an increased phosphorylation in response to ATP in macrophages from both WT 
and P2X7 deficient mice. However, macrophages from WT mice exhibited higher 
levels of phosphorylation suggesting that P2X7 is playing a role but other 
purinergic receptors expressed by macrophages from P2X7 KO mice might also 
contribute to this process. Several studies have previously shown that ATP 
induces phospholipase A2 activation. One study conducted on ductal cells of rat 
submandibular gland, showed that ATP activates phospholipases A2 in these 
cells and that the response to ATP was inhibited by the nonselective P2X 
purinergic antagonist suramin (Alzola et al., 1998). My results appear to be in 
accordance with these studies and demonstrate that P2X7R is certainly involved 
in this process, however it is very likely that other purinergic receptors are also 
contributing to Phospholipase A2 activation. In their study Alzola et al. indeed, 
showed that Phospholipase A2 activation was blocked by the use of suramin, 
which is known to inhibit not only P2X7R but all purinergic receptors. My 
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Western blotting results also reveal that ATP activates the mTOR signalling 
pathway leading to an increased phosphorylation of mTOR (Ser 2448) and 
ribosomal protein S6 (Ser 235-236). Both mTOR and S6 showed higher levels of 
phosphorylation in macrophages from WT mice compared to macrophages from 
P2X7 deficient mice. The data obtained by mass spectrometry analysis confirm 
that the mTOR signalling pathway is activated in response to ATP and nine 
peptides within the pathway resulted phosphorylated. Among them, only S6 
kinase and Akt showed higher levels of phosphorylation in macrophages from 
WT mice compared to the ones from P2X7KO mice. All the other peptides 
appeared to be more phosphorylated in macrophages from the P2X7 deficient 
mice. Surprisingly also S6 ribosomal protein, differently from what shown by 
Western blotting, exhibited higher levels of phosphorylation in macrophages 
from both GSK and Pfizer KO mice compared to the WT ones. Taken together 
these findings seem to indicate that either P2X7R contribution to the activation 
of the mTOR signalling pathway is marginal compared to the role of other 
purinergic receptors or that P2X7R might in some circumstances act as a 
negative regulator of this pathway.  However, the interpretation of these data is 
not so straight forward. Indeed, phosphorylation does not necessarily mean 
activation. Furthermore, the mTOR signalling pathway, regulating very 
important cellular processes such as proliferation, migration and translation, is a 
very complex pathway with many proteins involved and in response to different 
stimuli, some branches of the pathway will be upregulated while others 
downregulated. Therefore it is possible that P2X7R might play a central role in 
some of the mTOR biological functions and at the same time being a negative 
regulator of others. Another important signalling pathway activated by ATP is 
represented by the ribosomal pathway. Fifteen peptides within the ribosomal 
pathway showed an increased phosphorylation following ATP stimulation. All of 
these peptides interestingly, showed an increased phosphorylation in response 
to ATP treatment only in macrophages from WT mice suggesting that P2X7R 
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plays a key role in the regulation of this pathway. P2X7R appear to have a 
fundamental role also in vesicle transport as the majority of the phosphorylated 
proteins involved in this process were selectively upregulated in macrophages 
from WT mice compared to the ones from P2X7 KO mice. Several studies have 
previously shown that P2X7 regulates vesicle formation and trafficking (Solini et 
al., 1999; Gutierrez-Martin et al., 2011). An extensive study on P2X7R-mediated 
effects on membrane composition and trafficking in the plasma membrane has 
been conducted by Qu et al. who have demonstrated that P2X7R regulates 
multiple types of membrane trafficking responses including transfer of 
Phosphatidyl serine to the extracellular leaflet of the plasma membrane, 
shedding of plasma membrane surface proteins, plasma membrane microvesicle 
release and transfer of endosomal contents to the cytosolic compartment (Qu & 
Dubyak, 2009). Furthermore, several proteins involved in actin cytoskeleton 
organization such as vimentin, plastin 2, stathmin and phostensin showed much 
higher levels of phosphorylation in macrophages from WT mice compared to 
BMDMs from P2X7 deficient mice suggesting that P2X7R is also having an 
important role in this process.  
 
Limitations of the phosphoproteomic analysis 
Despite the great progress that mass spectrometry-based phosphoproteomics 
has made in the analysis of protein phosphorylation and molecular signaling in 
cells, it is still a considerable challenge due to the low stoichiometry of protein 
phosphorylation and the resulting low abundance of phosphopeptides. The 
isolation of phosphopeptides represents a key step in the entire 
phosphoproteome analysis and current isolation methods cannot always 
guarantee a high efficiency, selectivity, sensitivity and reproducibility due to the 
nature of the heterogeneous environment and nonlinear binding dynamics 
when dealing with extremely low abundant phosphopeptides.  This important 
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limitation of the phosphoproteomic approach needs to be taken into account 
when interpreting the results of a study and might explain the inconsistency of 
some results from one run to the next. The results of the phosphoproteomic 
analysis presented in this thesis in some cases show a poor consistency. Some 
peptides for example show an increased phosphorylation after 5 minutes 
stimulation with ATP, then the phosphorylation levels go back to basal levels 
after 15 minutes to finally go up again after 30 minutes stimulation. Other 
peptides have very high basal phosphorylation levels, then the phosphorylation 
levels dramatically drop after 5 minutes stimulation with ATP, go up again after 
15 minutes to finally drop after 30 minutes. On the other hand, when the effect 
of ATP stimulation on the phosphorylation of peptides within the ribosomal 
pathway was analysed, all the peptides showed the same pattern of 
phosphorylation, revealing low basal phosphorylation levels and a progressive 
time-dependent increase in macrophages from WT mice while macrophages 
from the two P2X7 deficient lines, starting from similar basal levels of 
phosphorylation, did not show any increase after ATP stimulation. The 
inconsistency of some of the findings clearly indicates that in order to guarantee 
data’s accuracy and reproducibility, the same sample should be run several 
times and a single experiment cannot therefore lead to unequivocal conclusions.  
 
 
Key discoveries in this chapter 
To my knowledge, this is the first time quantitative phosphoproteomics has 
been used to analyse the cell signalling cascade following P2X7R activation by 
ATP. Furthermore, the specific P2X7R contribution to the activation of the 
different signalling pathways has been investigated comparing macrophages 
from WT mice with the ones from two different P2X7 deficient lines. Taken 
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together my data appear to demonstrate for the first time a crucial role for 
P2X7R in the regulation of ribosomal activity as well as in vesicle transport and 
cytoskeleton organization. In addition, my data show that P2X7R contributes to 
the activation of other important signalling pathways, including MAPK and 
mTOR, indicating also an important role for this receptor in the regulation of cell 
growth and proliferation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
164 
 
CHAPTER FIVE-ACTIVATION OF THE INFLAMMASOME 
PATHWAY IN BMDM FROM WKY AND LEWIS RATS 
 
5.1 INTRODUCTION 
 
5.2 BMDM FROM WKY RATS SHOW AN UPREGULATION OF THE MAJORITY OF 
THE INFLAMMASOME-RELATED GENES COMPARED TO THE LEWIS BMDM 
Aim and experimental design 
Results 
5.3 BMDM FROM WKY RATS EXHIBIT HIGHER LEVELS OF P2X7 PROTEIN AND 
RELEASE SIGNIFICANT HIGHER LEVELS OF ACTIVE IL-1 BETA, IL-18 AND 
CASPASE-1 IN RESPONSE TO ATP COMPARED TO LEWIS RATS 
Aim and experimental design 
Results 
5.4 CASPASE-1 INHIBITION DRAMATICALLY AFFECTS BOTH IL-1B AND IL-18 
SECRETION IN BMDM FROM WKY RATS 
Aim and experimental design 
Results 
5.5 NEPHRITIC GLOMERULI FROM WKY RATS SHOW HIGHER LEVELS OF P2X7 
PROTEIN AND ACTIVE IL-1 BETA, IL-18 AND CASPASE 1 COMPARED TO LEWIS 
GLOMERULI 
Aim and experimental design 
Results 
165 
 
5.6 ANALYSIS OF THE INFLAMMASOME ACTIVATION IN BMDM FROM 
CONGENIC RAT STRAINS 
Aims an experimental design 
Results 
 
5.7 ROLE OF JUND IN THE REGULATION OF THE INFLAMMASOME ACTIVATION 
Aims an experimental design 
Results 
 
5.8 DISCUSSION 
 
 
 
 
 
 
 
 
 
 
166 
 
5.1 INTRODUCTION 
 
Several studies have shown that, in the rat model of nephrotoxic nephritis 
(NTN), the Wistar-Kyoto (WKY) rat is markedly susceptible to crescentic 
glomerulonephritis (CRGN), as injection of a small dose of nephrotoxic serum, 
that is subnephritogenic in many other strains tested, leads to rapid onset of 
nephrotoxic nephritis, characterised by the development of albuminuria by day 
4, crescent formation in at least 80% of glomeruli by day 11 and progression to 
severe scarring, leading to renal failure within 6 weeks (Tam et al., 1999; Smith 
et al., 2007; Maratou et al., 2011). In contrast Lewis (LEW) rats, which share the 
same MHC haplotype (RT1-l), when injected with the same dose of nephrotoxic 
serum, develop only mild glomerular hypercellularity with no crescents at all 
(Smith et al., 2007). Isome et al. have demonstrated the predominant role of 
macrophages in inducing glomerular injury in CRGN, representing the major cell 
type in the glomerular infiltrate and their accumulation correlating with the 
degree of histological and functional injury (Isome et al., 2004). Several 
phenotypic differences have been identified between BMDM from WKY rats and 
those from LEW rats including enhanced antibody-dependent cytotoxicity, Fc 
receptor-mediated phagocytosis and Fc-receptor-dependent oxidative burst, as 
well as increased inducible nitric oxide synthase gene (Nos2) expression upon 
LPS stimulation (Behmoaras et al., 2008). Further studies from Smith et al. 
(Smith et al., 2007) have shown that the susceptibility to crescent formation can 
be transferred through bone marrow transplants so that Lewis rats that receive 
bone marrow from WKY rats develop crescents but fewer compared to WKY rats 
unmanipulated or receiving isologous bone marrow. Aitman et al. have 
conducted a genome-wide linkage analysis of an F2 population derived from 
WKY and LEW rats and mapped seven CRGN quantitative trait loci (QTL) 
indicated as Crgn1-7 linked to crescent formation, proteinuria or macrophage 
infiltration (Aitman et al., 2006). The two most significant linkage peaks were 
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identified on chromosomes 13 (Crgn1) and 16 (Crgn2) respectively. Within the 
CRgn1 region, deletion of an Fc receptor gene, Fcgr3-rs, has been recognised as 
a cause of macrophage over-activity and CRGN susceptibility (Behmoaras et al., 
2010), while the CRgn2 region contains the AP-1 transcription factor JunD which 
is markedly upregulated in the WKY rat which explains the enhanced 
macrophage oxygen burst activity as well as increased iNOS synthesis and WKY 
susceptibility to CRGN (Behmoaras et al., 2008). Single and double congenic rat 
strains have been then generated by Behmoaras et al. introgressing either Crgn1 
or Crgn2 or both congenic intervals together, from Lew rats onto a WKY genetic 
background. After injection of nephrotoxic serum, introgression of LEW Crgn2 
into the WKY recipients reduced glomerular crescents by 8%, and the single 
phenotypic effect of LEWCrgn1 corresponded to a reduction of 18%. 
Introgression of both LEW Crgn1 and Crgn2 into the WKY genetic background 
reduced glomerular crescents by 34%, demonstrating a synergistic effect of both 
Crgn loci on glomerular crescent formation (Behmoaras et al., 2010). The 
identification of the quantitative trait loci Crgn1 and Crgn2 however, only partly 
explained the susceptibility of WKY rats to CRGN. Indeed, the double-congenic 
strain still exhibits significant glomerular crescent formation, indicating that 
other genetic loci are playing a role. Therefore, in view of the already 
demonstrated role of P2X7R in glomerulonephritis and due to the high 
reproducibility of the rat model of nephrotoxic nephritis, I decided to investigate 
the P2X7-mediated inflammasome activation in bone marrow derived 
macrophages from WKY and LEW rats.  
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5.2 BMDM FROM WKY RATS SHOW AN UPREGULATION OF THE 
MAJORITY OF THE INFLAMMASOME-RELATED GENES COMPARED 
TO THE LEWIS BMDM 
 
Aim and experimental design 
 
To assess whether there was any differences in the P2X7-mediated 
inflammasome activation between BMDMs from WKY and LEW rats, I have 
initially examined by Real-Time PCR the expression in these cells, under basal 
conditions, of several genes involved in the inflammasome pathway including 
P2X7, pro-IL-1β and its physiological inhibitor IL-1RN (IL-1β receptor antagonist), 
pycard (ASC), pro-caspase-1, pro-IL-18 and its inhibitor IL-18 binding protein (IL-
18 bp). BMDMs from double congenic (DC) rats were also included in the 
analysis. 
 
Results 
 
As shown in figure 5.2 A and B, under basal conditions, BMDMs from WKY and 
DC rats exhibit a marked upregulation of the majority of the inflammasome-
related genes analysed compared to BMDMs from LEW rats. In particular, the 
most significant differences in genes expression between WKY and LEW BMDMs 
were related to P2X7, IL-18, IL-18 binding protein and IL1 receptor antagonist. 
No differences were seen in the expression of pro-IL-1β between the three rat 
strains. BMDMs from DC rats show similar IL-18, IL-18 bp and pro-caspase-1 
mRNA levels compared to WKY BMDMs. Interestingly, DC BMDMs express 
higher P2X7 and IL1RN mRNA levels compared to WKY BMDM, although the 
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difference was not statistically significant. Macrophages from LEW rats express 
higher NLRP3 mRNA levels compared to WKY and DC ones. 
 
Figure 5.2A Inflammasome-related genes expression in BMDMs from WKY, DC 
and LEW rats. 
Expression of mRNA encoding P2X7R, IL-18, IL-1β receptor antagonist, pycard, IL-
18 binding protein, caspase 1, NLRP3 and IL-1β in BMDMs from WKY, DC and 
LEW rats under basal conditions. Mean expression at each time point is 
expressed as a ratio to that of the housekeeping gene HPRT. 
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Figure 5.2B Schematic diagram showing the differences in inflammasome-
related genes expression under basal conditions between WKY and LEW 
BMDMs. 
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5.3 BMDM FROM WKY RATS EXHIBIT HIGHER LEVELS OF P2X7 
PROTEIN AND RELEASE SIGNIFICANT HIGHER LEVELS OF ACTIVE 
IL-1 BETA, IL-18 AND CASPASE-1 IN RESPONSE TO ATP 
COMPARED TO LEWIS RATS 
 
Aim and experimental design 
 
In view of the RT-PCR results which reveal a marked upregulation of P2X7 gene 
in WKY and DC BMDM compared to the LEW ones, I have first analysed P2X7 
protein expression in these cells both under basal conditions and after 5 hours 
stimulation with LPS 1μg/ml. P2X7 protein expression was also examined in 
glomeruli isolated 4 days after the injection of nephrotoxic serum which were 
then cultured for 72 hours in serum free medium. Previous studies have shown 
that day four from the injection of nephrotoxic serum is the day of maximal 
macrophage accumulation and also maximal P2X7R expression (Turner et al., 
2007). In order to quantitatively examine and compare the levels of IL-1β 
released by BMDM from WKY and LEW rats in response to ATP, I have primed 
these cells with LPS for 5 hours using two different concentrations: a lower 
concentration of 100 ng/ml and a higher one of 1 μg/ml. The priming step was 
followed by stimulation with ATP 5 mM for 30 minutes. Supernatants were then 
collected and analysed by sandwich ELISA (RatIL-1β DuoSet ELISA kit R&D 
systems). Given the results of this experiment, which will be discussed in details 
in the results paragraph, all the other experiments were conducted using a 
concentration of LPS of 1 μg/ml as priming stimulus. Western blotting was used 
to detect both the precursors and the active forms of IL-1β, IL-18 and caspase-1. 
Furthermore, to establish whether the increased IL-1β and IL-18 secretion 
observed in WKY BMDM were due to an increase production of the precursors 
pro-IL-1β and pro-IL-18 in response to LPS priming, process that is controlled by 
the NF-κB pathway, I have examined the levels of both pro-IL-1β and pro-IL-18 in 
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the cell extracts from WKY, DC and LEW BMDM after treatment with LPS alone 
and LPS + ATP. 
 
Results 
 
As shown in figure 5.3 (A and B), under basal conditions WKY and DC BMDMs 
show similar levels of P2X7 receptor, while no band of the predicted size of 75 
KDa was detected in LEW BMDMs. After 5 hours stimulation with LPS 1 μg/ml, 
the WKY macrophages exhibit higher levels of P2X7 protein compared to DC 
BMDMs, while again no band was detected in the LEW ones. Quantitavive 
analysis by ELISA of IL-1β secretion in response to ATP in BMDMs from WKY and 
LEW rats which were primed with either LPS 100ng/ml or LPS 1 μg/ml revealed 
that in both conditions WKY macrophages produce significant higher levels of IL-
1β compared to LEW BMDMs (5.3C). The difference appears to be even greater 
when I used the lowest concentration of LPS. Interestingly, when primed with 
LPS 100 ng/ml, LEW BMDMs produce similar levels of IL-1β in response to ATP as 
when treated with LPS alone, while in WKY macrophages ATP stimulation leads 
to a tenfold increase in IL-1β levels compared to the levels observed when 
stimulated with LPS alone. Western blotting analysis of supernatants from WKY, 
DC and LEW macrophages shows that in response to ATP, LPS primed BMDMs 
from WKY rats show higher levels of active IL-1β, IL-18 and caspase-1 compared 
to both DC and LEW BMDMs (figure 5.3 D, E and F). Macrophages from DC rats 
release higher levels of active IL-1β, IL-18 and caspase-1 compared to LEW 
BMDMS but lower than WKY ones. The analysis of the expression of pro-IL-1β 
and pro-IL-18 in the cell extracts revealed no differences between BMDMs from 
WKY, DC and LEW rats (figure 5.3G and 5.3H), indicating that the increased 
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secretion of mature IL-1β and IL-18 in WKY BMDMs is not due to an increase 
synthesis of the precursors within the cell. 
 
 
 
 
 
  
 
 
 
 
 
 
BMDMs from WKY, DC and LEW rats were plated in six-well plates at a density of 
1 x 106 cells per well and stimulated with or without LPS 1 μg/ml for 5 hours. 
Aliquots of protein (20 μg) from cell lysates were separated by SDS-PAGE 
electrophoresis and transblotted to PVDF membrane. Detection of P2X7 was 
performed by Western blotting using anti-P2X7 specific antibody from Alomone 
Labs (Israel). β-actin was used as loading control.  
 
 
P2X7 
β-actin 
75 
37 
KDa  WKY         DC      LEW  WKY        DC     LEW 
untreated LPS 1μg/mL 
A B 
Figure 5.3A and B: P2X7R expression in untreated and LPS stimulated BMDMs 
from WKY, DC and LEW rats. 
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Figure 5.3C BMDMs from WKY rats show a lower threshold for the activation 
of the inflammasome compared to BMDMs from LEW rats. 
BMDMs from WKY and LEW rats were plated into six-well plates at a density of 1 
x 106 cells per well and primed with either LPS 100 ng/ml or LPS 1 μg/ml for five 
hours. Macrophages were then stimulated with ATP 5 mM for 30 minutes. 
Supernatants were then collected and examined by sandwich ELISA for 
quantification of IL-1β using the Rat IL-1β DuoSet kit (R&D Systems). Data are 
representative of three independent experiments. 
 
 *** P< 0.001 
**** P< 0.0001 
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Figure 5.3D IL-1 β secretion in WKY, DC and LEW BMDMs in response to ATP. 
BMDMs from WKY, DC and LEW rats were primed with LPS 1 μg/ml for 5 hours 
and then stimulated with or without ATP 5 mM for 30 minutes. Supernatant and 
cell layers were then collected and analysed by Western blotting. Pro- and active 
IL-1β were detected using a specific anti-IL-1β antibody from New England 
Biolabs (UK). 
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Figure 5.3E IL-18 secretion in WKY, DC and LEW BMDMs in response to ATP. 
BMDMs from WKY, DC and LEW rats were plated in six-well plates at a density of 
1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and then stimulated 
with or without ATP 5 mM for 30 minutes. Supernatants and cell layers were 
then collected and analysed by Western blotting. Pro- and active IL-18 were 
detected using a specific anti IL-18 antibody from Santa Cruz Biotechnology 
(USA). These data are representative of at least three independent experiments. 
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BMDMs from WKY, DC and LEW rats were plated in six-well plates at a density of 
1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and then stimulated 
with ATP 5 mM for 30 minutes. Supernatants and cell layers were then collected, 
filtered using Amicon ultra centrifugal filters for protein concentration and 
purification (Millipore) and analysed by Western blotting. Pro- and active 
caspase-1 were detected using a specific anti caspase-1 antibody from Santa 
Cruz Biotechnology (USA). These data are representative of at least three 
independent experiments. 
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LPS        +                     +                + 
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Figure 5.3F Caspase-1 activation in response to ATP in LPS primed macrophages 
from WKY, DC and LEW rats. 
178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMDMs from WKY, DC and LEW rats were plated in six-well plates at a density of 
1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and stimulated with or 
without ATP 5 mM for 30 minutes. Aliquots of protein (20 μg) from cell lysates 
were analysed by western blotting. Pro-IL-1β was detected using a specific anti-
IL-1β antibody from New England Biolabs (UK). 
 
 
 
pro-IL-1β 
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31 
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LPS      +            +        +          +        +           + 
ATP      -             +         -          +        -            + 
Figure 5.3G WKY, DC and LEW BMDMs show similar pro-IL-1 beta levels in 
response to LPS. 
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Figure 5.3H WKY, DC and LEW BMDMs show similar pro-IL-18 levels in 
response to LPS. 
BMDMs from WKY, DC and LEW rats were plated in six-well plates at a density of 
1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and stimulated with or 
without ATP 5 mM for 30 minutes. Aliquots of protein (20 μg) from cell lysates 
were analysed by Western blotting. Pro-IL-18 was detected using a specific anti-
IL-18 antibody from Santa Cruz Biotechnology, (USA). 
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5.4 CASPASE-1 INHIBITION DRAMATICALLY AFFECTS BOTH 
IL-1B AND IL-18 SECRETION IN BMDM FROM WKY RATS 
 
Aim and experimental design 
 
As discussed in the introduction, other proteases, such as the 
metalloproteinases MMP-9 and MMP-12, are able to generate active IL-1β in a 
caspase-independent manner. To establish whether the increase secretion of 
mature IL-1β in WKY BMDM was caspase-1 dependent, I have examined the 
effects of a selective caspase-1 inhibitor, Y-VAD, on the production of IL-1β and 
IL-18 in response to ATP in primed BMDM from WKY and LEW rats. I have then 
analysed by RT-PCR the expression of MMP-9 gene in BMDMs from WKY and 
LEW rats under basal conditions. MMP-9 enzymatic activity was assessed by 
SDS-PAGE gelatin zymography. 
 
Results 
 
As illustrated in figures 5.4 A and B, the use of the selective caspase-1 inhibitor 
Y-VAD dramatically affected the secretion of both mature IL-1β and IL-18 in WKY 
and LEW BMDMs, suggesting that the secretion of these cytokines in WKY 
BMDMs is mainly caspase-1 dependent. However, since the secretion of active 
IL-1β is not completely abolished in WKY macrophages, as shown in figure 5.4A, 
it is possible that other caspase-1 independent pathways contribute to the 
increased IL-1β production in these cells. Indeed, as shown in figure 5.4D MMP-9 
gene is markedly upregulated in WKY BMDMs compared to the LEW ones and is 
associated with an increased enzymatic activity as revealed by gelatin 
zymography (figure 5.4D and C). 
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Figure 5.4A Caspase-1 inhibition affects IL-1β secretion in WKY BMDMs. 
WKY and LEW BMDM were primed with LPS 1 μg/ml for 5 hours and then 
stimulated with ATP 5 mM for 30 minutes in the presence or absence of the 
selective caspase-1 unhibitor Y-VAD used at a final concentration in the medium 
of 100 μM. Supernatants and cell layers were then collected, filtered and 
analysed by Western blotting. 
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Figure 5.4B Caspase-1 inhibition dramatically affects IL-18 secretion in WKY 
BMDMs. 
WKY and LEW BMDMs were primed with LPS 1 μg/ml for 5 hours and then 
stimulated with ATP 5 mM for 30 minutes in the presence or absence of the 
selective caspase-1 unhibitor Y-VAD used at a final concentration in the medium 
of 100 μM. Supernatants and cell layers were then collected, filtered and 
analysed by Western blotting. 
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Figure 5.4C and D: MMP-9 enzymatic activity and gene expression are 
increased in WKY BMDMs. 
Detection of MMP-9 by gelatin zymography in BMDMs from WKY and LEW rats 
under basal conditions(C). Expression of mRNA encoding MMP-9 in untreated 
BMDMs from WKY and LEW rats (D). Mean expression at each time point is 
expressed as a ratio to that of the housekeeping gene HPRT. 
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5.5 NEPHRITIC GLOMERULI FROM WKY RATS SHOW HIGHER 
LEVELS OF P2X7 PROTEIN AND ACTIVE IL-1 BETA, IL-18 AND 
CASPASE 1 COMPARED TO LEWIS GLOMERULI 
 
Aim and experimental design 
 
To correlate the in vitro data with the in vivo model of NTN and to establish 
whether there was a correlation between the inflammasome activation and the 
severity of disease, I have examined the expression of IL-1β, IL-18 and caspase-1 
in glomeruli isolated from the renal cortex of WKY, DC and LEW rats four days 
after the injection of nephrotoxic serum. Glomeruli were isolated by sieving and 
cultured for 72 hours in serum free medium. No additional stimulus such as LPS 
or ATP was added to the medium. The decision to collect the glomeruli on day 4 
from the injection of nephrotoxic serum was suggested by the documented 
evidence that this time-point corresponds to the maximal macrophage 
accumulation and to the maximal P2X7R expression. After 72 hours of culture, 
supernatants and cell layers were collected, filtered using Amicon ultra 
centrifugal filters for protein purification and concentration and analysed by 
western blotting. 
 
Results 
 
WKY nephritic glomeruli show higher levels of P2X7 protein compared to DC and 
LEW glomeruli (figure 5.5 A). As shown in figures 5.5 B, C and D, glomeruli from 
WKY rats exhibit much higher levels of active IL-1β, IL-18 and caspase-1 
compared to glomeruli from Lew rats. Glomeruli from DC rats show higher levels 
of active IL-1β, IL-18 and caspase-1 compared to LEW glomeruli, but lower 
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compared to the WKY glomeruli resembling the grade of histological injury 
observed in vivo in these rat strains (figure 5.5E,F,G). 
 
 
 
 
Figure 5.5A P2X7 protein expression in cultured nephritic glomeruli from WKY, 
DC and LEW rats. 
At day 4 after NTS injection, glomeruli from WKY, DC and LEW rats were isolated 
from the renal cortex by sieving and cultured in serum free conditions for 72 
hours. Supernatants and cell layers were then collected, filtered using Amicon 
ultra centrifugal filters (Millipore) and analysed by western blotting. Detection of 
P2X7 was performed using an anti-P2X7 antibody from Alomone Labs (Israel). 
Beta-actin was used as loading control. 
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Figure 5.5B, C and D: WKY nephritic glomeruli exhibit higher IL-1 beta, IL-18 
and caspase-1 levels compared to LEW glomeruli. 
Nephritic glomeruli from WKY and LEW rats were isolated at day 4 from NTS 
injection and cultured for 72 hours in serum free medium. Supernatants and cell 
layers were then analysed by Western blotting.  
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Glomeruli from WKY, DC and LEW rats were isolated by sievieng at day 4 from 
NTS injection. Glomeruli were then cultured in serum free medium for 72 hours 
and supernatants and cell layers were collected and analysed by Western 
blotting.  
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Figure 5.5 E  IL-1 β secretion in nephritic glomeruli from WKY, DC and LEW rats. 
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Glomeruli from WKY, DC and LEW rats were isolated by sievieng at day 4 from 
NTS injection. Glomeruli were then cultured in serum free medium for 72 hours 
and supernatants and cell layers were collected and analysed by Western 
blotting. 
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β-actin 
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Figure 5.5F IL-18 secretion in cultured nephritic glomeruli isolated from WKY, 
DC and LEW rats. 
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Figure 5.5G Caspase-1 activation in cultured nephritic glomeruli from WKY, DC 
and LEW rats. 
Glomeruli from WKY, DC and LEW rats were isolated by sievieng at day 4 from 
NTS injection. Glomeruli were then cultured in serum free medium for 72 hours 
and supernatants and cell layers were collected and analysed by Western 
blotting.  A specific anti-caspase-1 antibody from Santa Cruz Biotechnology was 
used for the detection of pro- and cleaved caspase-1. β-actin was used as 
loading control.  
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 5.6 ANALYSIS OF THE INFLAMMASOME ACTIVATION IN 
BMDM FROM CONGENIC RAT STRAINS 
 
Aims and experimental design 
 
My previous data have shown that BMDMs and nephritic glomeruli from DC rats 
have lower levels of P2X7 protein and reduced active IL-1β, IL-18 and caspase-1 
compared to WKY BMDMs and glomeruli. When compared with LEW BMDMs 
and glomeruli, DC exhibit higher levels of P2X7 protein and active IL-1β, IL-18 
and caspase-1. Since in the NTN model, DC rats show a reduction by 40% in the 
number of crescents, there seems to be a correlation between the severity of 
the disease and the grade of inflammasome activation in both BMDMs and 
nephritic glomeruli. As previously described, the DC strain is characterized by the 
introgression of both the CRGN1 and the CRGN2 intervals from Lew rats onto a 
WKY genetic background. In order to examine the relative contribution of 
CRGN1 and CRGN2 in the regulation of P2X7R expression and inflammasome 
activation, I have analysed the inflammasome-dependent cytokine production in 
BMDMs and nephritic glomeruli from single congenic rats generated by either 
the introgression of CRGN2 from LEW rats onto a WKY genetic background 
(WL16) or by the introgression of CRGN2 from WKY rats onto a LEW background 
(LW16). Unfortunately, the single congenic rats with introgression of the CRGN1 
interval were not available. In the NTN model, WL16 rats show significantly 
reduced glomerular crescent formation, fibrin deposition and macrophage 
infiltration compared to WKY rats, whereas LW16 rats exhibit significantly more 
proteinuria and macrophage infiltration than the background strain (Behmoaras 
et al., 2010). 
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Results 
 
BMDMs from WL16 rats show lower levels of P2X7 protein compared to WKY 
BMDMs (figure 5.6 A). The levels of P2X7 protein in WL16 macrophages are 
similar to the levels expressed by DC BMDMs.  LW16 macrophages resemble 
LEW BMDMs exhibiting very low levels of the protein. As shown in figure 5.6B, 
when stimulated with ATP, LPS-primed BMDMs from WL16 rats release lower 
levels of active IL-1β compared to WKY BMDMs but similar to macrophages from 
DC rats. Interestingly, BMDMs from LW16 rats produce much higher levels of 
active IL-1β compared to LEW BMDMs and similar to WL16 macrophages (figure 
5.6B). The decreased IL-1β secretion in response to ATP in WL16 macrophages 
compared to the WKY ones was confirmed by ELISA as well as the increased 
secretion observed in LW16 macrophages compared to the LEW ones (figure 5.6 
C). Mature IL-18 was only slightly decreased in WL16 BMDMs in response to ATP 
stimulation, however LW16 macrophages exhibited much higher levels of active 
IL-18 compared to LEW BMDMs and similar to the levels of active IL-18 released 
by WKY BMDMs (figure 5.6D). Active caspase-1 in response to ATP stimulation, 
was also much lower in WL16 BMDMs compared to the WKY ones, while LW16 
macrophages showed similar levels of active caspase-1 as the LEW ones (figure 
5.6 E). Interestingly, macrophages from DC rats exhibit higher active caspase-1 
levels compared to WL16, LW16 and LEW macrophages, but much lower than 
the WKY ones (figure 5.6 E). According to the ELISA results, nephritic glomeruli 
from WL16 rats show markedly lower levels of active IL-1β compared to WKY 
glomeruli, while glomeruli from LW16 rats show similar levels of active IL-1β as 
LEW glomeruli (figure 5.6 F). No statistically significant difference in IL-1β levels 
was observed between glomeruli from WL16, DC, LW16 and LEW rats. However, 
when analysed by Western blotting, WL16 glomeruli exhibit similar levels of 
P2X7 protein, active IL-1β and IL-18 as WKY glomeruli, whereas LW16 glomeruli 
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resemble the LEW ones, showing a very low P2X7 protein expression and both 
active IL-1β and IL-18 were not detectable (figure 5.6 G, H and j). 
 
 
 
 
 
Figure 5.6A P2X7R expression in BMDMs from single and double congenic rat 
strains. 
BMDMs from WKY, WL16, DC, LEW and LW16 rats were plated in six-well plates 
at a density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and 
then stimulated with ATP 5 mM for 30 minutes. Supernatants and cell layers 
were then collected and analysed by Western blotting. For P2X7 protein 
detection, a specific anti-P2X7 antibody from Alomone Labs was used. Beta-actin 
was used as loading control. 
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Figure 5.6B IL-1β secretion in response to ATP in LPS primed BMDMs from 
congenic rat strains. 
BMDMs from WKY, WL16, DC, LEW and LW16 rats were plated in six-well plates 
at a density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and 
then stimulated with ATP 5 mM for 30 minutes. Supernatants and cell layers 
were then collected and analysed by Western blotting. For active IL-1β 
detection, a specific anti-cleaved IL-1β antibody from Santa Cruz (USA) was used. 
Beta-actin was used as loading control. 
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Figure 5.6C Active IL-1β secretion in response to ATP in LPS primed BMDMs 
from congenic rat strains. 
BMDMs from WKY, WL16, LEW and LW16 rats were plated in six-well plates at a 
density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and then 
stimulated with ATP 5 mM for 30 minutes. Supernatants were then collected 
and analysed by sandwich ELISA (Rat IL-1β/DuoSet Kit, R&D Systems). Data are 
representative of three independent experiments. 
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Figure 5.6D IL-18 secretion in BMDMs from congenic rat strains. 
BMDMs from WKY, WL16, DC, LEW and LW16 rats were plated in six-well plates 
at a density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and 
then stimulated with ATP 5 mM for 30 minutes. Supernatants and cell layers 
were then collected and analysed by Western blotting. For pro- and active IL-18 
detection, a specific anti IL-18 antibody from Santa Cruz (USA) was used. Beta-
actin was used as loading control. 
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Figure 5.6E Caspase-1 activation in BMDMs from congenic rat strains. 
BMDMs from WKY, WL16, DC, LEW and LW16 rats were plated in six-well plates 
at a density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and 
then stimulated with ATP 5 mM for 30 minutes. Supernatants and cell layers 
were then collected and analysed by Western blotting. For pro- and active 
caspase-1 detection, a specific anti caspase-1 antibody from Santa Cruz (USA) 
was used. Beta-actin was used as loading control. 
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Figure 5.6F IL-1β secretion in cultured nephritic glomeruli from congenic rat 
strains. 
Nephritic glomeruli from WKY, WL16, DC, LEW and LW16 rats were isolated at 
day 4 from NTS injection and cultured for 72 hours in serum free medium. 
Supernatants were then collected and analysed by sandwich ELISA (Rat IL-
1β/DuoSet from R&D Systems). Data are representative of three independent 
experiments. 
 
*P<0.05 
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Figure 5.6G P2X7R expression in cultured glomeruli from WKY, WL16, LEW and 
LW16 rats. 
Nephritic glomeruli from WKY, WL16, DC, LEW and LW16 rats were isolated at 
day 4 from NTS injection and cultured for 72 hours in serum free medium. 
Supernatants and cell layers were then collected and analysed by Western 
blotting. 
 
 
 
 
Figure 5.6H IL-1 β secretion in cultured glomeruli from WKY, WL16, LEW and 
LW16 rats. 
Nephritic glomeruli from WKY, WL16, DC, LEW and LW16 rats were isolated at 
day 4 from NTS injection and cultured for 72 hours in serum free medium. 
Supernatants and cell layers were then collected and analysed by Western 
blotting. 
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Figure 5.6J IL-18 secretion in cultured nephritic glomeruli from WKY, WL16, 
LEW and LW16 rats. 
Nephritic glomeruli from WKY, WL16, DC, LEW and LW16 rats were isolated at 
day 4 from NTS injection and cultured for 72 hours in serum free medium. 
Supernatants and cell layers were then collected and analysed by Western 
blotting. 
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5.7 ROLE OF JUND IN THE REGULATION OF THE 
INFLAMMASOME ACTIVATION  
 
Aims and experimental plan 
 
Within the CRGN2 interval the activator protein-1 (AP-1) transcription factor 
gene Jund has been recognized as an important potentiator of macrophage 
activity and it has been shown to be markedly upregulated in both BMDMs and 
glomeruli from WKY rats (Behmoaras et al., 2008). To assess whether Jund plays 
a role in the regulation of P2X7R expression and in the activation of the 
inflammasome, I have first examined the effects of Jund silencing by siRNA on 
the secretion of active IL-1β, IL-18 and caspase-1 in response to ATP in LPS 
primed BMDMs from WKY rats. Due to the possibility that a prolonged LPS 
priming might increase Jund expression and abolish the effects of siRNA 
treatment, the timing of the priming step was shorted to only one hour so that 
no new protein synthesis could occur. Although the siRNA approach is usually a 
very powerful method to assess the role of a protein in many cellular functions, 
however sometimes, especially when the efficiency of the transfection is not 
great, it could become difficult to make clear conclusions. Another factor that 
could limit siRNA-mediated silencing is the half-life of the protein. It might be 
difficult to effectively silence genes that encode proteins with long half-lives by 
transient transfection of siRNA. In view of the possibility that Jund might 
regulate P2X7R expression and the inflammasome activation during the 
macrophage differentiation process, I have analysed and compared 
inflammasome-mediated cytokine production in response to ATP stimulation in 
LPS-primed BMDMs from WT and Jund deficient mice.  
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Results 
 
Treatment of WKY BMDMs with Jund specific siRNA for 48 hours led to a 
decreased Jund protein expression as shown in figure 5.7 A. When primed with 
LPS 1 μg/ml and stimulated with ATP 5 mM for 30 minutes WKY BMDMs treated 
with Jund siRNA produce similar levels of active IL-1β as cells treated with 
scrambled siRNA according to the Western blotting results (figure 5.7B, left 
panel). However when the same samples were analysed by sandwich ELISA, 
there was a 20% reduction in IL-1β secretion in WKY BMDMs treated with Jund 
siRNA compared to the ones treated with scrambled siRNA (figure 5.7 B, right 
panel). JunD siRNA treatment in WKY BMDMs did not affect neither the 
secretion of active IL-18 (figure 5.7C) nor the activation of caspase-1 (figure 
5.7D) in response to ATP. LPS-primed BMDMs from Jund deficient mice show 
similar levels of active IL-1β and caspase-1 as the WT controls when stimulated 
with ATP (figures 5.7E and 5.7F). Interestingly, the levels of active IL-18 released 
by Jund knock-out mice in response to ATP were markedly reduced compared to 
WT mice (figure 5.7G). No differences in P2X7 protein levels were seen between 
BMDMs from WT and Jund knock-out mice (figure 5.7H). 
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Figure 5.7A Jund specific siRNA treatment decreases Jund protein expression in 
WKY BMDMs. 
WKY BMDMs were plated into six-well plates at a density of 1 x 106 cells per well 
and treated with Jund specific siRNA or a scrambled oligonucleotide for 48 hours 
before total protein was extracted for Western blotting analysis. For Jund 
detection a specific anti-Jund antibody from Santa Cruz Biotechnology (USA) was 
used. 
 
 
 
 
 
 
203 
 
 
 
 
 
Figure 5.7B Effects of Jund siRNA on IL-1 beta secretion in response to ATP in 
LPS-primed BMDMs from WKY rats. 
WKY BMDMs were treated with scrambled siRNA (control) or specific Jund 
siRNA. After 48 hours of incubation, macrophages were primed with LPS 1 μg/ml 
for 1 hour and stimulated with ATP 5 mM for further 30 minutes. Supernatants 
were then collected and analysed by Western blotting and sandwich ELISA. For 
detection of both pro- and active IL-1β by western blotting a specific anti IL-1β 
antibody from New England Biolabs (UK) was used. Sandwich ELISA for detection 
of Rat IL-1β was conducted using the Rat IL-1β/DuoSet ELISA kit from R&D 
Systems. 
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Figure 5.7C Effects of Jund siRNA treatment on IL-18 secretion in response to 
ATP in LPS primed BMDMS from WKY rats. 
WKY BMDMs were treated with scrambled siRNA (control) or specific Jund 
siRNA. After 48 hours of incubation, macrophages were primed with LPS 1 μg/ml 
for 1 hour and stimulated with ATP 5 mM for further 30 minutes. Supernatants 
were then collected and analysed by Western blotting. For detection of both 
pro- and active IL-18 a specific anti IL-18 antibody from Santa Cruz 
Biotechnology was used.  
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Figure 5.7D Effects of Jund siRNA treatment on caspase-1 activation in 
response to ATP in LPS primed BMDMS from WKY rats. 
WKY BMDMs were treated with scrambled siRNA (control) or specific Jund 
siRNA. After 48 hours of incubation, macrophages were primed with LPS 1 μg/ml 
for 1 hour and stimulated with ATP 5 mM for further 30 minutes. Supernatants 
were then collected and analysed by Western blotting. For detection of both 
pro- and active caspase-1 by a specific anti IL-18 antibody from Santa Cruz 
Biotechnology was used. 
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Figure 5.7E IL-1β secretion in response to ATP in LPS primed BMDMs from WT 
and Jund knock-out mice. 
BMDMs from WT and Jund deficient mice were plated in six-well plates at a 
density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and then 
stimulated with ATP 5 mM for 30 minutes. Supernatants and cell layers were 
then collected and analysed by Western blotting. For pro- and active IL-1β 
detection, a specific anti-IL-1β antibody from New England Biolabs was used. 
Beta-actin was used as loading control. 
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Figure 5.7F Caspase-1 activation in response to ATP in LPS-primed BMDMs 
from WT and Jund Knock-out mice. 
BMDMs from WT and Jund deficient mice were plated in six-well plates at a 
density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and then 
stimulated with ATP 5 mM for 30 minutes. Supernatants and cell layers were 
then collected and analysed by Western blotting. For pro- and active caspase-1 
detection, a specific anti-caspase-1 antibody from Santa Cruz Biotechnology (CA, 
US) was used. Beta-actin was used as loading control. 
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Figure 5.7G IL-18 secretion in response to ATP in LPS primed BMDMs from WT 
and Jund knock-out mice. 
BMDMs from WT and Jund deficient mice were plated in six-well plates at a 
density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and then 
stimulated with ATP 5 mM for 30 minutes. Supernatants and cell layers were 
then collected and analysed by Western blotting. For pro- and active IL-18 
detection, a specific anti-IL-18 antibody from Santa Cruz Biotechnology (CA, US) 
was used. Beta-actin was used as loading control. 
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Figure 5.7H P2X7R expression in BMDMs from WT and Jund knock-out mice. 
BMDMs from WT and Jund deficient mice were plated in six-well plates at a 
density of 1 x 106 cells per well, primed with LPS 1 μg/ml for 5 hours and then 
stimulated with ATP 5 mM for 30 minutes. Aliquots of protein (20 μg) from cell 
lysates were then analysed by Western blotting. For P2X7 protein detection a 
specific anti-P2X7 antibody from Alomone Labs (Israel) was used. Beta actin was 
used as loading control. 
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5.8 DISCUSSION 
 
My studies led me to the following conclusions: 
 
1) WKY BMDMs show a marked upregulation of the majority of the 
inflammasome-related genes compared to LEW BMDMs. 
2) WKY BMDMs show higher P2X7 mRNA and protein levels both under 
basal conditions and after stimulation with LPS compared to LEW BMDMs. 
3) WKY BMDMs release higher levels of both active IL-1β and IL-18 in 
response to ATP stimulation compared to LEW BMDMs. 
4) WKY BMDMs show higher levels of active caspase-1 in response to ATP 
stimulation compared to LEW BMDMs. 
5) The increased secretion of active IL-1β and IL-18 in WKY BMDMs is not 
due to an increased synthesis of the precursors in response to LPS priming. 
6) Caspase-1 inhibition dramatically affects both IL-1β and IL-18 secretion in 
WKY BMDMs. 
7) WKY BMDMs show markedly increased MMP-9 gene expression and 
enzymatic activity compared to LEW BMDMs. 
8) In response to LPS priming, DC BMDMs exhibit lower levels of P2X7 
protein compared to WKY BMDMs but higher than LEW macrophages. 
9) DC BMDMs release lower levels of both active IL-1β and IL-18 in response 
to ATP stimulation compared to WKY BMDMs but higher than LEW 
macrophages. 
10) In response to ATP stimulation, DC BMDMs show decreased caspase-1 
activation compared to WKY BMDMs but higher than LEW macrophages. 
11) In response to ATP treatment, BMDMs from WL16 rats release lower 
levels of active IL-1β compared to WKY macrophages but higher than LEW 
BMDMs. 
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12)  In response to ATP stimulation, BMDMs from LW16 rats exhibit higher 
levels of both active IL-1β and active IL-18 than LEW BMDMs. 
13)  At day 4 from NTS injection, WKY nephritic glomeruli express higher 
levels of P2X7 protein than LEW glomeruli. 
14)  At day 4 from NTS injection, WKY nephritic glomeruli show higher levels 
of active IL-1β, IL-18, caspase-1 compared to LEW glomeruli. 
15)  At day 4 from NTS injection, nephritic glomeruli from single and double 
congenic rat strains express lower levels of P2X7 protein than WKY glomeruli, 
but higher than LEW glomeruli. 
16)  At day 4 from NTS injection, cultured nephritic glomeruli from DC rats 
release lower levels of active IL-1β and active IL-18 than WKY glomeruli but 
higher compared to LEW ones.  
17)  At day 4 from NTS injection, nephritic glomeruli from DC rats show lower 
levels of active caspase-1 than WKY glomeruli but higher compared to LEW 
glomeruli. 
18)  According to the ELISA results, cultured nephritic glomeruli from WL16 
rats show much lower levels of active IL-1β compared to WKY glomeruli, while 
glomeruli from LW16 rats release similar levels of active IL-1β as LEW glomeruli. 
19) According to the Western blotting results, WL16 glomeruli exhibit similar 
active IL-1β and IL-18 levels as WKY glomeruli and also show similar P2X7 protein 
levels. LW16 glomeruli resemble the LEW ones showing very low P2X7 protein 
levels, whereas active IL-1β and IL-18 were not detectable. 
 
Analysis of inflammasome-related genes expression in WKY, DC and LEW 
BMDMs 
 
The analysis of the inflammasome-related genes P2X7, IL-18, Pycard and 
caspase-1 revealed that WKY macrophages, under basal conditions, express 
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significant higher mRNA levels compared to LEW BMDMs. Interestingly, 
macrophages from DC rats resemble WKY BMDMs exhibiting even higher P2X7 
and caspase-1 mRNA levels. However, when I analysed ASC, pro-caspase-1 and 
pro-IL-18 protein levels by western blotting, I could not find any differences 
among macrophages from the three rat strains (data not shown). As previously 
discussed, under basal conditions, P2X7 protein levels were much higher in WKY 
macrophages compared to LEW ones, while DC BMDMs, in accordance with the 
RT-PCR results, showed similar levels as WKY macrophages. In response to LPS 
stimulation, WKY macrophages exhibit much higher P2X7 protein levels than 
under basal conditions, while no major changes in protein levels were seen in 
both DC and LEW ones. The ability of LPS to induce an upregulation of P2X7R is 
well documented. Previous studies from Humphreys et al. have shown that P2X7 
receptor expression in human monocytes is upregulated by several pro-
inflammatory stimuli such as LPS, INF-γ and TNF-α (Humphreys & Dubyak, 1998). 
In their studies however, THP-1 cells were incubated for at least 48 hours and 
LPS was not used alone but in association with INF-γ. The observation that 
stimulation with LPS 1 μg/ml for 5 hours induces an upregulation of P2X7 
protein only in WKY and not in DC or LEW macrophages suggests an increased 
sensitivity of WKY BMDMs to LPS pro-inflammatory effects. These data are in 
accordance with other results which show that WKY BMDMs have a lower 
threshold for the activation of the inflammasome compared to LEW 
macrophages. Indeed, WKY macrophages release similar levels of active IL-1β 
when primed with either LPS 100 ng/ml or 1 μg/ml. On the other hand, LEW 
macrophages, when primed with LPS 100 ng/ml show similar levels of active IL-
1β as when treated with LPS 100 ng/ml alone, indicating that the latter 
concentration of LPS is not sufficient to induce the inflammasome activation in 
these cells. Among the inflammasome-related genes analysed were IL-1RN and 
IL-18BP, which encode the proteins IL-1 receptor antagonist (IL-1Ra) and IL-18 
binding protein, physiologic inhibitors of IL-1β and IL-18 respectively. To date, 
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three forms of IL-1Ra have been identified, one soluble form and two 
intracellular forms, referred to as sIL-1Ra, icIL-1RaI, and icIL-1RaII, respectively 
(Burger & Dayer, 1995). The soluble form of IL-1Ra inhibits both IL-1α and IL-1β 
by competitively binding to IL-1 receptor. IL-1Ra knockout mice exhibit growth 
retardation after weaning and an increased susceptibility to lethal endotoxemia 
and collagen-induced arthritis, suggesting that IL-1Ra plays an important role in 
both health and pathologic conditions (Ma et al., 1998). In humans, the 
circulating blood levels of sIL-1Ra are low in normal conditions while are 
significantly increased in several auto-immune and chronic inflammatory 
diseases such as rheumatoid arthritis and non-perforating Crohn’s disease 
(Firestein et al., 1992), (Gilberts, Greenstein, Katsel, Harpaz, & Greenstein, 
1994). The IL-18 binding protein (IL-18BP) is a circulating inhibitor of the 
proinflammatory cytokine IL-18. It is constitutively expressed in mononuclear 
cells, and elevated expression is induced by IFN-γ (Hurgin, Novick, & Rubinstein, 
2002). IL-18BP binds IL-18 with a high affinity and, at equimolar ratios, inhibits 
50–70% of IL-18 activity; at twofold molar excess, IL-18BP neutralises nearly all 
IL-18 activity (Dinarello, 2001). IL-18BP is constitutively secreted and was 
isolated in urine of healthy subjects (Dinarello, 2000). Previous studies from He 
et al. have shown that IL-18BP transgenic mice are functionally and histologically 
protected against ischemic acute kidney injury (AKI) induced by bilateral renal 
pedicle clamping (He et al., 2008). On the other hand, studies conducted on 
patients with active Crohn’s disease (CD) have revealed that the levels of IL-18BP 
transcript and protein are significantly up-regulated in active CD specimens 
compared with control specimens and that macrophages were the major source 
of IL-18BP within the intestinal submucosa (Corbaz et al., 2002). These studies 
highlight the complexity of IL-18/IL-18BP biology and the significance of IL-18BP 
upregulation is not fully understood yet. My data show that BMDMs from WKY 
rats express significant higher pro-IL-18 and IL-18BP mRNA levels compared to 
macrophages from LEW rats under basal conditions. One possible explanation of 
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these findings is that, even under basal conditions, WKY BMDMs exhibit an 
hyperactivated phenotype and the increased expression of IL-18BP gene is 
secondary to the increased pro-IL18 mRNA levels in order to modulate the 
excessive IL-18 activity that might derive from that. Similarly, IL-1RA mRNA 
levels are significantly higher in WKY macrophages compared to LEW ones 
although no differences in pro-IL-1β mRNA and protein levels were seen 
between macrophages from the two rat strains. 
 
Analysis of inflammasome-mediated cytokine production in WKY, DC and LEW 
BMDMs 
 
When primed with LPS 1 μg/ml for 5 hours and stimulated with ATP for 30 
minutes, WKY macrophages produce significant higher levels of both IL-1β and 
IL-18 and show much higher levels of active caspase-1 compared to DC and LEW 
macrophages. Since WKY BMDMs in response to LPS express higher levels of 
P2X7 mRNA and protein compared to DC and LEW macrophages, it is reasonable 
to say that the increased IL-1β and IL-18 secretion in WKY BMDMs might be 
secondary to an increased P2X7R activity. In accordance with this hypothesis, 
macrophages from DC rats which show intermediate levels of P2X7 protein 
between WKY and LEW also exhibit intermediate levels of active IL-1β and IL-18 
when stimulated with ATP. Since the only difference between WKY and DC rats 
is in the chromosome 13 and 16 intervals Crgn1 and Crgn2 respectively, it is 
possible to assume that either Crgn1 or Crgn2 contains one or more genes that 
are responsible for P2X7R expression regulation in response to LPS. Among the 
genes included in the Crgn2 interval is Jund, which encodes the activator 
protein-1 (AP-1) transcription factor Jund. It has been already demonstrated that 
Jund is a major determinant of macrophage activity and is associated with 
glomerulonephritis susceptibility. Furthermore, microarray and QRT-PCR 
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analyses showed that Jund expression is significantly higher in WKY than in LEW 
glomeruli both at baseline and in NTN-induced glomeruli (Behmoaras et al., 
2008). Therefore Jund represented a good candidate for a possible role in the 
regulation of P2X7R expression and consequent modulation of the 
inflammasome activation. I have then analysed the effects of Jund siRNA on the 
secretion of active IL-1β, IL-18 and caspase-1 in response to ATP stimulation in 
LPS-primed WKY BMDMs but I could not see any major differences, there was 
only about 20% reduction in IL-1β secretion according to the ELISA results. To 
further investigate the role of Jund in the regulation of P2X7 protein expression 
and inflammasome activation I have cultured BMDMs from WT and Jund 
deficient mice and looked at the inflammasome-related cytokine secretion in 
response to ATP but WT and Jund knock-out mice exhibit similar levels of active 
IL-1β, IL-18 and caspase-1 and no differences were seen in the P2X7 protein 
levels, indicating that other genes but Jund are playing this role. The analysis of 
inflammasome-related cytokine secretion also revealed that the use of a 
selective caspase-1 inhibitor (YVAD) dramatically affects both IL-1β and IL-18 
secretion in response to ATP in WKY BMDMs suggesting that the production of 
these cytokines is caspase-1 dependent. However, while IL-18 secretion was 
completely abolished by the use of the caspase-1 inhibitor, active IL-1β was still 
detectable in WKY BMDMs indicating that other caspase-1 independent 
alternative pathways might contribute to the generation of active IL-1β in these 
cells. Aside from caspase-1, other proteases are indeed capable of cleaving pro-
IL1β including bacterial enzymes, trypsin or chymotrypsin and enzymes such as 
leukocyte elastase  and granzyme A (Schonbeck, Mach, & Libby, 1998). Different 
members of the metalloproteinase (MMP) family, in particular gelatinase A 
(MMP-2) and gelatinase B (MMP-9) have been shown to be able to generate 
active IL-1β and are usually overexpressed at sites of inflammation. IL-1β itself, is 
known to regulate the expression and activation of MMPs, demonstrating a 
cross-regulation among these two classes of effectors of inflammation (Yoo et 
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al., 2002). My results show that both MMP-9 mRNA levels and enzymatic activity 
are increased in WKY BMDMs compared to LEW ones. To evaluate the 
contribute of MMP-9 in the generation of active IL-1β in WKY macrophages, I 
have looked at the production of active IL-1β in response to ATP in the presence 
of the MMP inhibitor Ilomastat (Millipore, UK) by ELISA and the use of the MMP 
inhibitor led to a reduction of about 20% of IL-1β secretion (data not shown), 
indicating that the majority of IL-1β secretion in WKY BMDMs is caspase-1 
dependent.  My data also show that the levels of both IL-1β and IL-18 precursors 
in response to LPS are the same in WKY and LEW BMDMs. These findings 
suggest that the increased levels of mature IL-1β and IL-18 in response to ATP 
seen in WKY macrophages are not a consequence of a dysregulation of the 
TLR4/NF-kb pathway but is the conversion of the precursors into their active 
form that is accelerated or more active in WKY BMDMs. 
 
Ex-vivo analysis of the inflammasome activation in nephritic glomeruli from 
WKY, DC and LEW rats 
 
Ex-vivo incubation of isolated glomeruli from WKY, DC and LEW rats at day 4 
from the injection of NTS revealed that WKY nephritic glomeruli, in the absence 
of any stimuli, show higher levels of active IL-1β, IL-18 and caspase-1 compared 
to glomeruli from DC and LEW rats. Glomeruli from DC rats exhibit higher levels 
of active IL-1β, IL-18 and caspase-1 compared to LEW glomeruli but much lower 
than WKY ones. The analysis of P2X7 protein expression in nephritic glomeruli 
also revealed that WKY nephritic glomeruli express much higher P2X7 protein 
levels compared to DC and LEW glomeruli. Glomeruli from DC rats showed 
intermediate P2X7 protein levels between WKY and LEW glomeruli. These 
findings are very important because they confirm the important role of the 
inflammasome-mediated cytokines in the pathogenesis of NTN and they also 
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show that the grade of inflammasome activation correlates well with the 
severity of the disease in vivo. Indeed, when injected with NTS, DC rats exhibit 
an intermediate phenotype between WKY and LEW rats showing a decreased 
macrophage infiltration and a 34% reduction in the number of glomerular 
crescents compared to WKY rats. Furthermore, these data confirm the positive 
correlation between P2X7 protein levels and the grade of inflammasome 
activation. The analysis of the levels of the inflammasome activation in 
macrophages and isolated glomeruli from single congenic rat strains is more 
complicated. According to the IL-1β ELISA’s results, glomeruli isolated from 
WL16 rats show significant lower levels of IL-1β compared to WKY nephritic 
glomeruli and only slightly higher compared to the ones seen in glomeruli from 
DC rats. When I analysed the same samples by western blotting, the scenario 
was completely different with WL16 glomeruli resembling the WKY ones, 
showing similar levels of active IL-1β, while in LW16 glomeruli active IL-1β was 
not detectable as in the LEW ones. Likewise, WL16 glomeruli exhibited similar 
levels of P2X7 proteins and active IL-18 as the WKY ones, while in LW16 and LEW 
glomeruli active IL-18 was not detectable and P2X7 protein levels were very low. 
Previous studies from Behmoaras et al. have shown that the introgression of 
LEW Crgn2 into the WKY recipients reduced glomerular crescents only by 8% 
(Behmoaras et al., 2010). There seems to be therefore a good correlation 
between the IL-1β levels detected by western blotting in isolated glomeruli from 
WL16 rats and the severity of the disease. It is however surprising that the 
results coming from western blotting and ELISA were so different. One possible 
explanation could be that by ELISA I have analysed only the secreted 
component, whereas with western blotting I have also examined the amount of 
the cytokine that is retained inside the glomeruli and the infiltrating 
macrophages. I found a poor correlation between ELISA and western blotting 
results also when I analysed the levels of IL-1β released by BMDMs in response 
to ATP. According to the ELISA results, macrophages from WL16 rats showed 
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about 30% reduction compared to WKY ones and about 20% higher IL-1β levels 
compared to LEW macrophages. Western blotting analysis of the same samples 
revealed that WL16 BMDMs release lower levels of IL-1β compared to the WKY 
ones but much higher than LEW macrophages. The two techniques in this case 
show a similar pattern, however the differences between the levels of IL-1β 
released by WL16 and LEW macrophages appear to be more dramatic in the 
western blotting results rather than the ELISA ones. One interesting result that 
has been confirmed both by ELISA and western blotting is that LW16 
macrophages in response to ATP release much higher levels of IL-1β compared 
to the LEW ones. What is surprising is that the levels of P2X7 protein from LW16 
and LEW macrophages are similar. The levels of active IL-18 secreted after 
stimulation with ATP were also much higher in LW16 BMDMs compared to LEW 
ones. These findings seem to indicate that the Crgn2 interval contains one or 
more genes that are able to control both IL-1β and IL-18 secretion in a P2X7 
independent way. This hypothesis is also in accordance with the observation 
that, although BMDMs from LW16 rats exhibit higher levels of both IL-1β and IL-
18 compared to LEW ones, active caspase-1 appears to be not increased 
suggesting that the increased secretion of these cytokines in LW16 macrophages 
does not involve caspase-1 nor P2X7R. On the other hand, BMDMs from WL16 
rats show lower P2X7 protein expression, lower caspase-1 activation and lower 
levels of active IL-1β and IL-18 compared to WKY macrophages. Although my 
data clearly show that IL-1β secretion is mainly caspase-1 dependent in 
macrophages from WKY rats as demonstrated by the observation that its 
secretion is dramatically reduced with the use of a specific caspase-1 inhibitor, it 
is possible that other alternative pathways might be switch on in the presence of 
different inflammatory stimuli. Crgn2 interval might contain one or more genes 
that control the switch of either the classical or the alternative pathways for IL-
1β and IL-18 processing and release. 
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Key discoveries in this chapter 
P2X7R levels as well as the expression of several genes belonging to the Nlrp3-
inflammasome pathway are up-regulated in macrophages of the WKY rat, a 
strain uniquely susceptible to experimental nephrotoxic nephritis.  Following 
P2X7R activation by ATP, WKY BMDMs produce markedly increased levels of 
active IL-1β, IL-18 and caspase-1 when compared with the NTN-resistant Lewis 
rat BMDMs. Similar results were obtained analysing isolated nephritic glomeruli 
from the two rat strains confirming a role for the P2X7-mediated inflammasome 
activation in the pathogenesis of glomerulonephritis.The analysis of both 
macrophages and nephritic glomeruli from single and double congenic rats 
appears to show that the P2X7R-inflammasome axis is at least partly under the 
genetic control of two previously identified Crgn quantitative trait loci (Crgn1, 
Crgn2) in the WKY NTN model. In conclusion, these results advocate the critical 
role of the P2X7R-mediated inflammasome activation in glomerulonephritis, 
highlighting it as a potential therapeutic target. 
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CHAPTER SIX-GENERAL DISCUSSION 
 
6.1 DISCUSSION 
 
The existence of plasma membrane receptors for extracellular nucleotides was 
recognised for the first time in 1978 by Geoff Burnstock. Since then, an 
incredible progress has been done in the understanding of purinergic receptor 
functions and their role in many important biological processes. Among the 
various purinergic receptors, P2X7 appears to be a very complex one, having 
different functions in different or even the same cells. It is now well established 
that P2X7R is not a simple ion channel with pore-formation activity but is instead 
a fundamental mediator of the immune response and is involved in many 
important cellular activities such as cell cycle regulation. There are still many 
unanswered questions about its mechanism of action and its exact role in 
inflammatory diseases. The work presented in this thesis embraces three 
different aspects of P2X7R activation: 1) pro-inflammatory cytokine production, 
2) activation of cell signalling transduction pathways and 3) P2X7R-mediated 
inflammasome activation and its role in the pathogenesis of crescentic 
glomerulonephritis. To investigate P2X7R contribution in the secretion of the 
pro-inflammatory cytokines IL-1β and IL-18, I have compared the levels of these 
cytokines released in response to ATP in macrophages from WT mice and two 
different P2X7 deficient mouse lines, the GSK and the Pfizer ones. Similarly, 
macrophages from WT and P2X7 deficient mice have been used to explore the 
cell signalling cascade following ATP stimulation and to establish which 
pathways were selectively activated by P2X7R. Finally, to analyse the role of 
P2X7-mediated inflammasome activation in the pathogenesis of crescentic 
glomerulonephritis I have analysed and compared both macrophages and 
nephritic glomeruli from the glomerulonephritis-susceptible rat strain WKY with 
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the ones from the resistant rat strain Lewis. In order to establish the 
contribution of the Crgn1 and Crgn2 loci in the regulation of the NLRP3-
inflammasome activation, I have extended the analysis to macrophages and 
nephritic glomeruli from single and double congenic rat strains. 
 
Analysis of the P2X7-mediated pro-inflammatory cytokine production 
 
P2X7R expression is necessary for the activation of caspase-1 in response to ATP. 
Macrophages from GSK and Pfizer KO mice do not exhibit any active caspase-1 
after treatment with ATP. P2X7R-mediated caspase-1 activation significantly 
potentiates the release of both IL-1β and IL-18. Compared to BMDMs from Pfizer 
KO mice, macrophages from WT mice produce significant higher levels of IL-1β in 
response to ATP, BzATP and LL37 and show much higher levels of active IL-18 in 
response to ATP. Macrophages from GSK mice behaved differently from the 
Pfizer ones. Although they do not show any active caspase-1 following ATP 
stimulation, they release significant higher levels of both IL-1β and IL-18 in 
response to all the P2X7 agonists tested compared to macrophages from Pfizer 
mice. When stimulated with LL37, they release similar levels of IL-1β as 
macrophages from WT mice. Since active caspase-1 was never detectable in 
these cells in all the experiments conducted, it seems that both IL-1β and IL-18 
are secreted through alternative, caspase-1 independent pathways in the GSK 
BMDMs. One other possibility could be that the Western blot technique may not 
be sensitive enough to detect low/moderate amount of active caspase-1. One 
important question that I tried to answer in this study was whether 
macrophages from GSK mice do effectively lack P2X7R or not. My Western 
blotting results clearly show that macrophages from GSK mice exhibit a band of 
the same size as the full length receptor using a specific anti-P2X7 antibody that 
recognises an epitope localized in a very distal region of the C-terminus of the 
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receptor. Using specific primers for the normal exon 1 and for the alternative 
exon 1 of the variant P2X7k, I could demonstrate by PCR that the band detected 
by Western blotting cannot correspond to the full length receptor, since no 
amplification was seen in GSK macrophages when primers for the normal exon 1 
were used. However, no amplification was seen even when primers for the 
alternative exon-1 of the variant P2X7k were used. An important limitation of 
this experiment was the lack of a positive control. Since it has been shown that 
the P2X7k variant is highly expressed in the spleen of GSK mice, I should have 
included in the analysis also spleen RNA samples. In this way I could have 
established whether the lack of alternative exon-1 expression in GSK BMDMs 
was due to a technical issue or to the possibility that GSK macrophages express 
another P2X7 isoform with a different exon 1 from the P2X7k variant. The 
expression of an alternative new P2X7 isoform, if confirmed, appears to be at 
least in part functional and  might explain why GSK BMDMs release much higher 
levels of active IL-1β and IL-18 compared to Pfizer macrophages, but lower 
compared to the WT ones. 
 
 
Cell signalling cascade following P2X7R activation by ATP 
 
Despite the numerous studies that have documented the activation of several 
signalling pathways in response to ATP stimulation in different cell lines, many 
questions still remain on P2X7R relative contribution in these processes. In many 
studies P2X7R involvement was demonstrated with the use of a selective or non-
selective P2X7R antagonist which partially or completely abolished the effects 
seen with ATP treatment. However the use of inhibitors in the study of cell 
trasnduction pathways could be problematic as many of them require a 
pretreatment which itself can alter the intracellular signals. Due to the presence 
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in literature of several studies indicating a role for P2X7R in cell growth and 
proliferation, my first objective was to establish whether ATP stimulation would 
differentially activate the MAPK and the mTOR signalling pathways in 
macrophages from WT and P2X7R deficient mice. The analysis was then 
extended to all the signalling pathways activated by ATP using a 
phosphoproteomic approach. 
 
Main findings 
 
P2X7R plays a fundamental role in the activation of the ribosomal pathway, in 
the organization of actin cytoskeleton and in the regulation of vesicle transport 
and trafficking. P2X7R also contributes, together with other purinergic receptors 
to the activation of other important signalling pathways, including MAPK, mTOR, 
B and T cell receptor signalling pathways, Fcγ receptor mediated phagocytosis, 
endocytosis, apoptosis, chemokine signalling pathways and many others. One of 
the most relevant finding that came out from the phosphoproteomics analysis 
was the observation that ATP stimulation leads to an increased phosphorylation 
of 15 different peptides within the ribosomal pathway and all of these peptides 
showed an increased phosphorylation only in macrophages from WT mice, while 
macrophages from P2X7R deficient mice did not show any increased 
phosphorylation following ATP treatment. The ribosomal proteins that exhibited 
an increased phosphorylation were: RLA1, RLA2, RL3, RL5, RL11, RL13, RS 14 and 
RS15. Ribosomal proteins are essential for ribosome biogenesis, a very complex 
process consisting of the coordinated synthesis and assembly of four ribosomal 
RNAs with about 80 ribosomal proteins which in turn interact with more than 
150 non-ribosomal proteins and other factors (Robledo et al., 2008). Ribosomal 
proteins have attracted a lot of interest since the discovery that the 
pathogenesis of a number of inherited and acquired diseases is linked to 
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mutations in genes encoding proteins involved in ribosome maturation, 
assembly, or export. An example is represented by the Diamond Blackfan 
anemia (DBA), an inherited red cell aplasia caused by mutations in one or several 
ribosomal proteins (Farrar et al., 2011). Since phosphorylation of ribosomal 
proteins affects critical steps of protein synthesis, the observation that P2X7R 
expression is necessary for their phosphorylation to occur, clearly indicates that 
P2X7R is a key regulator of the translation machinery. Although several studies 
in literature have documented that ATP induces the activation of the MAPK 
signalling pathway and this effect was attributed to P2X7R activation, my data 
show that effectively the MAPK signalling pathway is the most activated one in 
response to ATP, however this activation involves other purinergic receptors 
apart from P2X7. Some proteins within the MAPK signalling pathway appear to 
be more phosphorylated in the macrophages from KO mice than in the ones 
from WT mice, which might indicate that P2X7R acts as a negative regulator of 
these proteins. The contribution of P2X7R in the activation of the mTOR 
signalling pathway appears to be very complex too. Apart from a few proteins 
such as S6 kinase and Akt which exhibit higher levels of phosphorylation in WT 
macrophages compared to the KO ones, all the others showed higher levels of 
phosphorylation in macrophages from P2X7 deficient mice. This is not surprising, 
considering the many different functions attributed to the mTOR signalling 
pathway. It is possible that P2X7R might positively regulate some functions and 
negatively regulate some others within the same pathway.  
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P2X7-mediated inflammasome activation and its role in the pathogenesis of 
glomerulonephritis 
 
The analysis of the P2X7-mediated inflammasome activation and  its role in the 
pathogenesis of glomerulonephritis has been conducted using the rat model of 
NTN. I have first investigated the expression of inflammasome-related genes and 
the inflammasome-dependent cytokine production in macrophages from WKY 
and LEW rats and I have then extended my analysis on macrophages from single 
and double congenic rats. Furthermore, to correlate my in vitro data with the 
severity of disease I have examined the inflammasome activation in isolated 
cultured glomeruli from WKY, LEW and congenic rat strains. 
 
Main findings 
 
WKY BMDMs even under basal conditions show an upregulation of the majority 
of the inflammasome genes including P2X7. Not only the mRNA but also P2X7 
protein levels are significantly higher in macrophages from WKY rats compared 
to the ones from LEW rats. Similarly to what happens with WT and P2X7 
deficient mice, WKY macrophages that express higher P2X7 protein levels also 
show higher caspase-1 activation and release higher levels of both IL-1β and IL-
18 compared to LEW macrophages. Caspase-1 inhibition dramatically affects the 
secretion of active IL-18 but does not abolish completely the release of active IL-
1β in WKY macrophages treated with ATP. The increased secretion of mature Il-
1β and IL-18 in WKY BMDMs is not due to an increased synthesis of the 
precursors following LPS priming, since WKY and LEW macrophages exhibit 
similar levels of both pro-IL-1β and pro-IL-18 in response to LPS.  This suggests 
that it is the processing and release of these two cytokines that is different in 
macrophages from the two rat strains. Similarly, WKY glomeruli collected four 
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days after the injection of NTS and cultured for 72 hours in serum-free 
conditions and in the absence of any pro-inflammatory stimuli exhibit higher 
levels of P2X7 protein, higher caspase-1 activation and higher levels of both IL-
1β and IL-18 compared to glomeruli from LEW rats. The analysis of macrophages 
and glomeruli from the congenic rat strains appears to be more complex. When 
injected with NTS, double congenic rats show a 34% reduction in the number of 
glomerular crescents. DC macrophages, when primed with LPS and stimulated 
with ATP exhibit lower levels of P2X7 protein, lower caspase-1 activation and 
lower levels of both IL-1β and IL-18 compared to WKY macrophages indicating a 
good correlation between P2X7R-mediated inflammasome activation and the 
severity of disease. This was also confirmed by the analysis of cultured nephritic 
glomeruli which perfectly resembled the macrophages, showing lower P2X7R 
expression, lower caspase-1 activation and lower levels of active IL-1β and IL-18 
compared to WKY glomeruli. DC rats have Chromosome 13 and Chromosome 16 
intervals from the LEW rat introgressed into the WKY genetic background. Thus, 
in order to study the relative role of chromosome 16 and chromosome 13, I have 
used the single congenic rat strains WL16 and LW16. Unfortunately I could not 
use the WL13 rats because no longer available. Interestingly I found that WL16 
macrophages express lower levels of P2X7 protein, show attenuated caspase-1 
activation, IL-1β and IL-18 production compared to WKY macrophages but 
similar to DC ones. On the other hand, macrophages from LW16 rats, although 
they expressed similar levels of both P2X7 protein and active caspase-1 as LEW 
macrophages, surprisingly release much higher levels of both active IL-1β and IL-
18 comparable to the levels of these cytokines in macrophages from WL16 rats. 
However, this pattern was not completely reproduced in the nephritic glomeruli. 
Indeed, according to the ELISA results, glomeruli from WL16 rats showed much 
lower levels of active IL-1β compared to WKY glomeruli, while LW16 glomeruli 
exhibit the same levels as LEW glomeruli. My Western blotting data on the other 
hand, reveal that WL16 glomeruli release similar IL-1β and IL-18 levels as WKY 
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glomeruli, whereas LW16 perfectly resemble the LEW glomeruli. Therefore, 
there seems to be a poor correlation between macrophages and glomeruli data 
from single congenic rats. The analysis of BMDMs from single congenic rats 
seems to indicate that the chromosome 16 interval contains one or more genes 
that regulate the inflammasome activation and the consequent secretion of 
both IL-1β and IL-18. WL16 macrophages, indeed, show lower IL-1β and IL-18 
levels compared to WKY macrophages, while LW16 exhibit much higher levels of 
these cytokines than LEW macrophages. However, it still remains unclear 
whether this regulation is linked to P2X7R expression or not. WL16 
macrophages, indeed, exhibit lower P2X7 protein levels compared to the WKY 
ones and this is associated to attenuated caspase-1 activation and to a lower 
production of active IL-1β and IL-18. This suggests that whatever is controlling 
the inflammasome activation within the chromosome 16 interval, is doing it 
through a down-regulation of P2X7R expression. On the other hand, the 
observation that LW16 macrophages release more IL-1β and more IL-18 than the 
LEW ones, although they express similar levels of P2X7R and exhibit the same 
level of active caspase-1 indicate that the WKY chromosome 16 interval is 
inducing an increased secretion of both IL-1β and IL-18 in a P2X7R and caspase-1 
independent way. It is possible that the genetic background in which 
chromosome 16 interval is introgressed influences the outcome leading to either 
the activation of the classical or the alternative pathways for the secretion of 
active IL-1β and IL-18. The poor correlation between macrophages and nephritic 
glomeruli from single congenic rats suggests that, although the chromosome 16 
interval Crgn2 seems to regulate IL-1β and IL-18 secretion in macrophages, other 
genes not included in the Crgn2 interval as well as intrinsic renal cells are 
contributing to the pathogenesis of glomerulonephritis as previously 
demonstrated by kidney transplant experiments. My data also indicate that JunD 
is not involved in the regulation of the inflammasome activation. No major 
effects were seen on the release of active IL-1β and IL-18 using specific siRNA 
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targeting JunD. Similarly, macrophages from JunD KO mice exhibit similar levels 
of active IL-1β, caspase-1 and P2X7 protein as the WT mice. Only IL-18 appeared 
to be decreased in macrophages from JunD deficient mice and the significance 
of this effect remains unclear.   
 
6.2 CONCLUSIONS 
 
The work presented in this thesis demonstrates for the first time a fundamental 
role for P2X7R-mediated inflammasome activation in the pathogenesis of Crgn 
and indicates it as a possible therapeutic target. To my knowledge, to date there 
is only one published study that has investigated the role of the NLRP3 
inflammasome activation in glomerular inflammation. In this study, conducted 
by Lichtnekert et al., they used a mouse model of heterologous anti-GBM 
nephritis and concluded that the NLRP3-ASC-caspase-1 axis does not contribute 
to intrinsic glomerular inflammation via glomerular parenchymal cells. Indeed, 
they could not demonstrate any pro-IL-1β production upon LPS stimulation and 
no caspase-1 activation after an additional exposure to ATP nor in mouse 
glomeruli nor in mesangial cells, glomerular endothelial cells and podocytes but 
only in renal dendritic cells (Lichtnekert et al., 2011). However, heterologous 
phase of anti GBM glomerulonephritis used in this study is an acute model of 
neutrophil mediated glomerular injury with only a minor role for macrophages. 
In contrast, NTN is a severe model of crescentic glomerulonephritis, strongly 
macrophage-dependent, with progression to fibrosis and renal failure. Since 
macrophages accumulation within glomeruli occurs in several models of renal 
disease, such as in diabetic nephropathy, the results of my macrophages studies 
could have important implications also for the treatment of other macrophage-
dependent renal diseases.  
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Role of P2X7R-mediated inflammasome activation in other inflammatory 
conditions 
Recently, P2X7R-mediated inflammasome activation has also been implicated in 
other models of inflammatory diseases such as Chronic Obstructive Pulmonary 
Disease (COPD), a cigarette smoke-related inflammatory disease of the airways 
characterised by a progressive and irreversible decline in lung function (Eltom et 
al., 2011). In their study, Eltom et al. reported attenuated caspase-1 activation, 
IL-1β release and airway inflammation in P2X7R deficient mice exposed to 
cigarette smoke compared to the WT controls. Another study conducted by 
Kolliputi et al. demonstrated a role for P2X7R-mediated inflammasome 
activation in hyperoxic acute lung injury (Kolliputi et al., 2010). Culturing primary 
murine alveolar macrophages exposed to hyperoxia, they showed that hyperoxia 
induces potassium efflux through the P2X7R, leading to inflammasome 
activation and secretion of proinflammatory cytokines and these effects were 
completely abolished by the use of oxidized ATP. Furthermore, P2X7R activation 
has been reported to play an important role in pulmonary fibrosis. Using a 
murine model of lung fibrosis induced by airway-administered bleomycin and 
through the quantification of ATP levels in bronchoalveolar lavage fluid from 
control subjects and patients with idiopathic pulmonary fibrosis, Riteau et al. 
concluded that ATP released from bleomycin-injured lung cells acts as an 
endogenous danger signal that engages the P2X7R leading to IL-1β maturation 
and lung fibrosis (Riteau et al., 2010). Finally, an interesting study from Babelova 
et al. provides evidence of direct activation of the NLRP3 inflammasome by 
biglycan, an important component of the extra-cellular matrix, generally 
released under tissue stress conditions (Babelova et al., 2009).  The novelty of 
this study is represented by the discovery that biglycan, acting as an endogenous 
danger signal activates the NLRP3 inflammasome by directly interacting with 
Toll-like and purinergic P2X4 and P2X7 receptors without the costimulatory 
effect of ATP. The proof for the involvement of both P2X4 and P2X7 in the 
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biglycan-induced IL-1β secretion was obtained by the use of macrophages from 
P2X7 deficient mice, P2X7 inhibitors such as KN62 and specific siRNA to knock-
down P2X4 gene expression. The interaction between biglycan and P2X7 and 
P2X4 receptors was confirmed by immunoprecipitation experiments. Using a 
model of non-infectious inflammatory renal injury (unilateral ureteral 
obstruction) and a model of LPS-induced sepsis, they show that biglycan 
deficient mice release lower levels of active caspase-1 and mature IL-1β, 
resulting in less damage to target organs.  Taken together these data suggest a 
novel mechanism of downstream activation of the NLRP3 inflammasome and 
confirm the role of internal danger signals as inducers of inflammation. 
Furthermore, these studies highlight the complexity of the inflammasome 
activation process and indicate that modulation of P2X7R-mediated 
inflammasome activation may provide a substantial clinical benefit in a wide 
range of inflammatory conditions. 
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6.3 FUTURE DIRECTIONS 
 
The results reported in this thesis suggest that several areas of research on 
P2X7R role in the pathogenesis of glomerulonephritis are worthy of further 
investigation. 
 
Identification of genes within the Crgn2 interval that control IL-1β and IL-18 
secretion  
 
The analysis conducted on macrophages from single congenic rat strains has 
demonstrated that the chromosome 16 interval contains one or more genes that 
control the secretion of both IL-1β and IL-18 in these cells and the identification 
of this genetic link would be extremely important to better understand the exact 
mechanisms by which the inflammasome activation is regulated and could 
potentially reveal new markers of disease and new therapeutic targets. Since the 
chromosome 16 interval contains many different genes (about 300), identifying 
the right one is not easy and it all becomes more complicated if it is more than 
one gene involved. One possible approach would be to select a preliminary 
panel of genes on the basis of a previously described connection with the 
inflammasome activation, to silence these genes using specific siRNAs and by 
microarray analysis examine the expression of inflammasome-related genes. 
 
Contribution of intrinsic renal cells 
 
Both the kidney transplants experiments and my data on nephritic glomeruli 
from single congenic rats suggest that the severity of glomerulonephritis is the 
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result of a delicate balance between macrophages and intrinsic renal cells 
interaction. It would be therefore relevant to analyse the secretion of cytokines 
that might positively or negatively regulate the inflammasome activation in 
intrinsic renal cells including mesangial cells and podocytes. One thing to do 
would be to analyse by ELISA the cytokines released by nephritic glomeruli from 
WKY, LEW and congenic rats and once identified one or more cytokines that 
appear to be differentially expressed and well correlate with the severity of the 
disease, I would stimulate macrophages from the different rat strains with 
increasing concentrations of the recombinant cytokine identified and examine 
the effects of this cytokine on the inflammasome activation. Another possible 
approach would be to isolate mesangial cells from the different rat strains, to 
stimulate them with LPS and to analyse and compare the levels of cytokines 
released. Then I would transfer the supernatant from these cells into 
macrophages cultures and examine the effects on IL-1β and IL-18 secretion in 
response to ATP. It would be also worthy to analyse the release of the 
physiologic inhibitors of IL-1β and IL-18, IL-1RA and IL-18bp, in the supernatants 
of both macrophages and nephritic glomeruli from the different rat strains. The 
in vitro results will then be applied to in vivo studies to prove the biological 
relevance of the findings. 
 
Effects of P2X7 inhibition on the phosphorylation of ERK 
One important result that emerges from the Western blot analysis of the cell 
signalling cascade following ATP stimulation in macrophages, is that ATP leads to 
an increase phosphorylation of ERK only in macrophages from WT mice 
indicating a clear involvement of P2X7R in this process. Differently from other 
members of the P2X family, P2X7R is known to be potently inhibited by zinc and 
copper even at submicromolar concentrations. The molecular basis for this 
strong functional inhibition is not fully understood yet, although it has been 
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suggested that these divalent cations inhibit P2X7R directly interacting with 
specific residues of its ectodomain. To my knowledge, the functional inhibition 
by zinc and copper in regard of P2X7R mediated cell signalling cascade has never 
been investigated. The majority of studies available have indeed focused their 
attention on the effects of these divalent cations on ATP or BzATP evoked 
currents, failing to analyse their effect on other important aspects of P2X7R 
functional activity. Therefore it would be relevant to investigate the effects of 
zinc and copper on P2X7R mediated cell signalling network and in particular to 
see whether the addition of zinc or copper in the medium is able to prevent ERK 
phosphorylation in macrophages from WT mice following stimulation with ATP. 
The findings might provide a fundamental insight into the actions of these 
divalent cations and the modulation of P2X7R mediated signalling activity. 
 
Analysis of the cell signalling pathways activated in glomerulonephritis 
 
The phosphoproteomic analysis conducted on macrophages from WT and P2X7R 
deficient mice stimulated with ATP has provided very useful informations about 
the signalling pathways activated by ATP and the relative contribution of P2X7R 
in the activation of these pathways. One of the most relevant and novel finding 
that came out from this analysis is that P2X7R strongly regulates the ribosomal 
pathway and might therefore have a crucial role in protein synthesis. Functional 
assays are certainly required to demonstrate P2X7R role in the regulation of the 
translation process. Quantitative phosphoproteomics could be also applied to 
the nephritic glomeruli from WKY, LEW and congenic rat strains to examine the 
cell signalling network activated in response to NTS injection and to discover 
which signalling pathways are differentially regulated in the different rat strains. 
This complex analysis could reveal new insights in the pathogenesis of the 
disease and could help uncover novel potential therapies for glomerulonephritis.    
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APPENDIX-A 
 
 
MAIN REAGENTS USED TO STIMULATE MACROPHAGES 
 
REAGENT SUPPLIER 
Adenosine 5′-triphosphate disodium salt solution Sigma-Aldrich 
Lipopolysaccharides from Escherichia coli Sigma-Aldrich 
IL-1β Converting Enzyme (ICE) Inhibitor I, Ac-YVAD-
CHO 
Calbiochem 
LL-37 human Axxora 
CRAMP-18 mouse Axxora 
2′(3′)-O-(4-Benzoylbenzoyl)adenosine 5′-
triphosphate triethylammonium salt (BzATP) 
Sigma-Aldrich 
GM6001 MMP Inhibitor Millipore 
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APPENDIX-B 
 
 
 
PRIMARY ANTIBODIES USED FOR WESTERN BLOTTING 
 
 
ANTIBODY CATALOGUE NUMBER SUPPLIER 
Anti-P2X7 receptor APR-004 Alomone Labs 
Anti-phospho p44/p42 4377 New England BioLabs 
Anti-phospho mTOR (Ser 
2448) 
2971 New England BioLabs 
Anti-phospho S6 
Ribosomal protein (Ser 
235-236) 
4848 New England BioLabs 
Anti-IL-1β 2021 New England BioLabs 
Anti-IL-1β (R-20) SC-1252 Santa Cruz Biotechology 
Anti-IL-18 (H-173) SC-7954 Santa Cruz Biotechology 
Anti-caspase-1 p10 (M-20) SC-514 Santa Cruz Biotechology 
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APPENDIX C 
 
BUFFERS AND SOLUTIONS 
 
 
1.5 M Tris pH 8.8 (1L) 
130.8 g Tris base 
66.3 g Tris-Hydrochloride 
 
 
1 M Tris pH 6.8 (1L) 
1.72 g Tris base 
76.8 Tris-Hydrochloride 
 
 
10 X Running buffer (1L) 
30.3 Tris base 
144 g Glycine 
10 g SDS 
 
 
1 X Running Buffer (1L) 
900 ml  dH2O 
100 ml 10 X Running Buffer 
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APPENDIX C continued 
 
 
10 X Transfer Buffer (1L) 
30.3 g Tris base 
144 g Glycine 
 
 
 1 X Transfer Buffer (2L) 
200 ml 10X Transfer buffer 
1400 ml dH2O 
400 ml Methanol 
 
 
10 X TBS (Tris Buffered Saline) pH 7.4 
87.7 NaCl 
24.3 Tris base 
1M HCl  
 
 
1 X TBST 
900 ml dH2O 
100 ml 10 X TBS 
1 ml Tween 20 
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